var title_f1_22_1376="Lunate fracture and Kienbock";
var content_f1_22_1376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lunate fracture and osteonecrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5inmfzXG5vvHvTBI3GHf8zRPgzSHBxkn9abkEE4IxQA/zn/vMPxprSSEYEj5+ppMggHtRn8qADzZAwJdvTrSu8mBtkb86aApOc5pTgHgUAPDuRy7fnSmZ8f6xuPeowRjJ49qYvc5+XvmgCYyvg/O5/Gm+ZKyjDsB9aQEYyKMkDpxQAvmOBwzY+tKskmOXcegzUW7ccAcUuSOMnHrigCQTS5OWYf8AAqRpXY/6xx+NNbLYHalGAMf0oAeJXI/1j/nTfMlycSN+ZpoYZz+lIDyeSPwoAf5smRmVwfrStJJtGJH6+tMyMc80uTwM0AK0snQOwPrk0jSSH77uPoabt+brxTiDnINAC+ZKQAGYH6mgySY5ds/U00AZHXP1oAG44PNAEnmOejsPxNJ5rcgO+fqabnjmmhhkigB/mOSP3jfnQZZM/fbH1pnf8MUDg8n9KAJBLISBvb86QySZzvbI96Tk9Dikz8xBHTvQA4Svu/1jn8aFkk5O9gfrTTg9eD6UoXAxk/WgAMkmc+ZJ7809ZXP3Xf8AM1FtIP36U5A45FAEnmOOjt+dJ5kgP33x9aZnC5wR9aM5zngUAOeVyfmdvzo82QqQXbH1pmMgE80gB5xyKAJRNI3O9uPegyS95X/OowT/ALopcMehoAeJJCf9Y350vmP/AAyNn61Ft+bvSkY6GgC9ZO5ibLtnd6+wopbADyT/AL1FAFOb553IyMMRiomZtucVNMQJXyf4jUeR0BoARcsBjpSk7egyKAducdT1pQey0AICCMjijbhT70jL8wzSk88UABwOabgt0/KnHbn5utNK/PmgBWOFxtp2QF59KQL3NIyknrxQAKA3I4p27nBzQAfam5w2MUAKT82ACKcMjrimg/McChsNwTQAFueVyfalGecgU08AjqfTtVuw027vpRFaQSyM390cUAViOORSY5Fei6J8JNavl8y/ntdNgbkPPKp/QHNbUfwy8OafIBq/jOzIH3lhglY/mFIoA8fIGSadkbeBXsknhf4awjm/1u8l7+QAoI9sx08ad8MY4wqaZ4odx1LTwj/2SgDxYKC3vTlAGTXrsem/DXzzutPEpQnoJIuP/HKsP4c+Gt0+LabxFbr3MjI4H4LHmgDxlkGc5Jpr464wa9ib4ceFL+TbpnjK1hY9Bc20wx7H5RVTUvgxqcMW/StX0rURn/llOsZP4ORQB5QVwBT8/Lxya7e7+Ffi61jaWTSt8frHNHJ/6Cxrm7zQ9UsnKXOm3SAdSYmAH44oAzMkAcZpCRk5FDBlOMEYPSkGQDhcc0AKD3xk0jZxnOPalG1iQR0oz04oATOMEqQPU0uc8jOKCRtOc8GjJ4wODQA18H19KUcsVb0pfuml6GgAOD0pgOzcBT8qT0/Gk4zzQAhyU+Y4oBKtjPGKVsEdRSEDaB2oAXls4oJHQnnFAIAAAoZVJ560AXNPB8k4b+I0U6wwISP9qigCpOP3z8Z+Y0zjPA5qSYHc+Pvbj/OmDrjvQAg7lQDSdGOBzQeFwp5zzSgbiBjkUAGQTyDmnADsPxpuCoO4gEmkRDuznigBwKkmh2wOmaTI5AINAxxxQAuBtwGpASVwaUkDjb+NGeMgg0AHHQE5FKeTwOaRRk8dTXW+G/A2oarGLu4K2On/AMVxOSFx7daAORKlj3+nf8q29I8KatqexreylELf8tXUhfzr0HSNL0bR7wR6Tbtq150DuMjPsM816PY/Djxx4hhjnuUis7TqIT+7OP8AgIoA8t03wLpVhD5urXbXky/8sLcZXPuwJ/lXW6JHf3Kx23hrRZIxnG6CAuwHuwFe6eFfgxpumGGbU7l7uTq8HRM/UYNelR2+n6Ras8UVvawxr8zKoXAHvQB4TpvwivLiL7f4m82foBCrmRhnvj2z0rqdG+CHh2GUy3JaaKQZ8vy/LYZ6Z5NZPjf4+6dpxkh8NWhv5ImKtcznZAfdWUkn8R6V4pr/AMePFF+ZkOtSQwSkjyLS3iYAegcgNQB9PQfCXwrbjEVpOp7ES/8A1q5vxW3hnwLqltaX/hS2u7O4Ust7MVkYEYyCCvHX17V8r/8ACeTGdWlu9XYseSLpxz9N1bNp4yguovLub68VF73J8zH0yTQB9P6R4g+GOoKoFtolu7DJWaCNMfnV248HeBvEERu9NjidM7S2lSAAH32V8u2eq6bcznE0U7kYGxR0r3P4Va+U01LPTtXsYUQ4EMyBCx+qqSaALWqfAnTr8iSy1FrdW52z23mn8csK53Uf2c28hjaa3btcZyqpZiI/nvNer3F7rYSaKLVLBrxRvManOB/3z9a5G+8dXscOJr+PKHEg2gFvYHFAHnF38JviFoql9KvrpoEHPkX7Kx+iCsrUdV8eeGYlGrwy3kJBzHqNo0qkd8lq9C1X42z6FCFt9ESWLOctKxJz1PNZcX7SGl3UiR634eYwk4YhVfA7/eNAHnDXXg3xFG39u+HXsbhv+XnTn2oD7oq/1rF1H4UW97A0/hLX7LUe4t5WWKQe2CxJ/KvftM0f4efExXbw9LJpmoH5yABvx67MlfSsLXfg/ai0uz4V19r7VrJsTW5AiPTOPlGc8igD5d1zw7quh3DQ6pYXFtIOm+MgN9CRzWSd2cAYr2PxHe+JtMjew1i1llQr8ouI1Zl+hPNecRaXLqhaO1hJujztHU0AYOM49e/NOIwetWdQ0+70+YxX8DwOP4XGKq5B4xgUABHTvQDwep/Ck2gYwx+lL2PBoAQdMEdKU444zQAc9D9aQ9fvUAIQVBIx9MUvQAdSfalU/LnOaXr1OKAEGQTngUpAIHNI31zQMgc4/CgC5ZKfLbr96inWP+pPyt96igCrPnzXx/eNMYYXg5NOlJMzj/aNM2kcj8/SgAyTkDg0HIHHWlz39e9GATmgBDliNw4FDMVPTihiQRTj0oAZyegpxA6gZIpAR26n0oU7cjBzQAqZ5wMjsPStPQtHvdavEt7GHzHzgseFX3JPFbPhLwjNqqm81FjZ6XH8zTOuN/sM49q7WyR7l10jwtC8FvJwHQfvJffjnFAFO20XQ/CbqtxjV9axnav+piPv6kex7V3/AIN+HXifx9OLzU5Da2Cr+7aVcIB2Cr17da9A+FXwctLFYtU16H7RcBcrBOvBPuDXoFhr2t3WtJa2ujJbaVA2ySZnwgVTg7TjHAB4oAwbXwJo3gvwtd6poNk11qdvGZFkkHzMy9QBxxmuS8P/ABOup9c0+3jluIWllxcfalxEo59gfTvW18Uvj14e8KxT2WjumsawPlCQuGiXjnLjIyDgYr5d1P4k6xrusG5vEtotzZEUMQC/iB1oA+57zxCZQ8OkRiecLkyyfJEnvlsbvwNeF/HTUJoNIMOp6wNQ1OSQsttACLeHp93PPr1Y1kaP4t1i/trCW/u0ubSBcLaD93H36jkHr6VkeKXi1i9murhofMbpDHgKo9OKAPENYu5ZSsLucdx71QtkZpPLUKT712+t+EpLl2mtl2Ec4IrHh8Jam7Bo1AYHvQBBpWn2s4capdG0EZyCwJyPbArZtbXQb5WtrOWSa6YbVJHU/lU1t4F1DUGBvrjb0AA+b+tdj4U+GN1bym5sIZZ7hfuttIxQB5vB4curS78y7UwhDxg8muq0u6nSVBDLIsgOQc4NepQ/BnWNXMkuo6klrOFzHHJ/EfxIqrpfwq1vSgJ9YtzOu7AMakjHrmgA0Dxtq1rFJaXjs0h5W5PJHt+n61Y8QDVbqCLUZLZZomHzSRDJPueferms6NBb2ohsYVeU4y2Pu10Ph/VFt7C30q4T7OGwGlJ+U9OD+VAHivinUD/YM0kESNcZK7XB4FeQSu8rszH5u4AIxX2b4w+GFtrunvcaIginjBYsFykv0P4frXzl4p8B6ha3bLJC0M2eiqcGgDjtC1q/0C/hv9NupYbiE7lYHvX018PviFoGrG28R+JvDSjVkwj6jACV/wB5hknPFfPtr4H1K5dUYouTtGTX0J8Lfh14h0lY4IYh9jlXM8d1FvhcfQ8UAesalo/g/wCICC5SUTErjzYflP45HvXj/jX4KazouoPc+EomurfG5ZDIglT65xk/QVZ1rTNX8J22p6hYO2nW8Lf6hUMcbHjr0GK1fBfx4EdtEviz7MGfG2SKQf5JoA8qutR1JENn4x08alCPlf7QhV19weBXHa34HivY5r7wvJ5tt1+yucSL7DpX2ndWPhL4iaSSjWt4JV3CSNlMqHr25FfPnxH+HeteA70apppeawWT5Z4wcrzwHx/XrzQB85XEEtrKYbmF45VOCrjBFRSZw2T24r2XWLbT/HVq81wi22touEZF4l47+5wK8l1PT7nTryS2u4mjljO0qwwfagCqW+UYoIyASeRSDBwPSmu3tj6UAPY4pp+8OOKcv3elC7vwoAOwAoXrjApqk7j6ClJ54AoAuWQHltwPvf0opbLPlH5Afm/pRQBUkXM8hB6sa3PAnhe68Y+K7DQLKURTXTNmVlLCNQpYsQPYViTsvnSZ65PNXNA1rUvD+oR3+jX09lepkLNC2GAPUe4PoaEKV7O256B4s+Bnjjw9udNNXVbRf+Wunt5hx/uHD/oa80uYJLe4aG4jkhmQ4aORSrA+4PNe4+FP2k/E2nbItfsrTWIRgGRR5E35gbT/AN816XbfFH4V/ESBbbxRa29tcEbduqQAbT/szLnH1yK05YvZnL7WtT+ON/Q+PTkEk8inBhjINfWOv/s6eFtdtvtng/WZbNX+ZAHF1bn6HO4f99GvH/FfwK8ceHt7x6cmrWi8iXT28w/UocN+QNJwaNIYmnPS9jy0Zzk8Z7ivQvBPgtBbJrviPMGmocpGfvS+wp/gbwrFa+Zq/iiN4be3PyWsylWkYdsHn1/Ku20bQ9W+ImupKYmS1XiOCPhUX/JNQbkenxX/AI+1mGy061EdsnEFrGMAAc8/h/KvpX4c/D638M6eklwsL6k2MyBQdg9BkfWs7Q18I/CvSQl7d28N9IPny25z7cdK5zWvE/jbx2ssHge0+z6W3yteswUkH0yRnj270Aeg+M/iFoXhV/s9zM09+w+S0gAZye3cV89fFjx34o8QW0ln8+jWL8i3hOHcY4JPUdex716B4Q8FTeGYr1r+CEaiUMj6hcsDg4JO3mvHfE+tMdYuCJkvm3lcopJ69qAPOYPC8s0uZ5lRCclskn866TSNH0+ylC20Ju7ntkcCtDStFv8AULlrm8XyrPOfLPU10sUWyHy7VVhTpk9aAKLwXTIFkdY2I+5HT7e1SJlDduSWpHlijnMcOZJB941pGGKCLz7hlDEcAmgCnPfRn5I4skcbz0qMuYl3yypsYdhVWbVLR5tkpbGc7V6VWvPEulQnyhCgYdqALovJdpW1YyN2Apw1PxBZr5llJLG3cBqyLXxnBEkgS3iTPGR1qodX+1FpWb5e2KAOtg8V+MQN8c0sue7AHFWG8V+LZU23d1cNF3UAAVxEGtXuWSFmVPXFBu7tCGmnfYaAOwbxFOGUTJKgHU9zT5tSkvpI185iD90Cuct9TR41XzNw9q0LcK06MGA75PagD1zwX4vu9AeG1uUu5oJAAY9oOB6jn3r0ePT7LxFbNLC8VzD1eOSNVdD6ZA+vevCtH157FVO4zFT8pHUV6PoHxE0/7M9tqiSfvRtd8cj9KAN5PD+iWNwDqmmtb2oOI3YfKD7kHPrXZ6fCIViawdXtG67mPT/Zrj7fWWt5Iv7K1IXiS8JBOc7fx4xXXtcQWUAmmgMUzr9xedx+o4oA4z486XNqvw31SGyj3SBQzAdSMivga6eaEtbTEsAc/T6V+i2keMdP1CRra/Dafd5K+VcgqGHqGIwfzr54+NfwmkbWLnUbKD5JSXQxDIAzQB4b4M8aax4V1KC5028kVVP3M5B/Cvsn4OfEiD4n6Re2Oq2KLcwKEmQgFZAcjP14NfEWqaXPYXJjdCSG+9jvXoPwL8TzeFviXpsqkeRdEW06sePm+UMfpkmgD1T4rfCabwzJNq/hzzpLNmaTYvWI9fyry/Vbc+N9JTy0iGtW/wAhIJBkA4wffgV9rajqmnpdQebeyYwfkjG5HBxycA180fEzwXFaeKdR1XwsS1s6+cYgpBRsDJGcd80AfN15Zy2s0kVwjRyocMp6iq2MORntXp/jOxh1vQF1tCq3kP7u4j7nrzj14FeaOMNjjr+VADEGVPOaVeD1/Cm/xDgflQclvUZoAUnJxtNGQBgUp+Y49KCc4GcCgC5YuREQf71FPsceU3+9RQBTmx57gY25NMC8nHSnyYEr8fxGmbfm64FAApwORQOMmg8D5eRSMRuwKANbQfEOseHrkXGhapeafJ1Jt5Sob6jofxr3n4U/HLxdf6nFYa1b2ep24GZLjb5MqDjklflPX0FfOcMLzzJFCCzscKB3PavXLayi8K+HI7VCPt96P3jDquc8fypqTWxnOlCp8SPoi08X+CfiAz6ZqliJJkONl5b5Gf8AZkGcdeuRW/F4Yj07wxdWHga7g0uaXO252+fj/ZznOPxryvwT4Zh8LfDzUfE1y0p1EofKQj9f0r55/t/xHpmpyarpmqXtndSvuZoJSmfqBwfxq+dP4kYfVnD+FKx2/wAQPhB8R4NQlv8AUIn19d24z2cplY890bD/AJA12vw7+I2qeCbKzi1jebNV2i0kzGykDoVP4dqwvBn7Qvi+yMceu2Vrq9uDgyEeRN/30vyn/vmvaPDfjfwZ8TLmHTrzS9+ogGVIL22D428kq4yBj6ijljLZidatT/iRuu6GfF3QvEHizQ9Nv7K5khgCB7vT0JztYA5U8ZKjqPyryz+z9F0qCOLSYhPdMMtMw5B9q+p68k+K3gh44LnXfD9sXmUF7i0jHLeroPX1Hftz1qdO2qMsNjLvlqHmEshgiDySHPoxzVO7uo5cNE4J9Olcq2tx3U+WLkelTy7mTzVymOgrE9E1oGisJTPLIGZuwPWsTWNYBmE/mA/NwjNwKyNW1v7LBtGHc/drkGee7lMjFsZyR6UAbviDWPNvCbfKfLzs6Vgs5YF25djxk1bSBz+9HzIOtPMURHmjgelAFS1f59sg4rtdE0tp4EmVg0eeVBrjHfy1OMEMeK6bwZqzadqtusvzQy8FT060Ad2ttarZsVReOMAc1zHibP2q3tIVIZyAQD0rrprUQt5wyUZtw9Kt6BHa2fxLtr2/gSa3K5Ct070AdF4T+EV1NcWKTFbaKRN5kdM7uD2/Cu0X4U27/bXSX5IiUUgfeI79a9b0L9/YxXW5XEq7o+BhV9P51opGqBgqcMcn60AfMreAtQMlwdJcyPbgllU5zjPb8K5+CUtDJb6pEYZw5U5GDkGvqSWyNqt48WxEmBHyD5iTnj9a8t8b+CpLvT2cIIGjy+5vvMetAHnMMssKj7PcGNo+VHTJ7Vas/ivrGmXKR6ys11ZhgCu45+obtWRf2d5pm2O7BIcfKwrBluHjmEcyLJH1O6gD2/xX4r0zV9Fi3WNvq8Mi5RfOH2iH3zgn/wDXXN6P8TNU8OQzaf4itmutNmXEDy5LKPQkjnpXP+BtA0HxDcfYrm5urK7kb5J424HtjP8ASui+IfwV1saA7aPqf2owfP5Un3mHtxQBwPioeFr61l1G0uf3zZD27gAq3qOff9K4HwXo/wDaXi23itwM7tyhj1xWYxu7W5eO8j2kHa26vXvgRaafY+JG1fVQRZxqAkh6A4PX9KAOvsfH+laSZtO1aSS1vIPk2kYBxxU3hzxLZeKfHOn2+nSg2683Jd+GXI/zius+IXwwh8VazZ69piWksTRhpIZMqJAQNpBA9P513nhXwno3hyxSLTtOht3YAyHG4lsc8nmgD5c+JvhweF/HF5st8aRdkbVzuByByPfg14v4u0d9J1NlCHyXG6M47f5zX178efCstzoxms13+W2UjySw4PP518wavp13c6TcmfdJcWbZ5PQcf40AcID05ODSjjOB3oYBWK84/lQcDvigAY4zxzimnOFOKUEb+TSsOuOvpQBesc+Sf96iixx5Jyed1FAFKbDSuMchj/Omsdp5GM0+Q/vXLddxphALE55oAUZ5xSEk9sUcjJHIrT8OaZJqupw26ozBjl+OiDr+lAHWfDzTIrVJNc1GIGGP5YQ3Qt6j8q9U+DPhmTxl40+3XSFtOtTvfK8EgjA/LNcbYWFx4p1+z8PaNC32SEqgVemeASce9fYXw+8MW/hPQI7CBFEuA0xUY3N/XrQBy/x+uYNM+GtzboBG1ywgiAHfBP8ASvlnXdFews7ZYysjleqjPrXun7R+rfadU03SwcwQuHkHX5sHn8jUtr4a0u+0iGSS3W0tRHue6l6n6A/40AfM5spo2zKCG6gE8V65+zjqGkaZr2o3WpzldQlRLS0hSJnJBOWbIGByFHJ9a5HxJbWs9/cjTmaS1ibAZurfSvYf2b/BkJil1e8izyDFuX+tNOzuRUgqkXFns9211FLCkNlLOZBncrKoX65NYHiDVdcsJIktdOtvnYLulkJA/AAV3xHPJqKaKKQKJkRxnjcM1TqSMI4Okuh8/wDi7wLC2qyahcaXFbyzDzJGt1whc8lsc8nvXA+ItCFvbPNKpWCLnjq1fTvjK132yyR3JiZTnYzfIV+nSvBPilrQsPnWKOQdNhUbf/r1B0pWVkeB6t5F7dkiPyU/hBGKr26xQxu04ww4Dr0rs7u10zxGiy2s8Vtc45RsKtZp8HajbSiKUQzWr/xB6BnOtIUiV4Azbu46GqLSTT3AQLg91Aya76Hwu8CGFpUVf4GB4FUZJtN8JSyMI0vtRf7ztjav8/WgDAsdHur8iJLeQEHhyuBXU6X4Us7B1m1i8QKpyEB5zVB/Gd9NEy2oigVh/Co4rInee7ybiUux5BLUAesapJFHp8SRg4IyreoqfU7WK8srK6jkZAg+Zl7HmsLQ5Tq/hhVY5ntzjGe3P+Navh+5CJLY3Z+RvukmgD3LwZ4wmtPh3DdCEzC2kWAu7A8fKM46/wAVel29ys9pBKXAEqBwyj8etfNnwvuYLDV7/StYvg2nzruhhb5skc8An2Fe+eEb6G/0nyflVIwYRAepUDrigDfO2RVOVZeCD2PoaoXFms7XTTW6MzLhATy3FXYogqQpGNkUa7QmO2OPyqUqM7iBkDrigDw74laE5B89TA4QlXzx9K8N1ZZRIY5eG6ZYdq+wPGdnYX2hyjUBxHllBPJPPAr5r8f6bM9x9oREEeMLxgj60Acx4YvXtb9J4R88A+6Dgk+v619M/DDx5D4m08Wt04j1FRgq/wDGMf8A66+UdPwty6szKxH3lbFek/BEw2d6L+4mZ7mKTCRFdxwQB1/E0Adr8VfAul6i90xt9lwSWLBSAxJrxbRbS7ttcj8Oy5AaUBFU8HnvX1V8SL21TwrJdz3UVu0a79rYJb2r5Q8OasNR8bS6jG7phjtb72Bk/lQB9k+FBJb6PbWVyyC4gjVCEOeMcVry+YsTmMB5APlB7mvkjX/iHrXhjVFvbPUfNVf4H/jHoea3tO/amg/cJqGhOvOJJll4P0G2gD1zQtJ1rVYtXm8YW/lPISlvG0qsiJxyME46dz3r5m8Y6E3hXxSsc0qy2t6CHTH3evX8hX0rqvxD8Nal4Li1a1vGuIpj8kEL/vC3PysByOhrxH466npGu/ZtQ0tZLe5VQssMiY5yef5UAfPPiTTzpmq3FsDhUb5CP7tZoHJI611Pj5FGpQkZMjQjdz3ya5fGQSOMd8UAR4+b0z1qTAx64pvBA9fWjqQcZoA0LHmI8n71FFiT5Tf71FAFSfmV+P4jTDgjkU+UbZHx/eNMxxk80ABOM8cV3PhWJdN0Oa8Dlbq6/dxt6Dkf1rhl4Yf7Wa9H+y/8S3QNPth++uHXryeSv+NAHrPwp0q88MaE2ryL5U9w2FmYZ6k11d94s1Hw/ot7cxXrI8hyA2G3nBPGc16jH4Usr/wJYaPOrxxrBGSY8Ah9vJ5HqTXL6T8GNJi1eO/1e6n1AxHMcMhHl+2Rj+tAHIeN9LlvJPDV3fAtc3hG7cO/zdfwFa/xYlttO002rXGZY0AMScACtb4vSi28TeD8hVt/tQUk9B8r8V4R8WNbudU8e62UbfFC4QKv3cYH+NAC+EbO31fVLSyTiGSQFj3x/kV9gaLpttpGmwWdmgSGNQOO/HWvjLwxqIsbyCeJNkqEY9q+pPCPi2TVbGDeqbxgM/r79aAO3GPypCMgbvXiuf1XxZpukMx1OZYIl6SBg+fwXJrOXx/ot3IiaddxSA8lnUr+hxQB0OvKWs9oZEDHBZxkV8sfGaNmuZOd6A4XHHavps+JNKmtJSLmN2C8oD1+leB/FW3tr2EtbyIsjnIRu1AHzk7SQSEybhzwE7U5dQuzcDE0sipzs3dKsaxbPBdtywA6iqNzDHmMROSxGSe4oAkuNVuNr+VcSZkPMZOcVSuXaYBpsnHXPeriWMqRS3ccYKdATVXa8qKsIDyP94GgCG3ZUn4PyfyrStHDfe5AORWd5G2dVVd+374A4FXNPjkNyVs0Z37A8AUAdp8PLxE1ma2Y4Ey8L78VvX8ZEzLICrL0IrzeH7XaSx3ts+LiFssBXf3Ou2Wr2FtfRfLMTtlToQfX+VAF3Sb97LxTpt2IxNIny7T9D/jX1B4GihnuZrzfm5I3Mg425zxivkW6vfs17FLDJuZDkMO1em+F/ixqVsQdgLBQvIOGx0zzQB9Qj15pa8q8HfF/TdTZrbW4jZXinGVUsj/TGcV6Iuq2C2X2o3cfkEbgzNzj6UAJrMcE0AinkVGzuUkV82/Fu9g068nWaRJWbrtOBjFej/Eb4k6ZFp8sOmSmW5IKhlzXzDr1nfa9fma7nPXIGaAMi/1Y3oMVjBsP97PNSaJfa3pF5G8FxInc5A/wrpNM0iy0xC1xKnmnomc1IFE1zlkXAHBxQBPr3ivWtX0WYanP+6+6qHqa5XweJYJ3ljViR1UV0F1YG6hdlU7VySzGuy+GHgu/vdFvtQisv3BGEmdgvPPIz+FAHO+KfBmp6j4eOqSRiK2Azlj0ryW406SOJlkliIB+UCvb9Ul1nRLG8g1HUBd2zqQLctkd/Q14bqs5muXbyxCrEgIO1AHofwp0W41bW7bRLfUPImmG6MnlQc49Peun8f8AhOXwzdrZajqceo6lK2X8vpGvvwPT9a4H4QavPpnjPSb2Mb2gl43eldt8Udca58W63qhdSdoVMdAfl6UAeR+MLtLvWpdhyifu8j25rDJBXCnmnO5eQsxB59KaowOOhoARcgrkdBQMu2RwKXdg0jnggdRzQBfssCJgT/FRTrHmE/X+lFAFKYsZn443GmZ568U6ZyZnwMjcaACe3FAAPmIOejAfrXr3hlHn8SeHlhVTOsa+UDzlwFx+uK8fO7zAQOAQa9a0G7+x33hvVGG8QSRttXvgrxQB9DeEL/xtc+O7Vbmyu47OJSl15xYRBSVwQCMZwDivagwOdpBxVbTrhbjT7W5xjzokk/MA/wBaxvCOn6nYXGqrqkwmjecPbsP7uOR+dAHCftIRKnhjTL85H2W9ViR2+R/8a8bm0uFtVvmj+aG6QSI+M9x3/Cvpv4l6F/wkfgrVdNjQPNNCfKz2b1r5P0PVBa2UbTO63dqTFIjf596ALjaUIwDbbQxX5tw6msXUNe13TYvs9vdTW4xx5blcj8K6ddTt58f8sye78A1OdMs7xQsihpMEq4yR0oA4QeIdRlUC5meZsfN5jFv51oaJqCymTc5WfHB3YFUNSsmW7kiLKu18ZH1qhe2ckbDEhY+o4oA7y11eWKERSStu7MrVPeu1+qmY7xjBJPP515aJ72GQfxBemSa6fSNenkQRSpjPpQBn+KvDt7FE11ZSebEByrD5hXK+H7Vbm6LzOUccFTXpzTSTq2D5a993esDXdOiuLVlsYsXfUFOM0AczdxS27ShZvNst2SgPSl0+03SLdNEywE7RgdPxrLury5trV7K6t2ibPL+tMttUuPK8hJNsSjpQB0enxQ6XqMySiOSO5BAPXGf/ANda0GgzPBJ9kILD5g0I7ehxXFnV18lo2T5iMBvT3rS0TXp7CPyVuCgbkv1zQB1tnp1rLo7y3DxwXcTcoer/AFrO1hdGFulzpzGOc8PCOBn1rC1HXvth2pneDnK96jDGaRJHQhz1WgDb0mzfY9xM4CN0zWjb6lBauBbxtNJnqOgrJczzxpHCh21fs7Jkw0jLGB1Hc0Ab8WqLhHYeXL1+Wti98Yam9lHC7RpCowDgc1yySOx22cCoo6s5p+IicTTBnJ5HYUAMnvjIXZRukJzkDrVGWPUJyp3eREevPJrSRFE4EEZlb0HStfToYppGaa4SOVf4H6D9KAMuy0kR4lmSSQ4zufJq+oSMErGWUjjitGD9+yx73mcHGVUYIpPENk8duLdS6bjhFUAtQBX8N2Uer69BZ3szxwO4BXoo5717l4vlS0s9N8N+HzstUAE0sLfKo4646ng1ynw6+Hk9zDaz30bWWmwpvmllP7yY46DrgZHt1rO8RGc+I7tdKkNvpcLbQxOQwBPOTk0Acz8bNPttDNl9guhO0i8lh1PHvXh0mn3d/dMXTYoOWJ4r2fxloepay1tLJE0tuGxAy9XPFa/g7wLpQ1eOLxfcSWD7NyqRw3TGfzoA848P6P8AYrZZwpC9AwHOawfHl+gjSxicNKfmlYH6/wD1q9V+LXiHSrLfb6WiJBAuxJF/iPrXztcTPcTyPIxLE5zQA0/KSO3rmkDAYHbHWmsuGyfu0vOMjGO1ACnb7E0mBuz1NOyMduOKCCR6D1oAu2HEJGf4qKSx3CI4APzUUAVZ8iR8H+I00bgvHWpbgDcwBAO41ED6nkUAKXwhAHBr0nw3Mz+E4W3KWtZAxB64z/8AWrzdQpyCeK6jwNqEcd3Jp9yQYbjgEnv/AJNAH3d4H8Qx3fhPRJQjHzlSHr0PArsQTnHfHWvmP4S+IP7MvHg1OaSSythuiCsSqEdDX0R4e1iDW9NS8tgyxsSASMZwSOPXpQByPw/8Uf294g1mO7ldbuJtsduxwoj+XJAPvXzv8dNEbw14+v5oUZLW/IdF7f54r6wtPDem2niKbV4IEju5o9r4HXkc/oK8e/ac06LWdChurN45JbKQK+08j2/WgCn4d8HWWr+BdMvNRtbiS5jUACNc7hgex9a7HwZ4Gi021e6ulDxyHMcLRncAe1bvwZ1RNR8A6YoRUkt0ETKrZPAHJ/Ou6xzQB4P47+G9tfrd3umwlJFG5oxGR78V4jNYywXLQz7V2nGGHNfbd/bzXEZSOQRqeGI7185/GDQF0q+MiR5nlOQx6GgDyi7sYn+ZgVHdqzHtXSffbO+1fStaa2mQb7gs2eAM8VmahrVhpriKS4Z5+6xrwPxzQABrk8ieQkdmNXtOe4Dea+cD1PFR6PrunXzFFRA57EDNX57OWd9trcIsfUq5xQAtwbW74mhVvU44Nc7qHha0lkZoyYlbsK6ZdKuGgJUq2P7hqaHTbjYWk2g44DUAedTeFjb5Pmkr2NQR6NHzvdz7CvTX01WjzNgqOSKYbDTbeMTNG/PUjkUAcdpukRxDZbwtJIe5FaaWJhyboBSOw610MmpQwwtJZwqIlHMp4rh9Y8TQIxaPdNNnr2FAG6gijyIiyx+rHApi2SSkzRThgDzg8V57eatfXR2STsEPUKelanhJrh5bqGBpJITGT364NAHYfbbWCTbPdRcjG33ro9C8NW+uBZhqtpbw9WOef514deRvFcyJOG3A8bqveH76S01CFDLIIXcAhTwOaAPovRfhzfXxc2M0k0KnAdRgN+damo/D6ezhL6pJBbeUM43AsR+dbnhG/wDEh8Lo/hfWdKe1iXdJHIV3r/OuI8YatrNt5134hzLPeDZBtc7fy/A0ASaHq8dnqB0/S8XUknUlSQP84r1vwF4Q0yCOTU9TWSa+RiSJhtUcdsj+tcd4O8MWGgeH7a8SGa61qQeZJtBPlrn0/D9a7vxFrGn+KNDtba11E2zO4Eipw3Y9M0AeffEv4kXZvLvSru2Nvpy/cEXzF8HjJGfQVB8NvDd94jC6vrzSWvh6M/uLVhiS5I74Pbp25zXaeEtC0zTvFl7p17CmrJKoMbTQiTYQST1z6V6cunW6yQv5Q/cjbGgHyoPQDoMUAc9pXh23XUV1bUFjiSFQlrBjakS9ic9+Aa8y+PGs6ZHIq20kXmIMySA7gfbIruvi74j0/TNClsZ5mN5OPljR8EDHf0618W+PPEZupmsLV2MKHMjM24k+mfxoA53xLqj6lqDPkiIHAFZQAbBBP0o689MHIpwbv0JoAZznbuNA4Ix16UuBg5PNCnOfWgBSduBnrQOT057U3pwwz707GOlAFyyDeU2SPvUUtkoMRznO6igCpKSZmxjbuPNN9l5z1p02fPk9Mnj8ajA7EAD0oAceOMcetLE5jkWRSRsIYY9qQZHcBfSgEE57HqKAPbPCF+kaWepBi1tMvlXEI79B/Q19VfDCa1fw7FFbTh41bcidCmSTj9a+F/AepmCWSylJ8qQ5X6/5NfRPw+1m8udT0HSYp2htfPDs6n5sgkY/WgD274g6mmi+GrrUftX2aWEbkbg7j6Yrzfxh4duL3w5ukuA81+PM2dOfXp7V0WqTf8JF4/8A7GvbG3u9KtVBJyG545PPvR8apm0vQbfUIDslt2+RgOBwRj9aAPPf2e9TuNK8T3miX7bTIMICeuMnj8q+jV6c8V8Ir4tm0fxtaa3dlmmDAs2Dt5zn+dfZ/g7xRp3inR7e9066ilLoC6qeVOORigDfPtXFeOvD1vrxkjgnCamiZRWGR0+n0rtGIA3HAA7msfXNd03RbF7+8lAQcEqMn9PpQB81eN/CmraE1tNqNuqh22B15B+v5V87a9byQ63dRSgh2bj8q+6h4p0Xx7PJpMLEQ7S5NxE23d0GDgepr5x+JHgkxalc2t1D9mv1bMMnQOPr070AeRJu04rNHkTDqa37LxXcROvmqDnqR3qHXPD91p1igk5duSRzXOpkuEKkt0AoA9P07xhayTom7ykbg59a6S6uoI0jeaVijcg8YNeJwWcpJBB3bsj25rY8SX9xNaWttvfbAo798D/CgDvr/wAR2SB0yoAGMZ61zdz4wt4CY4YWdD1B/wD11wYd5XA+Zj6AUEMG+b5cdfagD0mC4t/EXhy5t9OzFcDnZ61599iuBP5CRb5EOGBrpvh/vgmlnC4yMc1k+Jr5m1SRbbMX94qetAE0egtDbfbr5kjt1GAoPJP+TWXHqk1vKDY/uVz/AN9Co7a+miHlOzPG33lJz+NLLa4iE0GZoW7jqv4UAbG5Net2VEC3yDOPWqGk6XN/aKGZCgiO5ie5BpdDt5lv45gGiiXks3y5/Ou20ezfU753itnlReshHyigDpvhoZjJNNazPCEbMiucKwFaGrD/AISfW1/enejjYWbCJXFeIdSm0yLyoiEA4IXvXCXmsX142Tcsig5AU9KAPuGf4c3erQWd0NXktJfKCMLfBVuvqK0NE+Hk2h2c81hfJJq3/LKWYZQDjqMfXtXA/srfEPUvElhd6HqxMz2CboZznlcgYY+uSa9e1LWbSWxvrS01SAX4TeGdwFQ56Anp09aAHadfx6bbxReILqwXVto8wwg4b3BwD60/xd4osfDWif2jcsWDLmGNernt/Svmvxf4iuTPFaXNozXiyhpLvqJCCDkHv0rlfjD8SrrVVsbSF8PbwiMEHpwAT+lAFD4qfEObVdTuZYz/AKTNkc/wDsK8kcliTIdxY5PuadI5kdpJDl2OSx70zHzZz+VAA2GINGTzheBTXPyr1ODTh+hPNACEc+lB7kdad16VGyjr27igB+eOaM4Oc035Rzn5fSnDgZFAF+xJ8o/71FR2Tfum4/iooArz5Mr567jTAMjOOfWnTHM7jH8Rpu7DYFAClWIGAD60mO44NORhzuODTQ3zGgDW8My+XqMbY+YsOD9a+gvhlbX15cnULNWijh+XzCM4Pt+VfOGnSf6QpU4INe+/Cz4iz+E9DubW3t4p552GzzBwnXmgD3j4eaZJDqt9JaF4lb/XzyDe0p44Geg/wrj/AI5eI4LgR6XBeg4b97bvgknnpz9K6nwnK8oi0/WdQV5rxfNSe34XOcbeg/yK8j8feHTZfEJrN5DKZjlHc84/yKAPKPF1nJJuaH8mHFQeB/GmveBr6C4sboRw5G+M8qR34r1PxJ4fgtYWh3LNcj/WAfwivNdV0W3nnYAHAGBQB9HeHvjMfGUdrpmkLHFfT4WSWUgAZ4OB+dc/8YdSvPAFzp5v7tdZgus+dbbdgj6fX1NfN/8AYl7aXRkspJECcqQxX+VXJrHxLfWxin8y5SQZ/eOW/U0Ae8eFPH1jpzLfabaweUxBktZgMkd9pIr0XxTp1r4xNpc6nG2m2bplbm4TGw+gzj371418EPB39oiCz18oYpJQEUNhxyRXsnxH8VaTcXreEDKILmFVYtKMKwwOAR9RQBxGvfC8zWcr+GdVtNfES5kh3AOo9gC2a8Xu/C8f9oyMImguYhhoZBtKt9K9Xa2bQ53vVnEDRDcGikOCc+nevYvDmnaZ4/8ADVlf+JPD3lzuoJaT5PM4+8Nh6fWgD4evdSFtdus1mdyNgndjP6VLe6tp4jilitmM7jlW5r628ZfArRLyC5udMn+xMoLiKUZiUDk5OC3Svk/xOdLt9Tu7CRVkFtI0Qnt87Tg4yM9uKAMRNTeKXzYLaFWznBAP9K0rOSw1kmG4g+z3bf3ejVUtbDTrn/j31Dym9JByf0rSsPDksd0txNMjxr0KZ/woA3LdPskEcaoFjX5SQMZ/GuF1uJ7fVZhMME8jJr0AbjHgMDatwc9Qap3Fut/ZlZo438k/I2Dn8fzoA4O3t5rpttrFJIw+9sXOPrXUeHrKa0t5fNjSRm52qc4r0D4c6d4Ym1Jo/Fk01rBtDRJABtfnox6/lXtPjvwr4LX4dTX+jaYkG4AxSxuzbeR15PagD5tVLUxhp1dpOgU/dH4V13gnVBbQXFsfKWAqSckA9648xJMu2zRpJGOGc9FFbui+Gb68tJfsELBMENOxIB9cUAct4vWTVXmezA8uNiOvX3rm7Tw9f3cyRxREM/QDqfwr3jSfB8+oeGZbPT9ElmMTbp9SuGCxx9emDk9fTtXZeCtMsNF8OzPbR2xmY4kvpckL7KPw9KAG/A3w1J4L8LX1xc21xvu1w06KflHHf8K5XUrfS9Ovbu41G+udR+0/6m1t3KlT2LEH9Kd4j8c3sljNpGk3TR6eDma6cAA/T9O1eSa14ujtomtNFLMzcPO/O76UAdD4s8TtYWaW88wmuYxtihU58odOT615Rczy3MzyzsWdySabJM0kzPIxkcnkk8mh+W4GM0AJgDJOMU0AHvxTmGBjpimLt24JoAfwMY5pAM7s+vFJgA49BmlUhs4PNABmmkAnI4H86U4+73oA46ZA4oACo9ABS8BccCjbnr0p23PK4IFAFqyz5TcD73r7UUtluMTdPvUUAVZAPOk/3jTCOOKdMxEsg4GGPNM3c+1ACAKfvCnngYTikBB5FA9wMfWgBY2KEEHoa7vwrq32aUNsV1YYIftXBOASADxV/TLwwyhXbKg0AfSWg+I1TRVW5tmutP3YYqeYfcen/wBeu81uTw5daVp82tanFdCIf6NJDzIOvDHn1PpXgfg/XZLaOSKMhoJlw8Z5BHHavT9H0Lwj4r0eOz0vVv7H1CM5MNwARI3tlv5DtQB0Vn8NdR1W2vby6McUcq77dgwYke+DXj/iK2uNF1E2FwY3ZeAQw5r6X0uTXfDWhwaZqscVyjIYkuI5OV4wMjH9a898I6R4Uu/EF/pfi64trjU1kPkytNtLgkjA9+KAPL7WwubqIJFY3LvjOI4mYH6ECo003xCHeG10rVEI5+a1kx/KvbdN1F/A3jF9CtrB7rTrlgYWbiRMnop5LdRjmvW5NVsbaW1t7q6jt7m4H7qGV8O/TjB6nkUAfK3hHQfFceqxXsek3McsTbi7IU6fWvdtT8Iab4t0yJ9e0JWuXj+a83qJVPTjPNegIyyIHR9y56g1z93od7Ffz3ul6jMssn/LCUlo8ccAE4HT0oA870P4N6Ba6pGb+91C9iU/uoJFPl5/2vlxivYoIkghWKFQiIMKoGABToyxRRKAHI5UHNOXge1AHP69o17eW9wlpqEqrOGWSKX5lIIwVHTHpXi1/wDs7waiwZJobBC+Wh2bs89QQa+ieOlYet6deXGq6ffW13IkNru8yFc4kBx+ZGD+dAHzZrf7NmpRXwGlyw3MBH38hMH6E1Jovwy+IGgt9mbRrDVbOQ4xLMnyj/vrivoLV7/7PdRapA12iR5SWBlO1lOOcZwCMfrVPVNe0fXLVrRNVl0y525Rmk8o5/A80AeN3vw7mtbeVrzw1cwzY3bLadGX9AaxvC1todjJqFprVpcxySjaFuImBQ8eo9q9A026vbDxdapqWt3UUL/LHcNMzwnnuCcV3uuvbahaXX9n2+nXOoQpk3NxboVY+xIOaAPm3R9Ais9fj+03UU9gj5ETkASL6EV6l4V8QaRaatqWlWGgImmXKbjZqysgPzHPHAHT8q83u9Q1pb6S81OLRkmjkx5bRJGPwG33qW81HXJX84XOk2VrcfeezC+ZjuMgA96ANGQeErbxFcxaiZjCZC6afpkRYRnJ4YgMOOPyr0/SfEfgI6c9o80yrsA8q5iYNHx0XKjmvN7XxP4V0vR2gtLmK0vwPnk+zo8kp7ncTnn+tcld6sJ7iK9s7UySxPuE1yv7vrnJzkUAeo+KvGVneaXLolvdT6VoKAhriaJhJcg9VVcA45PY9BXl/jDxgLnSoo7oR2mm2/yw268PL15I6+vaub8Z+PEnuTPdTJqWpKu2NVQLDDx2AyOw7V5jqeoXWp3Dz3kpklPb0+g7UAX/ABB4iudXk8vPlWi/cjXpWIPvDbjHfFCqcZJwaVR36D2oAU4/Gk6980EAd8U0YwSvX1FACt27c0hyAxzTh0+brSsoxjtQAwDgHPNO49M0AKMmjOD14oAa23vSgjuetLkMPajjGcUAIwzwOlCALxmgY+9mkJ5HQZ6UAW7QEox/2v6CipLEfuj0+9/SigCrKT50uV/iNMHI5FOlz50g6ncaaM9eMGgA56Y4pCQBg96Qk7xzxRk5weaAHcAbR1I4pFAX+tOIwPlP1pufXkUAaWmatcWB3RsCPQ12Wi+MdPcR/a0kjlU5DjjBrzvAzyOe1L1+71oA+k7j4i3+vaVDaJqSyCL7jdGH6V1+ieN9El0iytvGmgm4ubQqIrmDA3kY+YkMDnj6V8fRSOjfIxXHcGte08TatajEV5KVHGCxxQB9n23j7T5tSEkc1mwQfuEuVbdGvpkD6d621+IHhu9120i1C3ZLqIZS5b7ik46c59O3avi208e6jEEFxFDOAc8jH9a1V+IqPu8+w5x1Q4xQB9tLZ2l9HcXPhnUBb3LfekBJUk9Mhs/oKowTa7bzQZ1NL+ZWxJBGoAbr3wK+WNH+L0NrEI1a6jXHPz5/pW9a/G6GKLZFNNEp6vESrUAe+XHxDurW+mtLvR5YJUHAbHP601PEHjDC3FloSXNpJyFDjd/6FXz7qHxWtdSvI7i71S6do12LvJJA/L3qGz+K8emQslr4i1ZYycmNJCAp/KgD6Hfxrr9vNFaS6VbrqEvK27sd36HH61R1Lx74msneG60jT7a5UfKkkjEtn0wTXzvqPxYtbm+ivGmu5LmL7s7Pl/5Vi6h8TI7u4e4kjuJpyc+a75P8qAPYte8X+IrxpX1K6WBT0hQLgfpXA3uqXMzuPtuWP3t2OPyFefah48uLoMPLJB7ucmucuNaurgsPug+lAHr2/U7qGO3bUbdIVOVLueK0YvEOqWEflyeJ1iEZyuwKf5rXgDM8h+d3J+vFM2qrYI5oA9p8TeMrbVyTreum5ZRgeXEqk/korkG8SaJbMPLt7y4PYs2B+hriNqjpTeuSRQB2snjgRRuLHS7aLPG+TJP8zXPajrup34P2i6bYf4FwB+lZwwQKYEOTnmgAxx3HvRyeO47ikHHAFKcD8aAEyccc0K+VwetLkg+1IxU9R0oAXtQDxxxSABueRRypwBQA5sH6+tIX2/Ljn1oxzS9+BQA3tuJ6049eOlN3HODxRk5OBQApGRjpSAHA29OlOIJYY6U1stwO1ACr1IxSFCOOopTjIyetKPTtQBcsNwhIVcjdRRZA+U2H/iooAqy8TN2JY0zIzjNTXEbmVsxtnce1RiKQn/Vtx7UAM53cGg5UepqQRS5PyN+VKYn6rGxP0oAjQgDJ6+lIRzwQBUnkSHkxtn6GkEcn/PN/yoAaNxXoCaBuXt9TUjRSH+FwPpSLFKeGRvyoAjZlB6U7vx1IpzRS5wEb8qPLdeqvz320ARseQDjjvTh1yD+FKYJMj92ze+KcYX7I/wCRoAZx1wKQjA+XAqQxOBjY2T7GjyX24Mbn8KAIgGycAfjTsYH3R705Y5iCWib8qRUc/wADfTFAEQA/hIyafnaOCMjrUhgkyMRn8jSGCTr5TZ+lADFIY5HNJnJ5BxUhik4PlsPUYoMT/wDPN/yoAjwSOMj8ad0HPNAhmzwjY+lKYpME7GJ+lACck5prd/epBHIw4jbP0o8uRjgo4x7UANX5VFIxLAkcVIYpMfcb8qaY5NnCsT9KAIw2DycjvTvlI55pzJJjmJ8fSlSN+yNj6UARnBUc4NGAG+Y4p/kSOOY2B+lHkODyjk/SgBpxkcnHtRgHpTlhkAwUb16UuxzwqN+RoAjOf4aUZJ4NSCJx/wAs3/KmhH34KMD9KAGgc8nig4Vh1qURSd0b8qZslz9xvb5aAGlwB97NKMk8AY+tO8qQn7hA7/Kab5ciuf3bY+lACMM8YpOhAFSGNzyY2/KjypCfuN+VAFqyjHlNx/F60VJZRP5TfI/3vT2FFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This T1- weighted, axial magnetic resonance image of the wrist shows a curvilinear region of increased signal (arrow) traversing the lunate that represents a fracture. The decreased signal intensity throughout the lunate, when compared to the subcutaneous fat or adjacent navicular bone, is consistent with post-traumatic osteonecrosis of the lunate (Kienbock's disease).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1376=[""].join("\n");
var outline_f1_22_1376=null;
var title_f1_22_1377="IVP distal ureteral tumor";
var content_f1_22_1377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    IVP findings with ureteral tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intravenous pyelogram (IVP) demonstrating a distal left ureteral tumor, causing stenosis (arrows) and mild ureteral obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Machele Donat, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1377=[""].join("\n");
var outline_f1_22_1377=null;
var title_f1_22_1378="Patient information: Long-acting methods of birth control (The Basics)";
var content_f1_22_1378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/56/14211\">",
"         Patient information: Choosing birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/28/12738\">",
"         Patient information: Emergency contraception (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/17/18707\">",
"         Patient information: Hormonal birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/17/37138\">",
"         Patient information: Intrauterine devices (IUD) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/51/23346\">",
"         Patient information: Sterilization for women (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?8/60/9157\">",
"         Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/16/4355\">",
"         Patient information: Long-term methods of birth control (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Long-acting methods of birth control (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H102130751\">",
"      <span class=\"h1\">",
"       What are long-acting methods of birth control?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Long-acting methods of birth control are devices or treatments that prevent pregnancy for months to years.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102130766\">",
"      <span class=\"h1\">",
"       What are the different types of long-acting methods of birth control?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Long-acting birth control methods include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Intrauterine devices (IUDs) &ndash; These are small, T-shaped devices made of flexible plastic that a doctor or nurse puts through your vagina and cervix into your uterus. There are 3 different IUDs, called Paragard, Mirena, and Skyla.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Paragard releases copper. It can stay in place and keeps working for up to 10 years.",
"       </li>",
"       <li>",
"        Mirena and Skyla both release the hormone progestin. They can stay in place and keep working for 3 to 5 years.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Birth control implant &ndash; This is a flexible plastic rod that is 1.5 inches long and about twice as thick as a pencil lead. A nurse or doctor injects the implant under the skin on the inside of a woman&rsquo;s upper arm. It contains a hormone called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?34/54/35684?source=see_link\">",
"         etonogestrel",
"        </a>",
"        that is slowly released into the body. The implant, called Nexplanon, lasts for 3 years.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102130781\">",
"      <span class=\"h1\">",
"       How well do long-term methods of birth control work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Long-term birth control methods work very well. Fewer than 1 in 100 women who have an IUD or birth control implant get pregnant during the first year of use.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102130798\">",
"      <span class=\"h1\">",
"       What are the benefits and downsides of long-term methods of birth control?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main benefit of long-term birth control is that you do not have to remember to do anything or take any medicines on a regular basis.",
"     </p>",
"     <p>",
"      The main downside of these methods is that unlike condoms, they do not protect against infections you can catch during sex (called &ldquo;sexually transmitted diseases&rdquo; or &ldquo;STDs&rdquo;).",
"     </p>",
"     <p>",
"      Because of the cost of putting in an IUD or implant, those choices are best for women who do not want to become pregnant for at least 1 year. A doctor or nurse needs to remove the IUD or implant when you don&rsquo;t want to use it anymore.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102130815\">",
"      <span class=\"h1\">",
"       What if I change my mind and want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have an IUD or birth control implant, you can have the device removed. You will likely be able to get pregnant right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102130832\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=see_link\">",
"       Patient information: Choosing birth control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/28/12738?source=see_link\">",
"       Patient information: Emergency contraception (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/51/23346?source=see_link\">",
"       Patient information: Sterilization for women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18707?source=see_link\">",
"       Patient information: Hormonal birth control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/17/37138?source=see_link\">",
"       Patient information: Intrauterine devices (IUD) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"       Patient information: Long-term methods of birth control (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"       Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/22/1378?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86385 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1378=[""].join("\n");
var outline_f1_22_1378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102130751\">",
"      What are long-acting methods of birth control?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102130766\">",
"      What are the different types of long-acting methods of birth control?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102130781\">",
"      How well do long-term methods of birth control work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102130798\">",
"      What are the benefits and downsides of long-term methods of birth control?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102130815\">",
"      What if I change my mind and want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102130832\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=related_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/28/12738?source=related_link\">",
"      Patient information: Emergency contraception (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18707?source=related_link\">",
"      Patient information: Hormonal birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/17/37138?source=related_link\">",
"      Patient information: Intrauterine devices (IUD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=related_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/51/23346?source=related_link\">",
"      Patient information: Sterilization for women (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_22_1379="Potassium gluconate: Pediatric drug information";
var content_f1_22_1379=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium gluconate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20515?source=see_link\">",
"    see \"Potassium gluconate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/41/11924?source=see_link\">",
"    see \"Potassium gluconate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1032348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1032373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20515?source=see_link\">",
"      see \"Potassium gluconate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Doses listed as mEq of potassium (approximately 4.3 mEq potassium/g potassium gluconate; 1 mEq potassium is equivalent to 39 mg elemental potassium)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Normal daily requirement:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-3 mEq/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 40-80 mEq/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of hypokalemia during diuretic therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1-2 mEq/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 20-40 mEq/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of hypokalemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-5 mEq/kg/day in divided doses; not to exceed 1-2 mEq/kg as a single dose; if deficits are severe or ongoing losses are great, I.V. route should be considered preferred route of administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 40-100 mEq/day in 2-4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral: 595 mg [equivalent to potassium 99 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [strength expressed as base]: 99 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 550 mg [equivalent to potassium 90 mg], 595 mg [equivalent to potassium 99 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [strength expressed as base]: 99 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, timed release, oral [strength expressed as base]: 95 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4603922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Sustained release and wax matrix tablets should be swallowed whole, do not crush or chew;  administer with food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1032366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1032349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment or prevention of hypokalemia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1032351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the potassium supplement; severe renal impairment, untreated Addison's disease, heat cramps, hyperkalemia, severe tissue trauma; solid oral dosage forms are contraindicated in patients in whom there is a structural, pathological, and/or pharmacologic cause for delay or arrest in passage through the GI tract",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4603517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiac and/or renal disease, patients receiving potassium-sparing drugs",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13892561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium requirements are the same in pregnant and non-pregnant women. Adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, pre-eclampsia; may be more likely to develop hyperkalemia) (IOM, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1032377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, chloride, glucose, pH, urine output (if indicated)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1032368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium is the major cation of intracellular fluid and is essential for the conduction of nerve impulses in heart, brain, and skeletal muscle; contraction of cardiac, skeletal, and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism, and gastric secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1032369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from upper GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Enters cells via active transport from extracellular fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily urine; skin and feces (small amounts); most intestinal potassium reabsorbed",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1032381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     9.4 g potassium gluconate is approximately equal to 40 mEq potassium (4.3 mEq potassium/g potassium gluconate). Hypokalemia is highly arrhythmogenic, particularly in the setting of ischemia or digitalis toxicity. ECG evidence of hypokalemia includes flattening of the T wave. As the T wave shrinks, U waves may appear. There is no prolongation of the QT interval. Hyperkalemia may present as tall peaked symmetrical T waves. S-T elevation may present in severe hyperkalemia. QRS complex progressively widens with eventual apparent sine waves on the ECG. Hyperkalemia will also induce cardiac slowing and AV conduction abnormalities.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13038 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1379=[""].join("\n");
var outline_f1_22_1379=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032348\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032373\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211910\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211894\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4603922\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032366\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032349\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032351\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4603517\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299921\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211903\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13892561\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032377\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032368\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032369\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032381\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13038\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13038|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20515?source=related_link\">",
"      Potassium gluconate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/41/11924?source=related_link\">",
"      Potassium gluconate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_22_1380="Urethral caruncle";
var content_f1_22_1380=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urethral caruncle",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/22/1380/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1380/contributors\">",
"     Leslie M Rickey, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/22/1380/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1380/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1380/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1380/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/22/1380/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1380/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/22/1380/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethral caruncles are benign fleshy outgrowths at the urethral meatus. They are the most common lesion of the female urethra, occurring primarily in postmenopausal women, with occasional occurrences in premenopausal women and prepubertal girls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Urethral caruncles are quite rare in males [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethral caruncles are generally thought to result from prolapse of a distal segment of the urethral mucosa, most commonly the posterior lip of the urethral meatus. Their pathogenesis is not well understood, but caruncles are thought to be associated with estrogen deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, urethral caruncles contain a core of blood vessels and loose connective tissue covered by hyperplastic transitional or squamous epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. A dense inflammatory infiltrate is usually present and results from chronic irritation of the prolapsed segment of mucosa. The lesions have been subclassified as granulomatous, papillomatous, or angiomatous [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethral caruncles can be an incidental finding during the genital examination of asymptomatic women. In one study, an asymptomatic urethral caruncle was noted in 50 of 850 women who presented with urinary incontinence; all of the caruncles were &lt;1 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic women may present when they discover a lump at the urethral meatus or because of symptoms such as light bleeding, dysuria, pain, or obstruction to urine flow. Microscopic hematuria and postmenopausal bleeding are other presentations. Bleeding may be associated with urination or it may be noted on toilet paper, feminine hygiene pads, or underclothes. In a review of 394 women presenting with urethral lesions, bleeding was the most common complaint [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/9\">",
"     9",
"    </a>",
"    ]. Urinary obstruction was more common in women with a malignant urethral neoplasm than in those with a caruncle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of urethral caruncle is based on characteristic findings on physical examination. The caruncle appears as a soft pink or red sessile or pedunculated lesion protruding from a segment of the urethral meatus (",
"    <a class=\"graphic graphic_picture graphicRef80179 \" href=\"UTD.htm?10/32/10753\">",
"     picture 1",
"    </a>",
"    ). The exophytic mass is covered by epithelium and is usually &lt;1 to 2 cm in size. It may be friable, ulcerated, velvety, or hemorrhagic.",
"   </p>",
"   <p>",
"    When the mucosa is circumferentially everted at the meatus, the lesion is referred to as a urethral prolapse, whereas a urethral caruncle generally involves eversion of only a portion of the distal urethra, often at the posterior edge. However, these terms and the term urethral polyp are sometimes used interchangeably.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding from the caruncle may be attributed to postmenopausal bleeding related to vaginal atrophy or cervical, ovarian, or uterine pathology. Even when a urethral caruncle is identified, it is important to exclude potentially malignant causes of postmenopausal bleeding. Similarly, although a caruncle may cause microscopic or gross hematuria, malignancy of the kidneys and urinary tract must be ruled out in patients with hematuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"     \"Postmenopausal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transitional cell carcinoma, sarcoma, lymphoma, and melanoma should be considered in the differential diagnosis of a urethral neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. In one of the largest series of urethral neoplasms, 9 of 394 (2.4 percent) excised urethral lesions thought to be benign caruncles were found to be malignant after histopathological examination [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/9\">",
"     9",
"    </a>",
"    ]. Metastatic disease to the urethra is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports have described unusual presentations of tuberculosis and intestinal ectopia mimicking urethral caruncles [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Urethral condyloma should also be considered.",
"   </p>",
"   <p>",
"    Urethral varices at the meatus can mimic a caruncle. Varices may cause hematuria and may prolapse or thrombose (\"urethral hemorrhoid\") [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urethra should be palpated to assess for induration (suggestive of malignancy) or the presence of additional lesions not visible externally. Biopsy of the urethral mass is not required for diagnosis, but is indicated if the mass is irregular, firm, or has other characteristics suspicious for malignancy (eg, induration, local extension, inguinal adenopathy, increasing size, failure to respond to topical estrogen cream).",
"   </p>",
"   <p>",
"    Urinary tract infection should be excluded in patients with dysuria.",
"   </p>",
"   <p>",
"    Cystourethroscopy is indicated in all adult patients with unexplained hematuria. The evaluation of hematuria is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .) Cystourethroscopy is also indicated for further evaluation of the urethra if palpation reveals abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of their low prevalence, there are no large studies or randomized trials evaluating treatment strategies for management of urethral caruncles. In an asymptomatic patient with a benign appearing caruncle, no treatment is necessary.",
"   </p>",
"   <p>",
"    For first-line treatment of symptomatic patients, we suggest use of a topical estrogen cream for two to three months, accompanied by warm sitz baths and topical anti-inflammatory drugs, as needed. The patient should apply a fingertip amount (ie, about 0.3 mg) of estrogen cream to the caruncle once daily for two weeks and then twice per week for two to three months. A progestin is probably not necessary to protect against endometrial hyperplasia in women receiving daily local low dose estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/19\">",
"     19",
"    </a>",
"    ]. In a woman with a history of breast cancer, consultation with her oncologist is recommended before starting any estrogen therapy.",
"   </p>",
"   <p>",
"    If there is symptomatic recurrence, options include excision or repeat use of topical estrogen. Maintenance therapy with twice weekly estrogen cream may prevent further recurrence.",
"   </p>",
"   <p>",
"    If the caruncle is particularly large and symptomatic, symptoms do not resolve with conservative therapy, or the diagnosis is uncertain, then biopsy and surgical excision under local or regional anesthesia are recommended. The procedure is performed by grasping the polyp with an Allis clamp and sharply excising it at the base. If the resulting mucosal defect is small, the edges can be reapproximated with a small (eg, 3-0 or 4-0) synthetic absorbable monofilament suture. If the defect is large, the edge of the urethral mucosa is everted onto the adjacent vaginal epithelium to minimize the risk of meatal stenosis, which is the major complication of this procedure. A foley catheter is usually left in place for several days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on treatment outcomes are sparse. A review of 46 girls aged 1.5 to 10 years treated for urethral prolapse found that medical treatment was successful in 11 of 15 (73 percent) girls treated with a topical steroid cream [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1380/abstract/20\">",
"     20",
"    </a>",
"    ]. Repeated medical treatment was successful in two of four recurrences, while the other two patients went on to surgical excision. Of the 33 patients treated with surgical excision, 1 developed urethral stenosis, 1 developed symptoms of dysuria and the remaining 31 patients had \"very good\" results.",
"   </p>",
"   <p>",
"    There are no published reports of outcomes of estrogen treatment of urethral caruncle in menopausal women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urethral caruncles are benign fleshy outgrowths at the urethral meatus. They are the most common lesion of the female urethra, and occur primarily in postmenopausal women. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urethral caruncles are thought to result from prolapse of a distal segment of urethral mucosa. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urethral caruncles can be an incidental finding during examination of asymptomatic women. Symptomatic women may present when they discover a lump at the urethral meatus or because of symptoms such as light bleeding, dysuria, pain, or obstruction to urine flow. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of urethral caruncle is based on characteristic findings on physical examination. The caruncle appears as a soft pink or red sessile or pedunculated lesion protruding from a segment of the urethral meatus (",
"      <a class=\"graphic graphic_picture graphicRef80179 \" href=\"UTD.htm?10/32/10753\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In postmenopausal women with urogenital bleeding, the observation of a urethral caruncle should not preclude or delay evaluation for other causes of bleeding, such as endometrial cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"       \"Postmenopausal uterine bleeding\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Differential diagnosis includes transitional cell carcinoma, sarcoma, lymphoma, and melanoma. Bleeding may be related to vaginal, cervical, or uterine causes of postmenopausal bleeding. Dysuria and hematuria may be related to bladder pathology. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsy of the urethral mass is indicated if the diagnosis is uncertain. Cystourethroscopy is indicated in all adult patients with unexplained hematuria. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For first-line treatment of symptomatic",
"      <span class=\"nowrap\">",
"       perimenopausal/menopausal",
"      </span>",
"      women, we suggest use of a topical estrogen cream (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with a large symptomatic caruncle, symptoms that do not resolve with conservative therapy, or an uncertain diagnosis, we suggest biopsy and surgical excision (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/1\">",
"      Karthikeyan K, Kaviarasan PK, Thappa DM. Urethral caruncle in a male: a case report. J Eur Acad Dermatol Venereol 2002; 16:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/2\">",
"      T&uuml;rkeri L, Simek F, Akda A. Urethral caruncle in an unusual location occurring in prepubertal girl. Eur Urol 1989; 16:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/3\">",
"      Kim KK, Sin DY, Park HW. Urethral caruncle occurring in a young girl--a case report. J Korean Med Sci 1993; 8:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/4\">",
"      Sriprasad S, Kooiman GG, Hopster D, Muir GH. Urethral caruncle in a man. BJU Int 2003; 92 Suppl 3:e68.",
"     </a>",
"    </li>",
"    <li>",
"     Kaufman RH. Benign diseases of the vulva and vagina, 4th ed, Mosby, St Louis 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/6\">",
"      PALMER JK, EMMETT JL, McDONALD JR. Urethral caruncle. Surg Gynecol Obstet 1948; 87:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/7\">",
"      Becker LE. Urethral caruncle: a herald lesion for distal urethral stenosis? J Natl Med Assoc 1975; 67:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/8\">",
"      Ozkurkcugil C, Ozkan L, Tarcan T. The effect of asymptomatic urethral caruncle on micturition in women with urinary incontinence. Korean J Urol 2010; 51:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/9\">",
"      MARSHALL FC, USON AC, MELICOW MM. Neoplasma and caruncles of the female urethra. Surg Gynecol Obstet 1960; 110:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/10\">",
"      Cimentepe E, Bayrak O, Unsal A, et al. Urethral adenocarcinoma mimicking urethral caruncle. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/11\">",
"      Atalay AC, Karaman MI, Basak T, et al. Non-Hodgkin's lymphoma of the female urethra presenting as a caruncle. Int Urol Nephrol 1998; 30:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/12\">",
"      Nakamoto T, Inoue Y, Ueki T, et al. Primary amelanotic malignant melanoma of the female urethra. Int J Urol 2007; 14:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/13\">",
"      Omar A, Thomas A, Thompson I. Primary urethral transitional cell carcinoma presenting as a urethral caruncle. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/14\">",
"      Khatib RA, Khalil AM, Tawil AN, et al. Non-Hodgkin's lymphoma presenting as a urethral caruncle. Gynecol Oncol 1993; 50:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/15\">",
"      Hammadeh MY, Thomas K, Philp T. Urethral caruncle: an unusual presentation of ovarian tumour. Gynecol Obstet Invest 1996; 42:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/16\">",
"      Singh I, Hemal AK. Primary urethral tuberculosis masquerading as a urethral caruncle: a diagnostic curiosity! Int Urol Nephrol 2002; 34:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/17\">",
"      J&auml;rvi OH, Marin S. Intestinal mucosal heterotopia of an urethral caruncle. Acta Pathol Microbiol Immunol Scand A 1982; 90:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/18\">",
"      Arnold SJ, Goode R, Ginsburg A. Photostudies of urethral varices \"hemorrhoids\": a forgotten lesion. Urology 1978; 11:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/19\">",
"      North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007; 14:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1380/abstract/20\">",
"      Rudin JE, Geldt VG, Alecseev EB. Prolapse of urethral mucosa in white female children: experience with 58 cases. J Pediatr Surg 1997; 32:423.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5430 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.232-947418B5B9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1380=[""].join("\n");
var outline_f1_22_1380=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5430\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5430|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/32/10753\" title=\"picture 1\">",
"      Urethral caruncle",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_22_1381="Acamprosate: Drug information";
var content_f1_22_1381=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acamprosate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/11/10420?source=see_link\">",
"    see \"Acamprosate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Campral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Campral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      GABA Agonist/Glutamate Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alcohol abstinence: Oral: 666 mg 3 times/day (a lower dose may be effective in some patients).",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should be initiated as soon as possible following the period of alcohol withdrawal, when the patient has achieved abstinence and should be maintained if patient relapses.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F129075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: 333 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Contraindicated in severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13244449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, enteric coated, oral, as calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Campral&reg;: 333 mg [contains calcium 33 mg/tablet, sulfites]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F129053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals (administered with meals during clinical trials to possibly increase compliance). Tablet should be swallowed whole; do not crush or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance of alcohol abstinence",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Many adverse effects associated with treatment may be related to alcohol abstinence; reported frequency range may overlap with placebo.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Diarrhea (10% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema (peripheral), hypertension, palpitation, syncope, vasodilatation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (6% to 9%), anxiety (5% to 8%), depression (4% to 8%), dizziness (3% to 4%), pain (2% to 4%), paresthesia (2% to 3%), abnormal thinking, amnesia, chills, headache, somnolence, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (3% to 4%), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (2% to 5%), nausea (3% to 4%), flatulence (1% to 4%), xerostomia (1% to 3%), abdominal pain, appetite increased, constipation, dyspepsia, taste perversion, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (5% to 7%), arthralgia, back pain, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough increased, dyspnea, pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (2% to 3%), flu-like syndrome, infection, suicide attempt",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation, allergic reaction, alopecia, anemia, angina, AST/ALT increased, asthma, bilirubinemia, colitis, confusion, creatinine increased, deafness, diabetes mellitus, duodenal ulcer, encephalopathy, eosinophilia, epistaxis, exfoliative dermatitis, fever, gastrointestinal hemorrhage, gout, hallucinations, hemorrhage, hepatitis, hostility, hyperglycemia, hyperuricemia, hypesthesia, hyponatremia, hypotension,  hypothyroidism, leukopenia, liver cirrhosis, liver function tests abnormal, lymphadenopathy, lymphocytosis, MI, neuralgia, neurosis, ophthalmitis, orthostatic hypotension, pancreatitis, photosensitivity, pneumonia, psychosis, pulmonary embolus, rectal hemorrhage, renal calculus, renal failure, seizure, suicidal ideation, suicide completion, tachycardia, thrombocytopenia, urticaria, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F129056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acamprosate or any component of the formulation; severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F129039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation/attempt: Attempted and completed suicides have occurred in acamprosate-treated patients; use with caution in suicidal ideation. Monitor for depression and/or suicidal thinking.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alcohol dependence: Appropriate use: Should be used as part of a comprehensive program to treat alcohol dependence. Treatment should be initiated as soon as possible following the period of alcohol withdrawal, when the patient has achieved abstinence. Acamprosate does not eliminate or diminish the symptoms of alcohol withdrawal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute). Contraindicated in patients with severe renal impairment (Cll",
"     <sub>",
"      cr",
"     </sub>",
"     30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Traces of sulfites may be present in the formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Geriatrics: Use caution due to the age-related decrease in renal function.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F129068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Abstinence is required during treatment. Ethanol does not affect the pharmacokinetics of acamprosate; however, the continued use of ethanol will decrease desired efficacy of acamprosate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food decreases absorption of acamprosate (not clinically significant).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F129046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F129058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal studies. No adequate or well-controlled studies in pregnant women; use only if potential benefit outweighs possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F129078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F129059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Abstinence is required during treatment. May be taken without regard to meals. Each 333 mg tablet contains 33 mg of elemental calcium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F1793224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Campral Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     333 mg (180): $215.30",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F129060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acampral (KP);",
"     </li>",
"     <li>",
"      Acamprol (IN);",
"     </li>",
"     <li>",
"      Aotal (FR);",
"     </li>",
"     <li>",
"      Campral (AR, AT, AU, BE, BG, BR, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GR, HN, IE, IT, MT, MX, NL, NO, PL, PT, RU, SE, SG, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F129038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mechanism not fully defined. Structurally similar to gamma-amino butyric acid (GABA), acamprosate appears to increase the activity of the GABA-ergic system, and decreases activity of glutamate within the CNS, including a decrease in activity at N-methyl D-aspartate (NMDA) receptors; may also affect CNS calcium channels. Restores balance to GABA and glutamate activities which appear to be disrupted in alcohol dependence. During therapeutic use, reduces alcohol intake, but does not cause a disulfiram-like reaction following alcohol ingestion. Insignificant CNS activity, outside its effect on alcohol dependence, was observed including no anxiolytic, anticonvulsant, or antidepressant activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F129055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 11%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 20-33 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brasser SM, McCaul ME, and Houtsmuller EJ, &ldquo;Alcohol Effects During Acamprosate Treatment: A Dose-Response Study in Humans,&rdquo;",
"      <i>",
"       Alcohol Clin Exp Res",
"      </i>",
"      , 2004, 28(7):1074-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1381/abstract-text/15252294/pubmed\" id=\"15252294\" target=\"_blank\">",
"        15252294",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graham R, Wodak AD, and Whelan G, &ldquo;New Pharmacotherapies for Alcohol Dependence,&rdquo;",
"      <i>",
"       Med J Aust",
"      </i>",
"      , 2002, 177(2):103-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1381/abstract-text/12098353/pubmed\" id=\"12098353\" target=\"_blank\">",
"        12098353",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Overman GP, Teter CJ, and Guthrie SK, &ldquo;Acamprosate for the Adjunctive Treatment of Alcohol Dependence,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(7-8):1090-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1381/abstract-text/12841823/pubmed\" id=\"12841823\" target=\"_blank\">",
"        12841823",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9218 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1381=[""].join("\n");
var outline_f1_22_1381=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129071\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663219\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129085\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129073\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129074\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129075\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13244449\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129049\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129037\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129053\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129052\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129083\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129056\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129039\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298632\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129044\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129068\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129046\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129058\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129078\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129059\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1793224\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129060\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129038\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129055\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9218\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9218|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/11/10420?source=related_link\">",
"      Acamprosate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_22_1382="Evaluation of sleep-disordered breathing in patients with neuromuscular and chest wall disease";
var content_f1_22_1382=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of sleep-disordered breathing in patients with neuromuscular and chest wall disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/22/1382/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1382/contributors\">",
"     Naomi R Kramer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1382/contributors\">",
"     Richard P Millman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1382/contributors\">",
"     Nicholas S Hill, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/22/1382/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1382/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1382/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/22/1382/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1382/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/22/1382/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with neuromuscular or chest wall disease commonly have respiratory problems resulting from some combination of respiratory muscle dysfunction and decreased lung and chest wall compliance. These factors may contribute to difficulty with clearance of airway secretions, ventilation-perfusion mismatching, and eventually global alveolar hypoventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33896?source=see_link\">",
"     \"Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sleep disordered breathing is a significant cause of morbidity and mortality among patients with neuromuscular and chest wall disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. It is most often due to obstructive sleep apnea (OSA, a disorder characterized by obstructive apneas and hypopneas) or nocturnal hypoventilation, but central sleep apnea (CSA) can also be seen in patients with myotonic and muscular dystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19140?source=see_link\">",
"     \"Central sleep apnea: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR EVALUATION OF SLEEP DISORDERED BREATHING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of symptoms is the major factor favoring evaluation of the patient for OSA, CSA, or hypoventilation. However, some patients may have sleep disordered breathing without symptoms but with suggestive physiologic parameters, eg, severe restriction on pulmonary function tests or unexplained cor pulmonale. Such patients should be evaluated with an arterial blood gas and a sleep study.",
"   </p>",
"   <p>",
"    Classic symptoms of sleep disordered breathing include excessive daytime sleepiness, morning headache, and restless sleep, but insomnia may also be seen. In addition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients with OSA may awaken with choking or shortness of breath.",
"     </li>",
"     <li>",
"      Bed partners of patients with sleep apnea often describe snoring and apnea.",
"     </li>",
"     <li>",
"      Nightmares and enuresis are less commonly encountered symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even when pulmonary dysfunction is severe, dyspnea is often lacking in patients with neuromuscular disease, probably because exercise capacity is limited by involvement of nonrespiratory muscles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Specific diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of a particular disease may also be helpful in some cases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with polio who had initial involvement of respiratory, trunk, or bulbar muscles, particularly with associated scoliosis or vocal cord paralysis, are more likely than other polio patients to develop abnormalities of gas exchange during sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Kyphoscoliosis, even in the absence of neuromuscular disease, is associated with nocturnal hypoventilation and obstructive sleep apnea [",
"      <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Although daytime respiratory symptoms are more common when the angle of the thoracic spinal deformity approaches 100 degrees, nocturnal oxygen desaturation is not directly correlated with the degree of scoliosis or with either lung volumes or ventilatory responsiveness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=see_link&amp;anchor=H22#H22\">",
"       \"Diseases of the chest wall\", section on 'Kyphoscoliosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most severe oxygen desaturation is seen and should be suspected in those patients with cor pulmonale, polycythemia, and daytime systemic hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is desirable to detect nocturnal gas exchange abnormalities before secondary complications result [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/13\">",
"     13",
"    </a>",
"    ]. The clinician must therefore be alert to the presence of more subtle symptoms and signs to serve as a guide for the initiation of a sleep evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physiologic clues to sleep disordered breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain physiologic abnormalities may also suggest the presence of sleep disordered breathing. Patients with daytime hypoxemia and hypercarbia often have further deterioration of gas exchange in sleep. Therefore, patients with even mild abnormalities in daytime blood gases are at risk for significant disruption of nocturnal gas exchange.",
"   </p>",
"   <p>",
"    Patients with a maximal inspiratory pressure (PImax) below 50 percent of predicted, or a forced vital capacity (FVC) below 1 to 1.5 L due to amyotrophic lateral sclerosis (ALS) or other neuromuscular diseases, are more likely to have significant nocturnal desaturation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION FOR CONTRIBUTING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with concomitant airflow obstruction tend to have greater gas exchange abnormalities or cor pulmonale associated with their sleep disordered breathing than do patients with normal airway resistance. As a result, pulmonary function tests should be performed routinely for detection of coexistent airflow obstruction. Other treatable conditions that may contribute to sleep disordered breathing in patients with restrictive thoracic disease include hypothyroidism and hypophosphatemia.",
"   </p>",
"   <p>",
"    Impaired left ventricular function occurs in some patients with obstructive sleep apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/18\">",
"     18",
"    </a>",
"    ]. Heart failure, particularly if associated with Cheyne-Stokes respiration, contributes to nocturnal oxygen desaturation and sleep fragmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. It is therefore important to assess patients with neuromuscular and chest wall disorders for possible concomitant HF and, if present, to institute appropriate therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link\">",
"     \"Cardiovascular effects of obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential part of the assessment is to document abnormalities of oxygenation and sleep. Overnight oximetry, portable multi-channel devices (Edentrace II, Edentec Inc., Eden Prairie, MN; Nightwatch, Healthdyne, Inc., Marietta, GA), and full polysomnography in the sleep laboratory are all available, but the optimal test for screening patients with neuromuscular and chest wall disorders has not been established.",
"   </p>",
"   <p>",
"    The initial evaluation of patients suspected of having sleep disordered breathing can be performed by clinicians with experience in pulmonary and sleep medicine. However, if initial screening studies are equivocal or negative and if suspicion for sleep disordered breathing is high, the patients should be referred to a center experienced in the management of these patients, with an accredited sleep laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Polysomnography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polysomnography is currently considered the \"gold standard\" for assessing sleep disordered breathing (",
"    <a class=\"graphic graphic_table graphicRef79606 \" href=\"UTD.htm?20/44/21195\">",
"     table 1",
"    </a>",
"    ). False negative studies have been reported in patients with OSA, although it is not clear that this problem applies to patients with non-apneic sleep disordered breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/20\">",
"     20",
"    </a>",
"    ]. Polysomnography (PSG) typically includes two electroencephalogram leads, two electrooculogram leads, a submental electromyogram (EMG) lead, a",
"    <span class=\"nowrap\">",
"     nasal/oral",
"    </span>",
"    thermistor to assess air flow, a nasal pressure transducer, thoracic and abdominal monitors to detect excursion of the rib cage and abdomen, an intercostal EMG, a snoring microphone, ECG and leg leads, and pulse oximetry. Monitoring of multiple channels allows full assessment of possible sleep disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Oximetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overnight oximetry alone may be used to screen for oxygen desaturation associated with severe nocturnal hypoventilation. Oximetry may underestimate the degree of sleep apnea, however, depending upon the scoring criteria used [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. In addition, oximetry may have low sensitivity in detecting OSA in patients receiving supplemental oxygen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Portable devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portable devices with four or more channels (eg, heart rate, air flow, chest movement, and oximetry) are likely to detect moderate to severe OSA. However, the severity of sleep apnea may be underestimated, and mild disease may be missed entirely. In addition, sleep disruption or fragmentation, a significant factor in causing daytime sleepiness, is not assessed by oximetry or portable studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=see_link\">",
"     \"Quantifying sleepiness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, although oximetry and four-channel studies are adequate to document moderate or severe disease, they should not be used to exclude a diagnosis of sleep disordered breathing. If there is a strong clinical suspicion of sleep disordered breathing but oximetry or a four-channel study is negative, full polysomnography should still be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUPPLEMENTAL TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests that are more relevant for research purposes include assessment of respiratory control and intrathoracic pressure changes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory control can be evaluated by testing ventilatory responses to hypercarbia and hypoxia, but this is rarely performed in the clinical setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"       \"Control of ventilation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Esophageal pressure monitoring during sleep is helpful in distinguishing central versus obstructive apneas, because it offers a sensitive way of detecting intrathoracic pressure swings related to respiratory effort. Such monitoring is also particularly useful in detecting the upper airway resistance syndrome, characterized by subtle increases in respiratory effort that are not manifested by changes in air flow but are associated with arousal and sleep fragmentation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/24\">",
"       24",
"      </a>",
"      ]. Therefore, although esophageal balloons for pressure monitoring are not yet considered standard instrumentation during polysomnography, their clinical role is gradually increasing.",
"     </li>",
"     <li>",
"      End-tidal PCO",
"      <sub>",
"       2",
"      </sub>",
"      (PETCO",
"      <sub>",
"       2",
"      </sub>",
"      ) monitoring is also included in some polysomnograms, and is believed to be particularly useful in pediatric studies [",
"      <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"       \"Evaluation of suspected obstructive sleep apnea in children\"",
"      </a>",
"      .) However, one study found that PETCO",
"      <sub>",
"       2",
"      </sub>",
"      measured from exhaled gas in a mask, particularly during use of supplemental oxygen or positive airway pressure delivery systems that incorporate a flow-through to wash out dead space, did not adequately reflect arterial values in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/28\">",
"       28",
"      </a>",
"      ]. Transcutaneous CO",
"      <sub>",
"       2",
"      </sub>",
"      monitors were also found to poorly correlate with arterial CO",
"      <sub>",
"       2",
"      </sub>",
"      tensions [",
"      <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/28\">",
"       28",
"      </a>",
"      ]. For this reason, noninvasive CO",
"      <sub>",
"       2",
"      </sub>",
"      monitoring is not currently considered a routine part of sleep assessment in adults with neuromuscular and chest wall disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/27\">",
"       27",
"      </a>",
"      ]. If accurate assessment of CO",
"      <sub>",
"       2",
"      </sub>",
"      tension during sleep is desired, invasive blood gas monitoring using an arterial catheter is necessary.",
"     </li>",
"     <li>",
"      Inductance plethysmography may be useful in examining breathing patterns during sleep, particularly if patients develop asynchronous or paradoxical patterns. Detection of abdominal paradox may indicate diaphragm dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disordered breathing is common in patients with neuromuscular or chest wall disease and is a significant cause of morbidity and mortality. The detection and therapy of sleep disordered breathing have the potential to improve the quality and perhaps the duration of life in these patients. Indications for screening include symptoms of obstructive sleep apnea, abnormalities of gas exchange, or impairment of FVC or PImax. The assessment should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiologic measurements, such as pulmonary function tests and arterial blood gases, if not done initially.",
"     </li>",
"     <li>",
"      Metabolic studies, such as measurements of serum thyroid stimulating hormone and phosphate.",
"     </li>",
"     <li>",
"      An evaluation for concomitant heart failure.",
"     </li>",
"     <li>",
"      Most importantly, an assessment of breathing during sleep, which may include oximetry, multichannel devices, or full PSG. Although it is not perfect, PSG is currently considered the most accurate tool for evaluating OSA and other abnormalities of sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?1/22/1382/abstract/20\">",
"       20",
"      </a>",
"      ]. It is particularly useful in the evaluation of patients with neuromuscular and chest wall disorders, who may have a complex combination of nocturnal hypoventilation, central sleep apnea, and obstructive sleep apnea (",
"      <a class=\"graphic graphic_table graphicRef79606 \" href=\"UTD.htm?20/44/21195\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/1\">",
"      Perrin C, Unterborn JN, Ambrosio CD, Hill NS. Pulmonary complications of chronic neuromuscular diseases and their management. Muscle Nerve 2004; 29:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/2\">",
"      Shneerson JM. Respiration during sleep in neuromuscular and thoracic cage disorders. Monaldi Arch Chest Dis 2004; 61:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/3\">",
"      Bourke SC, Gibson GJ. Sleep and breathing in neuromuscular disease. Eur Respir J 2002; 19:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/4\">",
"      Guilleminault C, Shergill RP. Sleep-disordered Breathing in Neuromuscular Disease. Curr Treat Options Neurol 2002; 4:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/5\">",
"      Krachman SL, Criner GJ. Sleep and long-term ventilation. Respir Care Clin N Am 2002; 8:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/6\">",
"      Cirignotta F, Mondini S, Zucconi M, et al. Sleep-related breathing impairment in myotonic dystrophy. J Neurol 1987; 235:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/7\">",
"      Smith PE, Edwards RH, Calverley PM. Ventilation and breathing pattern during sleep in Duchenne muscular dystrophy. Chest 1989; 96:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/8\">",
"      Smith PE, Calverley PM, Edwards RH, et al. Practical problems in the respiratory care of patients with muscular dystrophy. N Engl J Med 1987; 316:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/9\">",
"      Dolmage TE, Avendano MA, Goldstein RS. Respiratory function during wakefulness and sleep among survivors of respiratory and non-respiratory poliomyelitis. Eur Respir J 1992; 5:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/10\">",
"      Steljes DG, Kryger MH, Kirk BW, Millar TW. Sleep in postpolio syndrome. Chest 1990; 98:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/11\">",
"      Ellis ER, Grunstein RR, Chan S, et al. Noninvasive ventilatory support during sleep improves respiratory failure in kyphoscoliosis. Chest 1988; 94:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/12\">",
"      Mezon BL, West P, Israels J, Kryger M. Sleep breathing abnormalities in kyphoscoliosis. Am Rev Respir Dis 1980; 122:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/13\">",
"      Simonds AK. Recent advances in respiratory care for neuromuscular disease. Chest 2006; 130:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/14\">",
"      Ragette R, Mellies U, Schwake C, et al. Patterns and predictors of sleep disordered breathing in primary myopathies. Thorax 2002; 57:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/15\">",
"      Gay PC, Westbrook PR, Daube JR, et al. Effects of alterations in pulmonary function and sleep variables on survival in patients with amyotrophic lateral sclerosis. Mayo Clin Proc 1991; 66:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/16\">",
"      Unterborn JN, Hill NS. Options for mechanical ventilation in neuromuscular diseases. Clin Chest Med 1994; 15:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/17\">",
"      Braun NM, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 1983; 38:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/18\">",
"      Bradley TD. Right and left ventricular functional impairment and sleep apnea. Clin Chest Med 1992; 13:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/19\">",
"      Yamashiro Y, Kryger MH. Review: sleep in heart failure. Sleep 1993; 16:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/20\">",
"      Meyer TJ, Eveloff SE, Kline LR, Millman RP. One negative polysomnogram does not exclude obstructive sleep apnea. Chest 1993; 103:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/21\">",
"      Bonsignore G, Marrone O, Macaluso C, et al. Validation of oximetry as a screening test for obstructive sleep apnoea syndrome. Eur Respir J Suppl 1990; 11:542s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/22\">",
"      Douglas NJ, Thomas S, Jan MA. Clinical value of polysomnography. Lancet 1992; 339:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/23\">",
"      Williams AJ, Yu G, Santiago S, Stein M. Screening for sleep apnea using pulse oximetry and a clinical score. Chest 1991; 100:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/24\">",
"      Guilleminault C, Stoohs R, Clerk A, et al. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993; 104:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/25\">",
"      Rosen CL, D'Andrea L, Haddad GG. Adult criteria for obstructive sleep apnea do not identify children with serious obstruction. Am Rev Respir Dis 1992; 146:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/26\">",
"      Marcus CL, Omlin KJ, Basinki DJ, et al. Normal polysomnographic values for children and adolescents. Am Rev Respir Dis 1992; 146:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/27\">",
"      Kotterba S, Patzold T, Malin JP, et al. Respiratory monitoring in neuromuscular disease - capnography as an additional tool? Clin Neurol Neurosurg 2001; 103:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1382/abstract/28\">",
"      Sanders MH, Kern NB, Costantino JP, et al. Accuracy of end-tidal and transcutaneous PCO2 monitoring during sleep. Chest 1994; 106:472.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7711 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-090AABC1AD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1382=[""].join("\n");
var outline_f1_22_1382=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR EVALUATION OF SLEEP DISORDERED BREATHING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Specific diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physiologic clues to sleep disordered breathing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION FOR CONTRIBUTING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Polysomnography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Oximetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Portable devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUPPLEMENTAL TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7711\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7711|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/44/21195\" title=\"table 1\">",
"      Sleep study indications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19140?source=related_link\">",
"      Central sleep apnea: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33896?source=related_link\">",
"      Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=related_link\">",
"      Portable monitoring in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=related_link\">",
"      Quantifying sleepiness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_22_1383="Effect of gestational age on UA Doppler indices";
var content_f1_22_1383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Gestational age effect on umbilical arterial Doppler frequency shift waveforms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 577px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJBAiUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5/ooooKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKtaZY3OqahbWNhC093cyLFFGvVmJwBQBVqK5mWJGycNtJX3II4P4E/lXa/wDCuvECeItU0a5htra50uJZ72We5RIYEYKVLSZxzuXgf0Ncn430W+8N6xPpesW5hvbU4kTIYcgEEEcEEEGgGUDdjLMzwxqGA2sTux64+n86uX0Nxpb2yanE0LXVol1Bll2yI/3Hz2BHPrXSyeIrzwdpOiwaHHYNHf6fFe3D3lhBdN5zF1OGdSVUBFwucDHuap3PxT8TXLwmddFkEcaRrnRrVtiLwEGY+g6Y6UEmJpcN1q99HY6VEbm+kDMkUbKdwVSzY59AT+FUhfoZIwGTkEEE4Gfc109r8UPENrIrwJoUMqZCOujWqOMgqRkJkAqf8jNKnxQ11DgWXhvB7f2Fa4/DCe36UAYDR3w0car9nxpzXDWy3B4QyqoYp9drA1Ua9bYCpXa5AViRkHjJ/Wuvk+Kuv/ZPsrW/h020beYsP9h2pXeQATt2YBIABI7D2FRH4mazhgbDww2T8p/sG05/8c/nQBW+Idnb+HvHOv6RYSSG0srloYjMys4A4y2AM8+1Y2ni9vxeSW8Jlhs4TPcGIA+UmQu4+25lH4it+6+J2s3l1NdXlp4euLqdi8kk2iWzO7HuxKck0lv8UNYtvtUdvpvhvyp4xFKBoluBKgYNhgF5GQDg8ZUelAHNPenaNrxhyvI9DUl8NQtre1nngaCC8RpLeRlwsqBipZSeoBUj8DXQ/wDCy74gBtB8IOQf4tBt/m+vy064+K2q3MVtFc6N4Wlito/KgV9FgIhTJbagxgDLE49TQBzWkyXepX9rZWkLT3VxKsccUY+eRiQAqjuSTT55p7aZ4riNUlQsrKx5Ugkc/iP0rfs/ifqFleW93ZaH4Vt7uBxJFNFo0KvGwOQwIHBB5FIPiNcZJbw34PkYnLM2jREk+vvQBiot9Lp01/FbObK3eOKefHyI75Kgn1IU4+lUxfuXAyoBGfm+n/1q65PixqkdhJZRaD4TSzldJJbYaPFskZQdpYdyAxA9M1D/AMLN1DcAvh/wfk9B/YNtj/0GgBvjuxg8P6npNvZu0kVzpFnfO0kgJMksQdsYH3cngY6d6xtMiv8AVr6Gy0qJby6lV3WOIgHais7nnGMKpPPpW7f/ABV1u+kSS803w1OyxJEGk0S2YhFGFQEr90DgDtio4fipr1nJ5ljZ+HrSbY0fmw6Laq+xlKsudnQgkH1zQBzhvwzOVZFXgqD1x+daLW93/ZCassIGmSXBtEnLLt84IHKdc5AZT6c1qR/FHWYgTHZeG1xxxoNpkj/vj2qx/wALf8Tm2SDGifZUcyLH/YtrtVyMFguzGSAAT6AUAcwL1NpDeUpUbiS2D04wM/8A161NUsLnRNVfTdXjjhvIQvnxhwTGWAIBIJHQ5P8A9atZfi94lIVc6Ijeo0a1/PPl/hUjfGfxhNM0z3umvMTuZ20m1JJ+vl5/GgDM0qwk1Q3n2CFJxaWzXcuJVXbEp+Zjk9tyjHvmsvVpUgtUMJjDGTbvVtx79ecen5V0T/F7xWBIFvrJA6bHCabbLuBxkHEfI46GqH/C1fFoz5epQqSQebG3IGM/7FAE2v2VrY+AfBurQk/bdSa9+15lGD5coVAoxxweTzmue0v7VqV3ZWVq8L3d1IsEalgoLuyhck8Dk8k8V00fxo8dqix/26PLQYRRY2wC+uP3fH4daki+NvxAUAHxLPH2/d2kC4H4J9f0oA52+hudL1S80+/8v7ZZyyQSqrAoHRirDI68ggY49609M0e8vtG1TU4fs/2fTEge63vgosrbUIHGTu6itGP4yfEKQFm8W6ht+6mAgJ9zhf8A69K3xZ8dylT/AMJfqypzj5wNw6DBA69u/NAGLFCXc7beZ1ByCgJ3DHQDGc8V2Nx8PtYso9KM+k3tydQtUvY1tbeZmRGz8kny4Vxt5X3HNZafFXxwoPneLNWDMflBufuj34/D61PpfxC8S3LhJvFmvgtxxqkoC9Oc7vWgDmb6B7W+uLeWJopIpGRo3BBQg4IIPII96gqzqU8lzqN1PNLLNLLK7vJKxZ3JJJLE8knqSarUFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXYeGfEml+FxaXun6fLfapLa3FtfLesUiTe2FaBo2V1Pl5UknPzHFcfRQB7P4i+J/h7XPFHjB5dP1C10bxBZ29u80Sq1yJItpDsjPs7bcBgMKp6k15n8XvFcPinxw+t2kDW8B2JbxygOwWNFVS3Yk7ckcjnHNYlZet9bcHGMnr+FAmdR8UtRuNSufDN7fNGZ59FgdvLiWNM75BwqgKo46AYrh2k2jaOqk9OR/nrXVfEUlovCY4GNCtx/wCPSVySqTlQMn1FAh0j72Ow4GAuCcmmoMtkEccjPXrTQBkdh0pwXaobI5OMjtQApOw8DaSOfb6U9iUjYDcDk5GexqJVLkhR0GfyFK4KjOc5746igBM8bRxzk8c0qHAJBXk4Ix/n0poHsSM0nbrQApBwM0gNOVSytgdBuJPYUh56cD0NAApyw43e1GT69O1J0x60pGAORz6UAJQOopWUo2GBU9eaQ47UAAoJ4APakpxBQ88HGaAEpcnnvnrmkNAGelABR2xUqQSuuQpI9cenb9aYUIGT09aAGk5PuaKmETc7CD+o+lDx7Yyf9oD370AQ0Dr1xR16npRQBIjkEADuScHBI9M/TP51JHKQWZjtZV+U9D/n+lQINxAUEtngAZqR4HVyrZBHTIIyKAOz+DXh6DxL8QdOi1MoukWe7UNQkk+4lvCN77v9k4C/8Crsvjvplmbnw14w8OrpsdlqsH2e4XSv+PeO6iOGC8DAKkYBGflJrxZVLHCgn6DNaOm2jPcGRwQqHPfp60AbTnLsenNNqa8jaG7njcYZHZSPcGoaCgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKzNaxmDJAB3c/lWnWdq0rwTWs8LlJY23Iw6hgQQaAZr/EE/u/C/zY/wCJFb4x/vPVjwj4etta06SFi41BZxlcHO1o2ZT9ODT/AIn3s+qXnhu91G4luLqfRbdpZpDlmbc4yT3r0j4e6Y+kfabGziVr5bhozfSLkpGBtUD8N4B/pQSfPpyMgjGOCMVKrloNu5uHyF/h5HJPv0rqPiRoLaTrRuUkElnekywuBjIwCf1NcsgLjZnAHY8/54oAlssxzxytEZFjIcrjgjOcH2I/nXbeMfCMWn+H7G/iOZlUi6RX+6CxCMB2Ge3pUHwq0KPX/Eos3cIWQsFdM70HLkehAwc16Zd21hqLeIfDumSiTVZYFjQy5GUxuHXuNy0AfPZ64444oOCx5J+gqxf2z2V5PbSkeZE7RuPcEg/qKhjUZ5x0PJzQB0mjeHrm+0aecNGisAYs/wAXzgH+YrnrqFoLmWFxho2KEfQ4r6C8K6Vp9vb+EbLV49kUtrlT/wA9CxLH1/pXk/xUsbex8eapDaTLLC8rSZ4+XJPFAHJDG3kc/XFdN4F0hdX1YwzQh4FRy3y5wSuP0zn8K5qTDkNx0/hGB/nivW/gbo8uoLq1zDP5bWpiLE/dAcMBn8qAPO/FVh9g1BIFcyxrGoWQD7/JBP55H4VjEHJBGDnpivX/AIn+ELZvCUHiezkjheGX7LPbJkjJdiSPxJryJGKrkNhgQQD3/wA8UATWKxNdwecP3XmLv9SufmNdBr/hv7Np1zeWbtLFZXRtZ2JyFzgp/PH4VR8J6XPrHiC0sbJx9onfZFu6FsEjP4ivo/xL4a0+4+FAt7FN7XggMk0WCS6tk5/Enr2oA+WEUntx9P8AOe1KsZLgLjk45qzIiJK6bzhCynHGQOM/icUtsgMm5gQoXlgcAcev0oA7Hw54Rutb0yObSYGbKSRXRAztZE8wY44yMVxksY8rb5ZLghQwPI65z+lfSXwqhvvB3gS6lvovMOqRieKJeCOdjMewG0rwK8T8c6A2g600KyB4pl85GI/vZ4OBzzQBz1vEzAtgcknr1PPGe3etOysUlglnuubSFSoAGTnYdh/r9arJEgj3uz7xtUdcs2f09BXs/wAIvDY8Q6DfWFnEsl0byOWR3XCxxrE2Dk8Elxjb15zQB4JqNnPp99PaXSbJ4WKOPcf0quPpmvRPiBYR6lph8RBna+aVYbhQm0NwcyY7DIxnp261wEcQkVmLYwPTJ6Ht+FAHRfDnTU1HxhpcNydtuJlkmJBx5YyW57cD9a1/HGl3duFvLmNoQ13Nb5VeAmcofxDD8BTvhbY3b65PJaxSOttYzyTKgJbYU5PHs3HvXrvj/wAOvqHh+OyublybS0TZEY8NIFBYykdeScDtwcUAfP8AZQnAZGDO6kbUAbAGe3rzkD2roNJijEAYfeJySoBOcHrn8scVkWCxp8s742r8642EZ/Unn6cmvTfhBo0Os+M9D0+6iVraaZmnjcAqyKNxUj3/AKY9aAOJ8TJ5XiTVYwxYJdyrk98OeazK6D4hKieP/Eyw48tdTuQuPTzWxXP0FBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXoHgP4cHxZpNtfPrVtp/2rUH0y3ikheQyTCISDleACD1PTHeoNU+Hs8F94Xg0vUoNTTX3aKCWOJ4wsiS+U4IYA7Q38XGQDwKAOGrM1o4MHuGHX6V7Dp3gPTvF/jDxFbeGrxbTS9NdY4I8Gee5Gdm9EyNwJUseeNwGK8t8WaZJZ682mASyyQ3MluP3TIzkNtHyMAVJx0Iz60CZpeN4SY/Cm75s6LasFx1HmSD/ABr6b8SpDo5WazwGlNsJJXP/ACzYujKf90HIPrXkF34QEjeGTrmi+K3urGxto54rKxEiKqs7FST0bkce9eh6n4rubm+vL638GeKvOma3RWk05vlhRiWXHr6H3NAjD+L3gV9T0LSNN0CEz3emEhZ36y25UEPxzjOR9QfrXzjeWklhdz213GyzwPsdR619d6345lvLafyfCXjGGVmKrs0s58sqRj2wTmuQv9J8OapZTS6h4I8bG/nYSTuNMbLPtI4yegx/nNAGL+yn9k/4S3WJLsotyLNUt95zhmc5A98DpXoPiPSLG38Xx3UkE1vfTTSXMtyq5ViEwEHvtGR2+WuK+Hdpb+CIr+eLw940udRn2qhk0dgihSWHT1OM/wBOa7Z/GNu9vbrc+EfFs08SRMkX9lyALKoYE+pBJ/SgDwD4ieDbvT9PsfEcMcrWepw/aXLcmNmYjn69fqa5vwZp6an4s0jTnVtl3cxwuAMnDHBH45r6f1fxBpusfarfU/CfjCbTriGJFthorgRFccDjJGRXESaPpdp8Q9C13R/DPjO2tNPEUjx/2PJ+8kRv6jv7cUAeoSaPDpemtYxSx3U5TMDy9FVI2DqpHIILD/vr0rzL4g/DgT+GUCJt1a3uPJt3wQJo3xtx+HB9CDXV6L4kg066jur3w14tmne7neUvpMoEcUmwgAY/2APcVp23jqyvrp73WPDviaOWGZ1gRNImIkjXmJicfK2S/HuM0AfIDQSRPsdQrHIIOc/j6V718EbSWx8A67Nh3GrFk3KBtjSEMSd3uxAArV17T/BOsxX7zaB4ohuTHstwujzABghCbsDnnB5rT+HfiLTvDXgW30e88P8AiKSZHHmD+ypsPuILk8eueKAL2jeEYNT8Q+H9Tu7gwaffwC7ktZMAyyM+ApXpjlOa+afFugvo+s3CB99qXJimC/K2ew9x0r6Vn8dWty8ovdC14x6fc+bppXS5VLopDKjfLwAyj6/hUI1bwTdaC1hq2k64onWR5N2kzFoWfjaCF9CTmgDyX9njS3uvilo82cJYObuVjyMKpwPb7wr6GvtEt18QzpFP5tjdzC/njj7yblKbf9nGK8t8HHw74R8Vaw+mrr7aROYhETpM2/C5LR8j1xye2eK6vxL400a61DTrzTrfXFkRlDgaVOqxDIIbGBkDaPlHUZFAHmfxf+HuoaRCNcKRmMulrcwwgnyn2lt54+6emfevLrKJpIymwEgHaOvPbH6DHua+uJ/Hfhu50i4sr6DX7v7Vl7hjo067mwBjGOBx+HHpXmS6N4YtfEGhatp9h4kkliuGmvbZtFm2upxgDjjHPTrQB7inh+0fwfoujX8q2aR28DeY2AVk3BgPfkkYryH4leFNS8Z3GoXOm2zq0TC4cSA4bl1MfH8Q2dPeuw1rxnY6tqGJNH8Uy2oAVAmkTKUCSmRW6de30q8/jOFYbVbXwv4zlCXCzMq6NKA53Fienv8ArQB8mra3FtM0F3btFKpO8SKC6HjGB6/rX0h8LtJvdL+FdzJE1zFe6nJ51mYWwz5VQcg9SAje2Caj12w0nX9DJufAnjOPWXWRmni0lh87Mem7rgetdVD4j1PTtO8Lw2PgrxtJHpMAgeP7Ai+YTEULfezx14wOaAOX8eaHbajpOzSrEQWh02CKSNVA2h5QznH94cnPavAPHXgfU/CWsyQyW8xsyoeK4CkqVKhs5/HFfVVv4rx9qhvPhn4weKYsv/HrGCUbsfn78Z5/lUvivxG3iPQNR0yT4aeJ3aW3NrEzrAuwY458zjkZ78CgDhv2VvCUd54T8Qa25IeXOmrhivygI5OR/vY9ea9dvtEg8TXv9qWEeyNETTrh5OB5CM2/aD35IzXmnguz1vw34WudAt/BviqCzu7ia4neK5tUk+eJEAVi/GCueld1p3jbWrO2tLH/AIQTVzp6xSRTBr2zLk5AXH73kY3A9KAPCfjf4Jl0zxjcaxpNuG8P3fzxOgBGBGu4g9hk/wAzUPwMFy/j7Rhpy77lpWZjjhl53Mc+gBr2865Ld2dxbP4B1a5tXVxHDLqliI44yu3av735VwPfHrivPrX7ZpXjuHxF4e0LStK2RSIbeTxHZOCzRlBj950zg4oA8o+JgA+JHisDoNWu/wD0c9c1Wv4vnnuvFmt3F2IxcS308kojcOu4yMThhwRnuODWRQUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAb2i+Ltc0S1tLfS73yIbS8OoQr5SNsnKBN+WU5+UAYPHtmun8N6r4wg0WLWk06a70vS7a7hsrpohGlq05PmSKwALsCzHvgntXF6Fa2F5f+Vqupf2bbeW7ef5DTfMFJVdq8/McDPbOa9Zm8Z+Er74ZW1hqQtpby00VrCCyayJnivN+VnSfGFQjlhuBPoaAOK05PGngfShqkFhNY2F6Y2E1zZRyoWGTGw8xW2nkkHgnPFef+Kr64v7lru9uJJru4laWSR+S7HksT65P617z8Q/Hfh3VdC8Yz6bfPcXfib+ztliYHU2P2cDfuYjac4wNpPWvAtRiWe7soZJ47ZJH2GaXdsjBIG5toJwOpwCfY0COg1LU9Cnh0OSaV5ntrC3t5okkdNx3MXyQOCuRxWcNT0ZYLtXW8eQSyiIrcP86HGzPPGMfjmpZ9D8O6Ri21/UtU+3kLKDp9rHLA8TqGjdXeRW5Ug4KirGlS+ArG4aWaTxBeBoZYtkllAFUujKHH708qTuHuB0oEc/pN7F9q3alc3XlKN5CSt+8I6L7Z55q3calp812y25u7W2aUyBjO7kJj5YyM8896tiHwJt5vfE+c/wDPnB0/7+1dkuPAD6Ra2OPECvDNLM9ytrb+ZKHVAEJ8z7q7CR7u1AFWx1nw9HFF9rs9QldlCzbbtwM92Hrn0qW/1Pw7/alrPYSanHYllE1v5zlgO5Dk/pUSr4BUqTL4obBBI8q3GR6fe/WrWr3fw/1DU7y8SDxFarcTPKtvBHbrHErHIRRnoM4H0oArR65pZuJnM+qpA6fu4hdOfLI7Zzznj6ZpLzxDp325ZLV9X+zvGMo16+Ubdk89+Kt2F/4BtLDUrc2mv3El5CsKTSpblrciRXLp6MQu3qOGb1qmn/CAh/n/AOEoKeg+z56UAaupXUGnjSrm8k1e1ttRtftMOy/aUlNzx7j0x8yHj0rn4tfImBbUtXAVgCVuW+Zcj34OM/n7Vva3rfgrVrTR7eWLxGkemWn2SMr5GXXzHkyffMhH0AqvoOoeA9K1qyv5bHXr5LaVZTbXHkGObBztcY5U96AC48Wwf2PbR2mpeIotRC/vZTfuULFT0GexI/I0ieMIjZy51HxLHdGFQhXUXKeaF5J5zgtj8KpBvAxYll8S/QGAf0q/BqXgOPQ7rT3sddd57iOcXR8jzYwiuPLU44Vi+T/urQA2bxaftNg0GveJUhC4ugbyQktj7ynd6549KpN4w1I3c+3X/EK2pz5YN9IWPHf5sdef8acp8B4+ZfFGfZrf/Cr2u6p4D1S/+0xaZrtmojiiEVu9uiYRFTdjb95tu4+7E0AZ0fjXWI7UhPEPiMXJKncNQcKP73GfyrY8RePWlW3/AOEf1vxhA6qBK13qjuGPU4APHOKr6NrHgfSri4lTSdcuvNt5bcLcXEDBPMQrvA8v7y5yD6gVnGfwQPu6f4kJ7ZvoB/7RoAvaprviu10rT9U/4SfWmsL95kt0OoymRTGVDbucD7wxjNZkXjPXhcp5+v67Jbg/Ov2+TJ+nzcVr3/iLwld6HpelPo2vfZtPaZ4mGpQh2MhUtu/cEfwjGAPxqnZ6r4Lsry3uItB12VoXWQCXVYtrEEEAgW/TjmgDPuPFesyyfu9b1hUyeGvJGwO38XXt+VNfxHqO4mW+1F0YZVDeyce5Oee9bGoeIPCN/qt3fz+F9SMlzM87omsIihmYsQoEHAyeBVmy8X+GLHS9R06Hwlctb34iE5k1cszbG3DBEQxz1oA5m51q4mkYrNeJGz9GunYgemSetVry7MkMCywy4wGzJIxD8EZH456V0yeIfB6bSvgXfj/npq8xz+QFXdX8e6DqcVklx4G0+QWdutpB5moXWEiUsQPldcnLE5oA4Mr9quI47S2YOx2rGmXLEnj8eg49KW2niidHktY5gvVXZgG4PXBB7jv2+tdnpHjzTdF1O01HSfA+gwX9o4lhma5vn2OOjYNxjOfaq6+NdMQYXwF4T65+b7a387mgCLQ7O3TwLrOuS20FzcWt3bWSJMjMoEqysW4YYI8oAdua5+S/jaBY/sForAY8wBtxOc5649uldnF8S1h02Wwh8FeEEtJZUneP7LO250VlUkmYngO3t8xpqfEIpG0qeCPBvl7gpY6WzKDjpkueeKAObdrrTHSS80u3ja5RJ1W6gxuU5ZXVePkYHjA2kAVs+F1vNTvYdN0qxtLvULs5WGKBC0u1c456DAbPQcZNbNz8Wb+9WNrnwx4Kd44lhjebREkOxFCqgLZ4AAAHTijQvinr8F7BJYw6DaTq2Fa30K0RkBBB2sEz0Jz7UAc9JIZnaU7cuSx2gAc+gHH5U2pbu5kvbqa6mWNZZ3aRxHGI1BY5OEHCjnoOB0qKgoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsrXf+WH/AAL+latZWu/8sP8AgX9KAZc8cY/tSxIzzpdh1/69Y+lc7XR+OT/xMdP+UA/2XY85zn/Ro652gkSiiigAooooAKKKKACilpKACiiigAooooAKKKKACiiigBaORkUUGgAJz04HYUHrnil2/LkdM4PtTaACiiigApRQOaKAPQv2f9C03xL8XNC0nXLVLvTrjz/NgZmAfbBIw5BB4Kg9e1bvxg0DRtMsvCOr6FZW1rYanZyu72yzRpJNG+xyIpiXQDKgZPOcj38r0vUr7Sb2G+0q8ubG9i3eXcW0rRSLkEHDKQRkEj6GtS61rVdbuornWtUur+5IEYmvLlpmC54BLEkc/lmgC2DuAIAGecAYAoo/AD2HSigoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs/UvI+12X2wSm23/vREQHKZGdueM4zjNaFZWu/8sP+Bf0oBmn8RjbHXbU6eky2f9nWnkCdg0mzyExuIwM49BXLV0njn/j70g/9Qmz/APRQrnKCRKKKKACiiigAopSCvUEcZ5pKACiipEhkeKSREZo48b2A4XPTNAEdFFFABRSqCT/ninSIUcq3b9R2NADKKWkoAKKcylDhgVPoRikoASlJz1opxjYRCTHyE7c+9ACKcd+1IRg4PWnr8qnBOTxgU0g4yfpQA2ip7O1mvJTHbpvcIz4Hooyf0FRyxvDI0cqMjqcFWGCPqKAGgkEEdRS5BOSPyNNp8UbyyKkY3MxwBQA+WQSLGiIFVAeM8k9zmrWmqTcRAK7KwyU3AZx3ye2R+VaOv+GL7w8bJ9SQpFcKHVk6qf7pz3FV9PLrG5Tc+8gMicHH3gOn06HsaANFQQoBxkDnHT8KWgHcAfXmigoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAvaNpV9repQ6fpNrJd3s27y4Yxlm2qWOB9AT+Fb2pfDvxbpljc3l9oV3Da20azSyEAgIf4hg8gd8Zx3xVTwD4j/wCES8VWms/Zftf2dJl8nzPL3b4nj+9g4xvz07V0EPxH8rSls/7Kzt8PSaDv+0f35RJ5uNvbGNv60Ac8vhi4bwtYasshafUL5rKzskjLST7QNzrjsGZVxjkmsP4geGNY8OGxGtWZtvOMgTMivkrt3A7ScEbhkHnmux8SeJ7T+3fDg0cTSaToEMEcA3NC0rq3mSvkcoWkLcjkcVnfF/x6viyfRZYtIhtpbJpHaecxzzTklSBIwjRWUY4BU9TknNAmcp43UC40chgc6Vak4OcfuxXODqOM+1dV8Qrhry+0m5kSNJJdLtmdYoliQHbj5UUBVHTgACuUoEdp8MPCA8XajqEMzCGztbVpprktgQ88Njv0PFZfjLw9L4e1BYnAEUo3R5YFsYHX06g/jXbfBi6TTNO1qaXdIb3ZbJbDjzNu5y3PBA28/WpvEOlJ4phuJ2CpqqWsJgjUfLIzbsr9eFAJIHrQB5ITn09OlS2kP2i6hhyR5jqmQM4ycdO9RurI7I6lWU4IIwQfSt7wDYTal4x0iC2i81xcLIVzj5UO489uBQB6D488BSQaQxt7XbLYQLKGiJkaSI8AMB90gAc/WvHq+qLjUBJeSLqSu0l7AESS1kwJITtVB3wc5B98npXz38QdHl0bxXqML2zW8LzyNEuPlA3HgHoce3tQBzdepeCtCiT4fX17f2kTpfykbpJdrLFGp+dF7necf/qry6vqOwtWtfCOjaRJp4SBLeEahLIuTAHXOV+oxkDPXmgD5k1Gyn069ltbuJopoyMqw55GQfxBB/Gq1epfGDSY3NhqFp51xObeMTSLG2PLwVjJOMZxGea8toA9C+CXhdfE/iuSK5V/sEFu7zlU3Zzwq49z/Ko/jD4Yk8P69BOeY9Qi8/HdWyQwI7cjp6V6P+zbCmn+H9U1SVnHm3caMgTJeOMEtgjvllqx448Nya58PRHJZzpdacJruOYP5rSSPID5R9sOeeg2+9AHzlWn4a0uTW9f0/TYvvXMyx59ATyfyzWc6lHZHBVlOCD2Nesfs0ab9t+Ivn8D7HaSzbiAwycKOD/vGgA+K/gmHTNFt9T0+S3lKSETJG25liYkxN/u4B5+leTV9r+MYrHXrO90q2aKV4oRFPaomB8xVS27r8gOcD2FfIPijQLzw7rN1YXcM6mKRo1eWMx+ZtOCQD1H9MUAZCIW5AJ9RX0l4X+GNqPAC21yiSajdos0kLgkrkHY2R0HysR3r580W0nv9QtrS1QNcTTpGgzjLE4A+lfcs4mtbmygt1jzJ+6lTofLVM4GPTI/OgD4Vv7Q2d5cW0wO+CVoiOp+U4+lQSjMSMBg9/f39v8A61ewfG3wLfaVrN7riWkMWmXE5chG6HvnI6EmvJpk22K8AEsB15/i/LrQB7T+zd4Hi1eK88SXFsk/2K6SCMSYKKpRt7sp+8BleByfzrkfjr4Vl8NeNZUWOUwSxJIZSCwLkYb5u+SCR6A47V9CfBV7XSPhDpFuhxc3ttJclIyQ0mZW3c+uAo9ql+I/h0fEX4YQf2PZzG/lYNawCUAx7NyhXz3655zQB8X16B8EfDEXij4h6Pp95As1mWeeZSxGY0Uk9OeoGK4e/s7jTr+ezvoWhuYHMcsb9VYHBBr3j9ldJbPxNq+vKkb2mnWaid3BxFHISXIA/i+QfhQBuftC6Je6lBqATSLjbp9ylraTGPA+ziNXeQY6/Nkc14DApknjWQ7oo8BSoKk4AAKrx35z3ya/QTQNUsfEMkhnhdmdV8wspCrIq4Mf15J65xzXyH8SfBlz4X8QGUWctlpuoM7QIY8iIb8BWb+9t59eaAOFf77cg89R0/Cm1JOCJ5AxyQxyemeajoKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArK13/lh/wAC/pWrWXrSNI9siKWdiQFAySeOBQDPVfAui2+veMNE029YG3uPDSlzjoAxOP0xXHfFLwU/hvVftOnRTPo11l4nK/6psnMbH1GM/Qiuy8MnUvD3ivQL+fRdZeOHRUtZvIspHZHJY7WGPTHH0r0K08fRaoGh1jwtr0EO4NsTTZJd/BBByvHbpQSeZeFLO1X4ZWkhFuby5kuIts3QKeAfXJwcfSuh+H1tp9m8qzXL3L3cwiuTxsRQGTD/AO8STx/s0njC7i1O2iXSPCviO3hhgeAW/wDZkgBLHn5scHlq5SGHW0tZbZfC+vrEgSWF00+TJZWU7WGMEEL1PNAGn8Rfhs15PresaNBLA0Za68lwNk0eMsUxklweSOBiua+DOlGfxHqb3MhtVtbCQs0nABbC4bPYgmvUfD3ivUbGWNb7QfFFxaSxlnh/sxz5MrnDYJHzDaP1NP1vxBFqaz3P/CE+JrfUdRhFtqHk6dIPkXJG046g7efSgCl4N1GV1uBZaf8AY7sQLMAeYowC+SRnOSpyfYnviur8d+HNG8ZeDriNvLtprWR47C5bq0hIYhfVWJxjrxXmxv8AXrUzJp/hfxI4kAtmnl0990lvxxgDhgFGP1rp7DVEjyk3hvxsyGdpgn9mHaxaUOSfTgbeO1AHgKaBfx+IotGvLeS3vWuEt2jccqzEDt9a+hdb1fWk8QXts6Tw6JG8McfmsCWbhATjqjdSPTFOTWrK91651TU/A/iqVhcJcWijTCfLKKdo7dySa4nVW8VajfQTp4a8RRRGdZJbdrRigU4yFPU4PIz6mgD2iaGC2sNT0y5iUgSiNLdQAY4yFAUfQOT+J7183/FL4d3fgzUA8QafSZZTFDcZBy+ASp/Pj1wa9eXxR4huXuI9R8E6/NaTOpLizPmZwd7cnrkLjPb8K0Idde+sEg8R+BfFF7GtyLgCSyUr0HXkdSM/j6UAcH4S1ibRvhTDYQyG2u7uK7vt4U78KcJtPYk559CK9Gtb7Vbe1imgu7KOPVIhHZicM6pnj5gDy2cDPSubvDNNaW4s/AniUtbr5CSSwJxHv3MvXng4qlpr67Y28MUvhDXZ1tE8m3jaNQscZIbccN94MMjtQBW+LnwqinuL7VvDLlnto4hPabSSxK4DKeOuMmq37NqnTbrxLeTQSFlgS3b5thQEsxBz6lQMCvQbbxfri6ilzL4K19yIUh2BEwxBJyfm9/1NYl/Pc3FxdPb+CNcso57j7RMYnhVpG2EAvlscEhh7igDsfDGoRnWWubGL7TbMblWugwHnOCSAqden3vU4PGKPiT4Ig+I2hwT2kyQXkSiWBuCQSOUbnuMfTFecafFr+mC0bTvD+uxva71iZ54AWR2DPu56kjrXeWnjbWLGJYrHwPdRRYz81xAN0gQAM3z+oH/AcUAeNfD3wJqln8WNF0nWbdrGS1m+0ytjKlYl35U9GzgfnXvtpe3d3ZvdQIZLhbk5aQkAzmQEn/cK7cLnHvWefG94bpLubwVcm4WMhpHvbXK8BcLmTgHkGuVutc18wQtb+H/LngdPK8zV7Ty9isWXK+Zy3I+b2FAHpc2g2XiWzXSL6Waa2s7qRJmP3pptgZuv3QCWGOenXivl74i/DfWvClnLPLYyvpqSj/SeoGQcZ9Owz9K9rsfG+uxXMcjaHYKTIslwf7cs0aQjBOP3nGf5Va1D4lahdaVNa614b8P3aSyjdHL4msY4yu4sAcuQeAPxH4UAF3qmqaHofhnQtH067uxaWturDytvlOI0ZgeOUO9st9fSuq8J61Bp1n9q1G3FsTc3NxAFdmMisVcqg7k8kd/l+teM+OvEXiHxVf2UtrL4W0i0tmRvs8XiizJcLn5WYSDIIwD1HFXbPxPrduAyXXgmKVLhriB5PEMMgtyRgAKGPABNAHX/AB8+D3/CU3UuveG7cDWAY0ktoSAJFxkOf9rtWT8GIZPCPgC8OtL9i/tDXvsl1CynfJbxwcqp+p5J7Z7mtGL4s65HM0k9/wCAd/YnWmOFH8Pyqc8ZGff8K53x/wCMJ/GdjBa3+vfD60toY2EapfXTlCxGTlYuuBg/U+tAHs3hnWrKOTWUykdudQhmtJYk5QTBQvuM7dpx688Guo8b+FdN8b+H7bTNSuHMBuVmV4jtLMobjP8Auk/lXy7o/iH+yb+CW08YeBkdbg3LIkV9IskhUDLL5ODjaMCu90Pxv4kjg/tE+LfC1xbwwMwlOkX8gjRmBO3CLntx1oA+ffE+mnRvEmraWziQ2V3NbFx0bY5XP6VmVqeKbxtR8TavevNFO1zeTTGWGNo0kLOTuVW+ZQc5API781l0FBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWj4f0i617WLXTbBQ1xcNtBY4VABlmY9lABJPYA0AZ1ZetMyPbujFWUkgg4IPHNer3PwvvbHxL4i0zU9Usra10GCKe9vtrugEiqUCqBuJO/HTsa4L4o+G7vwl4kk0bUHikmg5EkRykisqsrA+hBFAMu6b4kuL1or++stVvdM0uySG9WDUXh3OXISRnwcZLKuMHp1qynjbw2szM/h3WZULZCt4glHGOBkJ2PNZl3Lq3gvSLK0WFrWTVYBcXlrf2Ub7tkriP5ZEJC4AI9Tz6Vmr4w1RV2pHpKD0XSbX/wCN0EnWXPibR9OiszqHhXVx9ptxPEzeIJR5iFiA/C/7OPwq/wCE9d8K+ItesNHPhfUYGunKef8A27M5HBI+XaAegHauJfx1rsgiEktg4iQRxhtNtjsQdFX93wBzwPU0638eeILaZJra5tIJUJKPFYW6MpIIJBEfHBIoA1J/F3hh1Ai8J3sZGef7cmOfb7tTy6zoL6OmpDwXcC1FyIGnOuSks23cUxjPI5ziufHjXXB924tl/wB2xgH/ALJUh8eeJDGI/wC0AIg/mBFt4gobGM4C4zjjNAGgvifwoPODeDJXDMDHu1mbMYHVR8vIJ5p+rajoOmXRsL3wdJFdwBVm/wCJxI2WxkngYGQRx2rJHjnxEqhV1EqB0Cwxj/2WpX+IHilnZ31q4Z25ZiFJJ9zigDc0/V/DV/ZXRtfAMbGxtfPuJTrEqtt3Im/nqdzKcD1NVIPFXhGNAH8BQTMM/NJqk5J/KsweP/FQJK65eLnrtYDP1wKP+E/8Vc/8T2+57B6AN7UNX8MW1jptzL4Bt0iu42lhK6vMSyrIyEsOx3KR+FXfD3iHwjrGt6bpg+H9jF9ruI7Zpv7QnYqHcLuxnqM1yjfEDxazZPiHUs9P9cacPiF4v/6GTVRng4uG/wAaANZ9f8ORm7t4/AltI3zIH+2zsUI4yB6/WtOLU9HfQ7q9X4c6eILW4SJma7uBIWkDbQB3A2HP4etcsPiF4vCFV8TawAfS7f8AxpH8f+Lmyf8AhJtZyen+myZH0OaANmfXdIkiKr8OraNhj5lnuOMde/fvWhq95aWmowN/wrWwwYI5vLikumTDoGAbJ+8ARnHfNckfHfi0jB8Ta0c9c30n+NRf8Jp4p/6GXW//AAPl/wDiqAOys5Dqd7bpa/Diwt/s6yXEhkS6KyrGpcq3J5IXaAO5AptvfSp9oA+FVo4lYsC9tdny/YfN0rjH8X+JXGH8Q6wwPreyn/2amnxZ4iPXXtWP1vZP8aAO9trfVLXR7S7Pw40+4LztEIWsLkzfIFYsw6bDvAHclTTFuNbcyqnwqsfnlWUH+ybglMY+Xr93g5HvXASeItacfPrGpMT1zdOf6+9MbXNXlPzapfs545uHJP60AexeIU1vTddvbDRvhZpl7pttO6w3DaHM5lXPBLg4PXjtSWcHjC7guGl+F+h2hsoPPRZPD0pM5DACMAk7m+YnHoprxg6nfkAG+uuPWZv8agmup51AmmkkGc/M5OT680AewMfHNxuRfhXo8Rzv/wCRbCEA88ZHSr8mlePrGys7q18I6IJ7tHSe3OjW6/Z8SHaGLdCevbjFeFUUAe/6QnxPW/jhbTPDul29xcKZpjZ6diIbuWwx5A5OKml1f4u2NzPHYaj4cS2jkaOOYto8G5Q3DbSeM9cc9a+eqeEyu4kBc4yaAPoyHV/iRcafqNzq/jPw1aanCkf2NBd6SPN3PiTew+6FXP1PTNS23iX4mTWQgufiP4OQqCEc6zYqU6AEbVPOMgfXpnmvm9omBTHzB/ule/tWvpunXsF5JbzW00Fy0RYRTBozInUjB6g4oA3NZNw2sXxvbqK8ujPIZbmGQSJM+47nVhwwJyQRwc1TpsX+rTp0HTpTqCgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArqdF8W/2BbWp0LTbaDUDbTWt/cXAFyl4kjhgDE4KphQF46jOetctRQB6prPxbXWfEviK91DQIjpWt2kVrPZRXAjkHl4Kv5wT5mznkqeML0UV5t8WfE03i/wAUS6zcQJbGbCpAhLCNFVVVcnrwBz61UrK13/lh/wAC/pQJlrxBI0mgeGy7FmFtKMk5P+vkrn66bxVZS2Gi+HIp2t2f7PKcwTJKuDM/8SEjPtnI71zNAgooooAKKKKAFxxnNJRS0AJRRRQAUUUtAAMggg4PrS5zjPbikooAO3WkpxGMbgRxSUAFFFJQAp9aKKKACkopSMAcg5/SgBKKKKACpXYNCgHVcg1FRQB6F8CNW0nRfiTp95rk8NtEI5kgupk3R207RkRyMPQMevY4PbIXx5d+ILLUtJfxD4vsfE0sTyuhttR+2iFSV3AuOgbHC54x0FeeU5c7hjOe2OuaAOpVkdQ0YwjcqPbtRUdv/wAe8WDkbRz68VJQUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWVrv/ACw/4F/StWsrXf8Alh/wL+lAM0dY06b/AIQbw/qSrutvMntmYH7r7twB+ozj6GuYr3zw/wCETqPwR1LTme2uryNje2xtZllXev8ADuHAbBIx714HQSFanh7Qr/xBeS2ulw+bNFC87DOPlX+uSAPcisuvdv2ZtPR11q8mVHR5ILdVPXILSE/+Orx3oA8KIKkgggjgg0ldX8UNIOj+NdRjWOeOC4f7VCJk2Psk+bBHbByPwrlKACtPxBot5oOomy1BVWby0k+U5BDKCP8AD6g03w9ave69p9vFjfJOijPQcjrXsP7Q/h9Tbafr1rExJVY5/LX5I1P3c+mTux9aAPDaKKKANA6PejQ11fyv9BaYwb8j7wAPT0561n19CeD/AAzp958I7XTb+eP7ZqSPNCgHIkcsIct06jOPrXgd/ay2N9cWlyu2eCRopBnOGUkH9RQBXqzY2r3ckiIQNkTykn0VSf6Y/Gq1en/ADTE1HxZercWsdxbCzZXWUAr8zLwfqARQB53qdrc2N9LaXoIngPlsCc4x/Sqldv8AFuxeDxdqFxFbTpYmdoEnkHEjoAGwfbOK4kn2xQAldT4p8IXGgaXpd+Z4rmC8gSVvLOfKZhkK34VzdvE88yRRLukchVHuTivrjxH4PS88Fy6HGESG3skQhkB8yQKW8zd1GGXGPegD5DwcA8j0NHGOc5peoxnpTkUsw4OcgcUAeifB7wHJ42/txYzbYgt1RfOByHduGXHQjHf1rz++tZbG9ntLlNk8EjRup7MDgj9K+mf2VbSQ+GNemyqia7VFkGDtKJwOnP3hXnf7TuiLpnxGN7EMRalAk/C4G4fK31+6D+NAHkVOVSzBV6k4FNq9odoNQ1rT7NiVFxcRwkgZxuYD+tAHYfFX4d3HgOXSy07XNveQZ8wptxKv3l+nQj61wNfYfxY8LHxx8P8AVTpMt5MNLzeW63JBO5AyFF9F8tCee5Br48oAKv2emy3djPcQbnMMiKyBegbIBz9cD8aoV6T8ONKj1DSxp9wdo1a5VInx8odGAALdj87HHfAoA56FSsMakYwoH+cU+tTxTZf2b4m1ex4/0W8mh4GB8rkf0rLoKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACium+G/h2DxX4ysdGu7iS2huFmZpY1DMuyJ5OAev3MV2178OfDkmhXF5pWpaubhtCbXLdLmGMKESQIyOVbOSTxjgdyaAPI6ytd/5Yf8C/pXqk+iWNt4a8H6TcxrFqmu3QvZ7oQmSW3tmbyolVRywOHfaOT8tZ3xv8C2fhW00i80iae50+5kmiFzJcQushXbjaEwwPXII445OaBM9L/ZzUL4CSYLuYTSoR26g8j+teAfEfQpPDnjTVdPdNsSzNJAcYDRMcoR+Bx+FfQ3wMgs4fBMFnZ6mly88kmySKNkKkgbsBgCWUnGenIrE+PXgW78RW1t4i0TFzJa2wjniyd8kYOVKj1A3EjrQI+b6+kP2bLAw+D9Tv3Zis90VUKSNgRAS3v1A/zivnCvqr4Dwmy+FljIGJe4up5Vi6eYM7duf+A55oA4n9pDTri6sdA102zRKVeCVSuWizh0Vj+LfyrwqvufxZ4ftPEHhvUNJuAiRXiFSy8bZOCrZ74IU/hXxb4m0K+8N61c6ZqcRjuIHKkjlWHZlPcGgDZ+Ewf/AIWLoTRRCZ0n3hD0bapPP5V9LeM9L/tnwfr+l2kYa4ltvMUHkeZwwB9GyMj8K8J/Z2tftHxHjkAXdb2k8qbhnnbt/wDZq+iILZLXVZZo5HKx4DuikLny2LMyj7/IAHpQB8U0V6f8a/Aa+G9XXUdKV30y+3TlFQ4tju+6T6HIxXmSqWYKOpOBQB9PeGbSST4ceHVRJ7kXMaRBUj5g/dYbJ69g4NeK/GHRhovju+ijhWG3mCywoOoXG3n3ypJ+tfRmlxzaYLyxsIPNuI5MRQzHyFZI9oIBPYAqAR1qv8VfAMPjPw2HsHRdThT7RaZxhs8tHk9myPoQKAPkWva/2dTBb2fia9urpLNI1gQTMQNu7ep/DkZrxieKS3nkhmQpLGxR1YcqQcEGvoD9neyP/CE6/cRgC4mulhiYAMVKpnJB/h+bJ/8A1UAavxx0qTUfhpDLC32ptPmW4QqCWERUq7HnoSN30xXzNX3Osa3kdxb3ltFJbSRNBIhPBTBBXHQ8fzr4/wDHPhO48Nao0aFp7B0WaG4A4KPnaG9G4Ix7UAUvBlubnxbosW1m8y9hTC9SS44Hua+3tEaM2FtE+PMRCsqMQ7KQdrKx7kHIPvXx18I7b7R8SvDUT/IDexsH9CpJH8q+vNJs0d7vMUpnceTK0mA7DO4MMcYO45+nTvQB8ffFHQ00Dx7rmn28YS1juC8SDjajfMAPYA4/Cucs0DN84BQnkgZxX1Z8dPAUnjbSLLU9Ajhl1K2B+cdZYcfKoI688jPrXy/bW5Sd47hdjRkh0bOdwyCaAPqH9mD/AEf4fXJZcO+ozGHA5mwig/T0qn+09p0N/wDD6yvwmbm0ulaIquSYXU793p82PyrqPgqI7P4WeHXzhi07xMw+QMzsBuHXngV3Vvolm0N7BeJ58V87CWCfDZBU5Tp0wT/KgD88a6P4daXfaz450Sx0mQR30lypikIzsK/Nux7BSa0vi34Ln8D+MbqwKsbCUmWzkP8AFGe31Xofp71ufs02xufjBpBWRY5IoriSNmG4BvJcDgdeT070AfZ+kQyNp9vYahb+bI1usV1MF2rL8m1jgcDcDwO/PpX5++PNC/4RrxnrWjZJSzupIoyepQMdpP4Yr9APD9lLBbzrNqDXTEiPd5ezYRnIHPOSSfavnz9p/wAAarqup2ev6XbyXhhsvKvHWLYzMrfL8vc7WPT+7QB8yV9KfAjw/JfeDrKS5jtri3N0ZYIlU+cP3iCRz0GFUDH+81fNyDbKu/IAPPqPzr7F+BvhW8ufhV4Ums53s7mS+eZZgPuxBmLn33bVxkdVFAHgfxFDD4g+Jw67WGqXWR1wfNbiuerpPiVn/hY3irJJP9q3WSRz/rmrm6CgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCxYX13p12l1p9zPa3KAhZoJCjqCCDgjkZBI+hqyut6qsQiXU74Ri3NnsFw+PIJyYsZ+4Tzt6Z7VnUUAa2t+INQ1jWU1O5lEd1GsSRGAeWIljUKgQD7uAo6Vh+NNZ1TWprWbWNSvdQlQMqvdTtKyjjgFieKmrK13/lh/wL+lAM+hf2eLKKfwZaXRANzbXNwqHr8j7Ny499o5r2DKshXGOMDJ7d+vf/ABr5l8Na2dA8DWsGla5JDbXMkzTTppbSsrhY9yA7hjaDnd3z7VrL8UtQYBU8SqTICy7NBP0+X959aCTpvH3wX0/Xr251LR7prO8m3M8RA8ov1GABke9dV8NdDn0PwVo1hqsaLf2JmKkNlVLM36YYV5iPihqkyny/Ek8gb7oXw8CG47fvPSq918RtWN0inxLqayyj5ETw8gL8nOAZcmgD6DsplNspvHhMsACSspyiucZAz2J6ZrnPH/gfSfGunmK/iEd5GNlvdLw8RzznsR6ivF4/iVq1pvaTxPq6oo3kP4fhwBuxyDL0yCPrxSR/EnWbdWB8Sa/5eR97w/bnBYkjrL36j+tAHV/D/wCH194I8T6/eWc8F4IbLbbO4IKFnzhuOoVT045Feo6Xueczs1wLe5CCKHIwoWPJz7Etj/gIrwM+P9au7e6SLxB4qlgbiUx6Hb/KMEYyJPl4pLXx1rEVmTb674vNqjBS39kW5C9MAHccE56UAfR2pWFpfWclrdwRSwyxCOSKRAQyc/L+g/KvDtZ+BkNvfJPod8fLikE5jn+YlNy/KPfn8ayZPGOuWU8ay6p40ikaYqqtplumZG5C4J547fWlTxxrUkgb+1PGhk5ACafbqODg8D0ORmgD27xJp82oi+lYSQNHHIsewYYY53Z7hscDHarVgzyQ6PdwRGN5IvLeNmGQpUEj3YOo5+teDReK9Yui5S98byGJQG/0eBdqsPlzx3HfvTV8S6s8kR+0eOGmhPlJxAMMwyB93vt/SgD0Txv8IdG8QpNPa77XUipZGQZyck4f+8STjPpVv4b+G7j4f+EJLPUWE00t00xaJCQoZVXOPbGTXndz4m8QxlxNJ45AQmNl8y3QgjGQcR+4/OqNxqutXazyvF47kVcxuTexDATqDiLtmgD6B0id4gYZo3DMqSqSCchj/eGQWUYz3OaNc0PS9Zs3t9Qto5YXKhkZMAhenPb73b1r51tNY1O9tbmKyj8bSxQOyTBdRiASQHLA/uvWp9Q1TXre0kN/b+OPs8UyxOW1eNQshZcDIi65K/nQB6JonwhtfDnjzTdc0y6m/s63kM32dlLOhPAC8EkANyfavU7IyAv9oQLKJSrBDnI3YB3d+MfqO1fNQ8Qa61xdQ/Z/G7S26k3C/wBvoCo9/wBz/nNQR32qvZ3OzSfGJtoJQk3/ABUI2B2I44i7nnjuaAPpq6uporPMaukXlqsUka7mEpYrtK/3Rxyff0rnPHHwv0TxUiSRxJp96jMftFug+cddrDoRn8QT1rwmG81Ro0ij0XxS6TyECIeIj8zBipziP1BGasWes6pLo/2+30jxI1nEjEj/AISSXcArYI2hcj2GKAPojRfDqaB4V0zT1jN5b6cECiXjDB8mbjqVBJxW+t8xdfKTzrhJNjrH94L14z1IBGR6ZNfNMKaxdRRo3h3VZVnjDgS+KJsOjDPT09c0l9ZX2nxJO/hhYMzIC0niecMGYFeTuHXGPXFAH0jrHhrRNfl2axpsF/GjsR5kW4ZIAIz9Mce2e1ebfC/4JT+DPiUPEC3Uc2mxpKttCATIrOMcnGMBWPNeU20d5JdWEcXhOxBvN3lynxDdbVPzD5yJvl3YwM4zxXVT+AfEkds2/QPDIJj8xbd/EN8XKjqAPOwccfTFAH0Pp8tvLpVhc2rqyl/vI+FBDFWJJxnGG/Okv3vBPpX+lWfli5ZrstwPKAO0Lk5D7io3fX1r5Es9Emu7m+s18IeEoWspzBN5+p3wVHwDn/j4+7kjn1/Gn6jol7YNdq/hHwZcfYZY45ZI7q9mAd8AA5nPqDz0FAHo3xD+EOg6vqMl1pktjpz3tw7giVAiEAfJgd2IY56A/WvT/hVBL4S8J6foniTXdLFzay7LaOOVMGMAHbweDnJr5ths7mIRNJ4T8BxRyjCs63LgnHTmXg4/nXsFh8GNXltoZ00/4c+XJGHBGlTOMEZHWTn60AeDfEpg/wARvFTKwZW1W6IZehHnNyK5utLxLb/ZPEeq2wa0bybuWPdZpsgOHIzGvZPQemKzaCgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKytd/wCWH/Av6Vq1la7/AMsP+Bf0oBhp3iLV9N02fT7DULi3sp93mxRtgNuAB/MAflU3/CV64FtguozKLZSsJUAFAeuDioNWhSDTNF8oFftFs08mTnL+fKmR6fKijHtUGk6rfaRctcaZcyW0zJsLoeSuQcfmB+VBJp6RrfiKe9srTTNQufPB8qCNZAoGRjHPA47mq7+KNbe5tLh9TuWntM+RIWy0eSScH6kn8atDxx4mHTW74HOciTnP1p6+PPFK4xrt8MDA/edqAIr3VfEN/o0t1d3s8tg0v2Z2aQcsxMpXHUjILemaiXxZrq2otxqc/kjy/lJB/wBXnZz14ycfWrX/AAnnirGP7ev8enmnH5Uf8J54q/6GDUv+/wCaANHxTr2raF4nvLXStRureCMKBH5m4HdEgbdnrx61V0nxL4rujOLDVJ9ttE93INyqoVQMkg8E9AB9MVAfHviw9fEWqH/t4b/GmN458Ut18Q6r0x/x9P8A40ARz+MfEVxLLJPrF5I8n3i0me2Mj0PuKPt2v6bb2Wqi+uI1uxMkEgmyxG7EnHbJP408+NvFBAz4h1Y46f6U/wDjTH8ZeJn+94h1c/8Ab5J/jQAth4l8Rtfxiz1W9F1M8aLtlILEDao/I4/Gn3mt+I9M1C6sZdTu1uLe4cSBJS37xSQTkdcHPNRHxj4mJz/wkOrg+17IP60g8X+JR08Q6wPpeyf/ABVAFi11PxNe6Zqt1Hqd61rAVlui1wfmMjBQevJJ/lVRtf1+WJYzqWoNH0CiVsdc/wBKf/wl/iX/AKGHWOuf+P2T/wCKpf8AhMPE2c/8JFrOf+v6X/4qgDY8QXmp6XDo0ml3V9DJfWSXt0Y5X/ezmSQb2564Vfy96qaXeeK9ZkXRoL/UHS5ODHLI2w4+b5s/SqJ8YeJj18Raz/4HS/8AxVDeMPEr53eItYOeub6U5/8AHqAHx33idZZpo5tWElwuyRgZMuPQ+tX7aPxfbeF/Mt59Ti0z7T5P2dGkB3ld2duOmAOfWs3/AITDxMBgeItZx0/4/pf/AIqkbxb4jY/N4g1c9ub2T/4qgCzaN4ut3SS0GtxMmQrRrKCO5wRV660/xpoGqXNtC2sedlWkktPNKyEqG+8Bz1/OsgeLfEYOR4g1cH1+2yf/ABVM/wCEo18cDXNV/wDAuT/GgDf0zSfG+omdozrMRtLV5lMwmBKjGUQ46k9B0rNu9L8X3kRS60/XponKkiSCVgSucdRzjJ/M1QbxLrrfe1rUz35u5P8AGmyeItbkUrJrGpOp6hrpyD+tAHT6rouvReEtF8jS9Wjnmkna6KwSgyFXXYW452849OazINH8ZXktvELPX258uMtFMQu4jPbgHjOKxP7W1LJP9oXmT1/fNz+tRtqF6x+a7uCfeVv8aAOgvfB3i631K6t/7H1meVZHRpIrWZhKVbBYHbkjIzmp7PwJ4zurS+kXRdaQQIsxje0nDTEuqYQbfmYbs/7qn0rlPtM+c+fLn13mn/bbvcG+0z7ux8w5oA6NPBXjlySvhrxKS3JIsJ+f/Ha6WXwj8UINL0yWG38WTpdROTbJFc5gVXKBHUjHIG4DptIrzeKW7ml2xPPJI5zhSSWP9aa5ngk2T+ahH3kYlTQB0z21xZO1rexSQ3cB8qaKVSro68MrA8ggggim1HbnNvEQScqOT16VJQUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFdR8OvCb+MvEf9nC6W0gjgkubicru2RoMkgZGT0HUda5euq0Dxte6C2mtp9hpaNZwz28rG35vY5iSyzkHLgZwMYwAKAOpm+G1naahrs2qSarY6PpNjDePvSGSecSttTyyjmMqefmDHpivO/jF4YPg/wAWzaOLn7VFEBJFNt2l0dFZSR2ODg/Sutb4oazJqFxNPZ6ZNYz2EemnTHif7MtvGcogAYONpyQd2eTXC/EjxBfeKdfk1jVWQ3dwfmEa7UUAKqqo7AAAUCZU8XWN1p1r4etdQtpbW5TTyWilUqwBuZyMg8jgiudrZ10H+yvDrEHH2FwD6/6TPWOBk4HWgQlFFFABRRRQAUUUUAFFFFABTht2HOd2Rj0x3/pTaKACiiigAooooAKKKcVIAJBAPQ460ANooooAKKkMUghExjcRMxUPtO0kdRn15qOgAoopcEgnHSgBKfFjzBuOBzzTKUHBoA9L/Zv1Ky0j4zeH73VL22sbKIXHmz3MqxRpm3lAyzEAZJA+prT+K+sQ3Hw98M6brWs2mu+L7a5lklvILtbwxWxAxHJOCQ5LcgZbA9K8iLE59+uOKbQB01p/x6w/7i/yqWorT/j1h/3F/lUtBQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZWu/8sP+Bf0rVrK1w4MB/wB7+lAMk1xWGk+HWIO02T4P/bzNW18IdDi13xvaRXUSy2luDcTRsuQyggAH8WWs3xZbLaWegQpd292i2TETW+7YczynA3AHIzg8f411vwBZV8TaoHB8t9PZJGH/ACzQyx7nPsBQScX400n+w/FeqaaAVWCdgoIxhTyP0IrEr034+2axeMIL2MqY7u2UjbyAV+XAPfjafxrzKgDo/AHh/wD4SbxNb6c5ZLdlZ5pB/wAs0A+9+ZUfjVHxRp8Gla/fWNrJJJBBIUV5Bhjj14HfNekfs62T/wBs63qsO1p7Kz2RIxwGeRsDnt93H41mfG/Q5tN1y0uxLJcWlxFhZmHRwzEpx6Zx+FAHmtbHhDR/7f8AE2naVudRdTCMsgBKjuefasevRfgLaCf4gw3BYr9igkuBgZ7bf/ZqAOa8caC3hzxDPY7XEW1XjLHO4EDv9cj8K5+vSvi6gMGntKk0UsU01vGrqAHRSAzD23cj2Nea0AWdNtGv9RtbRGCtPKsQYjONxAz+tb/xB0W00PWzbWUhZAMbShHA4DZPXcOeKb8OoVk8XWcknleXBunbzfufKpPPtnFeh/Gy2jvtKW6tbaULpzxwvIeQm9SdnHQcpigDxapIY2mmjijGXdgqj3PFR1s+DtPl1TxVpVlbxySyy3CAJHjccHJxn2BoA3vG3hKDQvD+m3cckgumlkt7iOQYJYM2CB7AYPbpXEV9AfHe1i1TQYLi2nSeaGQTRKDlmiKMZCP9kECvn+gAr0bxr4Wls/B2jXEERUWVnHJebwQQ0zErtyPfmuB0+Fri/toUALSSqgBGQSSBX1r8XtOS58DarpyB555IZLqJVI6RMrHB9Bkf54oA+QqUUlPRC5wPTNAHuH/CMLc/AmyjFuUu4objU3DD5ztbjHHTaQfxrwyvtyXTYNX8M2lpE8tp9o08wHB48vywHwPqw6+lfFV7B9mu54N4fypGTcOhwcZoAgr2X4deCbPVPhT4mu9RhH2yeMS6cWO1i8e/kdyvXP5141X2d8K9He2+Hfh57+3Au7OzkEYJBUiRt3I7/KwGfRiKAPjGitrxpYR6X4t1ixhULFBdSIij+FdxwPwHFYtAHsPwM+Hq+MdF8UT3VsTGtuILaVsqPOOSu045wQufqK8mv7WWxvrm0uABPbyNE4ByAynB/UV9e/s5X9nZ/CG1S7drdYTcXczCMvvjMpjJGPQge/evmz4s6C/hr4jaxp8zlws/mq5Ayyt8wJHrzQBTtP8Aj1h/3F/lUtR22fs0WTk7B3z2qSgoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsrXf8Alh/wL+latZWu/wDLD/gX9KAY/Ww39keHyen2NwP/AAImrrvgXFBceLLyG8kEdq1i7SZfYGUOhwT2HHPtmuY163dfDXhm52ny3t5owe2VnkJ/9CFavwqu4bXW79bq2Nxbz2EsTgEDaDjnnr6Y96CT0b9oDT45PC2kXFmiG3s5AoZTn5ZAf/iB+YrwSvp+G0s/E/w+v47oSIJo9sCMMFdqLsKr+FfM15bTWd1NbXMbRzxMUdGGCpHUUAeq/BqeS08N6/8AZZmt7q8kigjnC7ghXLDPbuT+Favx4sLu/wBE0rVbNQukW8So6lsMZGY/Nt9OnPvVb4Vq9p4MikLQJFdX7tmRch2jVMIfwLkGum1FDqfh/U9DMc13DMrzzSq+DbkEmPGeo3Y+UduKAPnKvSvgnfxaZqOp3NzIsUTxJCZCQGUkk8A9fu9K85uIZLeZ4ZkKSoSrKeoNeg/Dbw9DrGjXTXMogVrtFjm6lGRSx47jaxzQB2fxjsNLu/B2l6oXMup3G4QOpyHXdvZvTGD1HHNeD19GeCV0m/0zU7FXD3RllljkmXdHbxo3RR/CpQLxx1rwPX7L+z9ZvLUfcjlYIR3XqP0IoA6H4YWS3etX0rMFNnYS3KEnHzLgAY75z0r1XxEr+J/hnMmmQiO3lu5JyoJMihSeHX+HBAHPpXm3wsvDpEXiDV2jikit7MRFXwSWkcBcA/Qn8K9cW4m07TY7K0tUgMqot7OkgwVJw2F7lg2fY8GgD5mrsPhFEkvxE0fznWOFHeSR2OAFWNicnt0rF8U6PJoOvXmnSkMYZCoYcgrk4Oe/HpW18MZo7TWb27lj81YLJzszjduZEx+TmgD6G1B9L8SaedNSdnN3bXUIniUEwoGG4Y+m0D2r5LkQxuyMMMpII96+qdJ8T2dvBJ/Z9ulvuXaIp1Cbio+9uOODggkV4d8Y/DjeH/GVz5carZXWJYCvQ8DcPzoAxvh6iv450EOjSL9tiO1epwwNfWmnajpOoJd6XHCXASaPb3cA7pcf8CP518x/BQEfEzRpQpbyGkmwBn7sbH/69fQNpd2ttr0NlqR8yQofKu4gdsyy7lZSR9zJPHc7qAPljxDZPYazd27QvAokLIjDBCE5Xj6EU7w9GsuuWEbH5HuYlceoLivVf2ivDTQ6jaa5a7Ht5Ea3kEXzJF5Z2oSfUjj6iuE+Gdr9q8eeHoY1R3a8ibDHC4Byc/h60AfYVpdRw308TRR20u50VF5Ex9cHnABUn3NfJXxm8ML4X8YNbxGMxzxLMfKzsDn723PbPP419U2t/e3mtRXgdUgw0clnIgVo3ZsBw2MnIXpivLf2l/B73thb+JLRpZ7y2jSO7hRd22LDHzWA+7yOlAHzcil2CqMsTgD1r9CNFtYIBZ2tuxD21qltGwP3FCAceg4/OvgnwtD9o8T6RDjd5l5CmMZzlwK+1da8bWdv4nXS7e5aG489YXZI96xsTlSx9DgjB6ZPpQB83ftJ6LPY/EWfUhblLDUYopIZQpwzCNVcEnjcCOceoryevr39pfwpJ4h8GpqGlxTPeaRcMsluiFiY9vzEeygdR1r5DFAH3L8H2Fp8OPDunG1lNqNLiu5Z8AIPMLuxPOcADBx/eFeC/tS6LNp/jKxvzKLi01CEvBcZyXAOcE+oDDn0xX0F4b1az8KaFYaHLBKtxY6HauJXGEuQw+ZOecjkY9+lcr8WPCN/41+GcOussloLayjnh0t1yI2UNkZ4O5gRxQB8w2v/AB7Q/wC4P5VLUdrxbRD/AGB/KpKCgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDrvhRodj4k8eadpWrJI9lMk7SLE+xjsgkcYPblRXfXnhDwleeHZ7ix0m7s7qbwy+uROb4yiF45QmwAqNwbOST+AFeJ0UAelXljb2Oi+CfCtxHIZdUuY9U1EQ7RLtlYJCiluARFlsNxmQZqj+0P4Q0jwwmiSaRbizFw0w8mR5RMUBXBkjkGVx6jKtk4xt54/VdSvNWvpLzUrh7i6kChpH6kKAoH4AAfhXPa7/AMsP+Bf0oEzpfFpsZPh74ZfT45oYhLOBFNKJH+9ySwVQRnpxx71keArWS+1z7HEWDzJhWU4KlWDBvwKitHXf+SX+GcjJ+0XOD6fMeK5/w7dNZ3ksyBy4iO0p1ByP/wBX40CPo7wBrSalqLFIHkktpBZTXE+NyttJOPbOB+Ncp8cfBsN+t14h0nYt9bnfqMJ4Zw2NrgDjPDE+2PpTvCfiBlktYo90d5dwl422hRlnVXUY64Qgg16hp13pV1ZPY2cuYEiUFj8w2HKjknkZVhQB4Vo7PafDLTIB5jC+nkkdO21X4/PZ+legeEtZgs9ZtrSK2ke3l037VMqAEySRqpCgZxkA89qqeP7bTtPt9F/s6zEMFsQU8zIQxsWLK2ejA849wKxNK1CHR/ESzaVO0torLD9mOCX3EB9vuDgEen0oAt/Fr4aXGpySa5oK+dPKFY2qnLyDBJI7HHHHp+Fcz8OY2TwbdSeTALj7a6WsrL+8UmILIQewCkE17UusiSOb7KBLIg5SD55YD/ErIegA2j6H2rivEEVhoenw6TYLEI9SEt1BzwwJBfJ9NnQ/SgCLwpPpouZ4EYbHiW2dkGWkeRi25vVQqMAPSqPjv4dza/DFdeFTFLAgLiIEg8qpIOep6fnR4ftNRt204C9WR7FWnHl7SOcjbnHJ27yPrXqHh/VtOnNstnHcXEl0EYhVBKYjwMj+6QvX1oA+e/hvZRY1GK/mS3ltbu2dopVJDEM64IHXlq9H8D6gbi9ukvUt1jtdQYBmUbUJDEAjqSdyjjuldD440O1jsLy7tEVFlmSW52qMsVGVYfmv5V5Z4Wk1NtUtrFpSLyef7RctKduNuDH/AMBx8p9M0Aen/EfwJp3jHSVubPy7HU7aM7I1A/eAk7d2P7wwQfevJvh54clsvEOuaX4jVrJPsOyTcf4i6vGcjsSn9K950jWRJHPdefst1EO+AH57VgCJOP7rMFyT+lZHj/w88MepzWgmuLy+WFJ5cKfLjDdM/wB4g/TAoA5rR7gLbNd6ytrqkUYOVCcw9Cic/wAJJOcfpXWeMtD0vxP4Tilvo2iEnl2kW0AtFIzqPMGOoAx+Ga4P7dqItrRtDzbJ9l2pFDyxjZskgHq2zPXucV3fhOaC1urOHatrA1oPscC/eiBlOXYdicqO/OKAPFfhbpmpad8QNQtdOhE+pQWl2tsrfKJGCkZGfUZrt4tUtYtS0qNJpL20ige3NrF8pba4IbPTcjbhn2r1PXNFsls7rWbPS47fUoyRBIF2umcA8g9ya8o1Jn8LC6a3tIoNRS7McTqPnTgN34G8kn8aAPW9f0qy8S+Er3S4IliluIXlEJQYRtwPIHU55/lXiXgbwTf+GPjFpNnc4mEZlmSQrgSbYye/1Fe2afrCf2v9piw1rc2+8FT8zT5x5Y7c42j3re1GPT7qNL5oozqVtbSvA5H72IEFWA/Hg0Aecae91p2t6ZcvqIewtx/pBcEtK7OSAeedvv0xXqmlCC/0Z90CSCdNk8b8+Yp3fKW7jBP5141cXMERS58qW2jdmS8tpQGEcxQqXIHGSHU59K7zw1q15ptkbKS4062s9OiijI3Eh9yglUz/ABcrjPrQB4t4q+Fc3gT4g+E7yzl+1aTc6nbLvZdvlv5q/Kf9k9j+FdV4mWy1XxxqkEO21uINWWS9lMu37rkqi/3wdznivbNWuLLUfD8ro9rNJLb+fCs2HG5BuV8deGGa8Nm8Mxa7c3GpXQFo0hkjUXOPkuFG0nIySDhWH+8fWgD6M0lft6zSyXKS20mViVcsAhXHUdfw9cV8nfGv4QN4W1KPUtCtXTQZplhALmV0JwSxGOF6jr2r2/4R/bNLtZdN1OaKOSAoYLRWwI7fywS3/oWe+cV6KJYNUmvrC4tfMEOzfvUbZFYBhtz2/wAMUAeYeKJ3TxbJZavcwNp6xR/ZBLiNUmVFx838QO4/THvXdeAzc/8ACKWjXsvmFm3XCL++LhsKFA7YPJ+leYfEfULGDxjp9wbX+1ZoZpLJ7GUb0gP+sJUHjewwevau38E3FreTLqWnKLSyaHEyxgK5k4OH9OGH/fJoA+TvG1nHp/jPX7KFQsVtqFxCoAxgLIwH8qxK6D4hqE8f+JkU7gup3IB9f3rVz9BQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZWu/8ALD/gX9K1aytd/wCWH/Av6UAzZ1uVP+FceHIt483z7h9vfbuIz+eao+BntYteSS9eNURC6eY21S4IKg+oyOlS+Kbs3eheHXMFrDmCUAQRBOkrD/6/1zWJpl6bC4My29tcZUrsuIhIvPfB70Ensmkahojx2Uz39sgtsxxLvAZ2Zyu/OcqBt59Qc109jq3h2WSzb7dbQ2axRIxE6gMcsFQqDwAWYk/jXhQ8USD/AJhGh/8AgAlKPFUoORpGhZ/7B6GgD23xRrWm3uuBHvbF0Zo3iDXCFNuDliM4HIPFef6NPFBaXUqXthIvmpcqWmRZIyG/eBQefmBB47jFcp/wlUoVcaVoPB6f2dH/AIf5xQfFk/B/srQOP+obF/hQB7Xb6zpWmRXlxFfWEcoZoSftSu1yZEHznupBAyPasvWtd8OT3mnSS6jAV05/KgKMp8lSuGGB94fL+O/2ryhvFlxu40zQfw0uHn81qU+KZUs0kWy8PmZnZWi/smHKgAYbJXHOSMf7PvQB3sGoaMIZBBrlvY3TGBg6MHUeWHU8Zxzux/8AqrqNM8T6ToOjyadZajp0M8IEELCdX2KYywO7uCxx7V4p/wAJbd9tO0Id/wDkE2//AMRTP+Equ85+waJ/4Krf/wCIoA9f8beJdPvtP8PaLca1ayyThXu54ZAFjIHdh8vtz6VX8Ma/plrHbXVvqGmxSOyiSKaVd24sARknONvPtXl48RymweYxaGtwsiotv/ZEGWUgkvu2YGCAMe/tVc+KrzAxY6IPf+yrb/4igD3nRPEOm6Zc3KTeI9NkiWWMlldMKzM0gwc/MMDYfQkVe1jxDodtYXMd3r9k1tcb8pDciRiZWz65AUDH/Aj6V89p4rvMAfYdC47nSbb/AOIqxB4nma0uHeHQY5Y1HlxHRbdjLlsHnZxgc0AeiWuoaFZF1s9ZtYLbe0bzCcNL5QXIVVJ6Hp9RW5Z+I7e7trgHxRplk9xKsh/ep8sCeWF5/hY7T8v+17V5FpniZ7q8WO/XQrGAj5pxodvJt/4CEqO58TzxXkq239iywoTsl/sS2Xfjpx5fGaAPoC98YaTL4ZvxqHiHTLidbk/JFdAgxZ+QKB1IGCfcYrmtK8ZaGts15Jcafcwz3ADrdTbZ0CcA7D2PXNeUWvjG9ZpGlGjQFYyybdEtW3MOi/6vjPPNMt/F+ryvjy9KCKMsV0a1bavrjy/pQB7zpfiHwtY6Vplout6a0zXC5lWccDlmLf3eePxrZHj3RY7rUQ/iLSls3jZbVVuFLLkDn8D0/Gvm5vG2riUqj6WYycbv7ItBx9PLq5beMNUF68N1f6XDEobMsekWsgPBxgCPnJwPbPtQB6VpGqeGrbWcaprVjfW7q8bqZhtzuHlvn6cmuk0j4haFaywz3Wr2c0sJnimUyAJNEylhgjvnAHHUV4SfHuuokXl3WnliPnH9k2o2nPTPl88YNS3HjrWXuEt2vbBrYOpEjaRa8AjlseX79KAPoTSfiN4bsNO1AXXiW3v/ALLFJJDOxCzSAgjylTGGAzxjr3ry6XXIdMe1mi8S2U8U+J71I5d7kSAb0A6ZwFHt8348Bb+M9Wa4iE02nxx7xuf+yrZto6E48vnjtUY8Z6wCTnTsng/8Su15/wDIdAH0vZePfDNv9ga013SE0yW2YXEMsv7+J8ncRgZJIPQntXT6J8SfAy6s0f8Awk9mhS2VFkkl2x7AxIXcf4sHoOe1fIa+N9bQgq+ngjpjTLX/AON1o6Z418S3s8VpZNZS3csgSOFNHtGLE+n7v9KAPavEnjXw9Jew6jY6ppD7bt54yJv327GMuMYwcHnrgitjwx4r8MtdeJI4fEuj2d3qiFrl5bry4mlGAgjYjlCpIY8HnGK8C1jx3qltqM8OlapYXlnE48idtDtYTIMdSvlnGOmCaksPiNrbEG51WzhI4GNEtHAznJ+5/TnNACeKGhfxNq7Wtwt1bteTGOdDkSrvOGB7gjn8ay6luLp764lu5nDyzsZXYIqBixySFUADr0AAFRUFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVnT7G61K9hs9Ptprq6mbbHDChd3PoAOaAK1ZWu/8ALD/gX9K7dfBXiR9afSE0e6fUUi854FXJVOm4kcAZ4ya5HxdY3Wm332LULeW2u4WZJIZVKsh44INAMWKLTYLWCHXpNTMoQSQpbMjIsbgMPvHgkkk1ZNz4S/s/7MLXVzJ5pk+0bog+3GNuMdO9ZviT/j5suCP9Ct+v/XNayKCTez4Yw3y61nPB3RdPyq1qV54WvdQluEsdUt45GyIopIgqjA4HyVy9FAHT2d74XtluQ2n6pN50RiHmTRHy8kHcPk68frVTzPDeP+PXWCf+vmP/AON1h0UAdHd33hya3tYY9N1KPyFKlxcx7pMsTlj5fUZwPYVFZXmg2t9Bcf2fqEwikWTZJcx7Wwc4I8vkGsGigDakuNAeR3+wamAzEgC8jAA/79Vaj1Hw9HYT2q6bqZWZ0dna8j3LtDYA/dd93P0rm6KAN4TeGc82Os/heRf/ABqrN1f+F7kxFtK1WLy41j/dXkQ34GNx/c9T3NcxRQB0+n6l4ZsbtJ10jVJ9qspjlvotpypB/wCWPvke4qs1x4Yx8um6znHfUYv/AIxWDRQB0v8AafhwacbMaRqe1pRKZDfx78gEAA+R056etVTceHccaZqxP/YRj/8AjFYlFAHSapqnh+/vXuP7F1CAsFXy4tQjCKFULwPI9vzzUmma3oemi7+z6TqhNzbvbPv1JOFbqRiAc8d65eigDbFx4cxzper5x/0Eo+v/AH4q7cazoE+m2Vk2iagEtTIVddRQOxcgncfI5xjiuXooA6ex1XwzZ3tvcpoWpyNDIsgWTU0KkqQcEeR0OKfqOreF764mnfQdUjlmlaVzHqqAckkgDyMAc/pXK0UAdTbav4Zt7W8gTQNSdblFQvJqcZeMBg3yH7OMZxg8Hiq5u/C2ONF1rPqdWi/+Rq56igDrbzWvC92lmknh3Uo1tYBAvlarGu8Bmbc3+jnLEseRj6VPofiHwzpGrWeoWvhvUpLi2cSIsmrKVZh0yBADj8a4uigDrvtfhYAMfCms4HX/AImwwf8AyXq9D4p8KRaHNpLeEr17aW5S6Zzq4EgdFZQA3k/dw54x1qv8J/C9v45+IOleHZZPskV75uZgpcrsieTpuGc7MfjUPxN8KxeD/EMWmw/2oN1uszDUbVbeQEsw4VXYFcAc59eOKAGs8EjF7SFoLZjuiiaTeY0PRS2BuIGBnAz6UlRWgxawg/3B/KpaCgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr0n4WaxoPhPV7LUrrVsz31jd204Nm7DTZD8sbk8+YGAydo4BxXm1FAHttz4q8GTTeItJsZ7bTINV0e1tpdRt7F47Z7uNt0jLCq7kRgQPu9V5HOa8x+PHiKw8TfEG41XTA01kRHGjyqVMwSNELEdRnaffGOlYFZWu/8sP8AgX9KBMs+M5I5tTtpoYI7aOSyt2EEZYrGPLXgFiT+ZPWsCtnxMMTafk8/YIP/AEAVT0nTL3V7sWum273FwVLCNOuB1oEUqKcylGKuCrA4IIwQabQAUVb0zT7nU7xbWxj82dgzBcgZwCT1+lVKACiirWnWF1qM7Q2ULzSKhkYKPuqOpPtQBVooooAKKs6dY3OpXaWtjC89w+SqIOTgZP6Cq1ABRRUkEMs77II3kfBO1Rk4HWgCOiiigAoqzY2F5qEjR2FpcXUijcVhjLkD1IA6VWoAKKK6Hwr4R1TxNDfS6ZFvjtEDOT3J+6o9SaAOepaCCCQRgjtSUAFFbfh3wvq3iKHUJdJtjMljA1xNzj5R1A9TjJx7fTOJQAUUVv6P4T1fV9B1HWLG2aSxsFZ5pB0G3bu/IOD9M+lADvAPiu98EeLbDxDpUVtNeWfmbEuVZozvjZDkKQejHuOcVX8Ua1HruoR3MWj6XpCpEI/I02N0jYgk7iHdju5x16AcVjUtAHS2n/HrD/uL/KpaitP+PWH/AHF/lUtBQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZWu/8sP8AgX9K1ay9aYo9uy4yCSMjPpQDHeJQok04qethAT9dtek/AbSmjjvtbL7tzfYY44xmUOdpLrnjABOfQZrgPG93LfajY3dy2+eWxgZ2KBQTt9AAMfhXqvgW0T/hTsEtrI0Goy30kiMgLMXzsDAfQYwKCTzL4naJ/YPjK9hSUzW9wftUEhGC6OSQfzyPwrlK9k+NOkatcaLYapeGOaCwc2vnoADIj/OjEdsfcI7Ee5rxugD1H4J+HZ9Qk1XUwitbxwm2GRnEhKsD+lcZ430STQPEl1ZSJtX5ZY/TY4DDH0zj8K9j+Csc2meErCa3njQ3lzNcymU7REigRK4Pf5s8e9cX8dtNTT/E1rb2tq8dvb2aIHwdpGSeM9sk8+pxQB5lXsPwQ0M3Wg+Ib4LMxutulqYcBo1cbmf6DC59s149X0r8FbBofhbbTR+Usl3qBlyxI+VWVST642/rQB4F4q0K58Oa1Lp12G3oquCRjcrAEHFY9ezftFaCI9Rs9etXaW3uF8l2xwCM4x7Y/pXjNAHuH7NelJK+s6m0SySp5dvFnrzksAfcAZrzP4i6R/YfjXV7JUZYVnZ4gRj5GOV/Q4/CveP2fdCaP4dNeLPIh1C5ZyuFxtQ7COex6fhXE/tEaERrD63bw7Y1lWzuDkk7/LDKT6cZH4CgDxmvZv2etAXUotdu5QsWzyYoLhsfJJu3EY7jAGR9K8Zr6g/Z70e2Hw0W5ul80XGoNcjPAjaPCqf0J/GgD5/8f2a2HjbXLZIjCiXchWM4+VS2QOPY1z9eyftBeEJ9Mu7XW0jLwXLukrIPlj+bMYPuQW/KvG6APoP9l7TFSz1fVSZBI8q26KOjKo3N2/2lrxzx/o8egeM9Y0yGVJYre4YIyjA2nkD8AcfhX0r8C9Iubf4SWqwzNDcX0kk6yKASgLADAPB4X9TXln7QXh6G3vYNbsIoBDPI8U0kRJ3vnO5s98kg/hQB47X1R+zZpcNt8P2vmz5l1duzBumEwB9ehxXywOuOOfWvtL4I20C/CnQE8sHMTSHcMjJkY/zxQB8v/GDRU0H4iaxawqVt5JPtEOf7kg3fzJH4VxlfQv7U3hphPp/iKJty4+yT8cjnKn9T+lfPn8PHTNAH1T+zDpltH4Dku5ov3s91NlmJw8eFUrjHPK+9fPHxF0BvDHjTVdLKbYopd8PXmJxuT/x0j8c19f8Awu0qGH4P+GIbTyuLeK7RmPHns28j35LV4v8AtYeGjY67peuxMzxXcRtpDjhXj5Hbup/8doA8Er7N/Z88O28fwVtYpU3LrBnmuFbkFSxj6em1R1r4yr9AfBWmjSPA3hXTooLgtFFErbBkoxXJLdwmeuPagD4T8UaS+h+JNT0t9xNpcPECVKllBOGweeRg1mxLucckY5yK9u/al8MX1n4ksfEtyYzHqkQikWMkiKWMAYyexXBH0NeN6fF5pOc8nBxjj/PNAG6ieWoQ9VGKWtLxJGIfEWqRABQl1KoA6DDms2goKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK6b4b+HYPFfjKx0a7uJLaG4WZmljUMy7Ink4B6/cxXbXvw58OSaFcXmlalq5uG0Jtct0uYYwoRJAjI5Vs5JPGOB3JoA8jrK13/lh/wL+leqT6JY23hrwfpNzGsWqa7dC9nuhCZJbe2ZvKiVVHLA4d9o5Py1nfGvwLaeGjoT6LLcXdrfSTxJcSTRPHIVKAbduCp55DDjjk84BM4LxUMSaXwOdOg6f7teoazaHT/D/hCOxlkTULXS/tn2ZWIEjswbcex4J468ZrL8afDvVR4O0zW0SPNlp8cdxCvzMdrHLAgkEAHqD0FP8ZzSL4t0DToQP9CsoD50PDPIkQQl8+hXB9qBHf8AhnR01/wX/Z2sSyS6FJK+xhPtYBSWDse5yM4/GvnLWtNuNI1W60+8XbPbuUYfyP4jBr3f4U6tYL4ZjjnZcJcN5Nu/3nmY4A9gw4Oe2KwvjN4Tju7f/hI9ISaWUSNFfoo3LGysVIGOmCCPTFAE3h+9g0/wJ4esJEcz3UEjLICdoDXBO09uQoGPevStN0O38S+CJLPUoZCs6SxtJMhEkJ3/AC4zzgcEfSvJfHV0uh2Oi+HkdfszabES+zLrNncCCOxbB/CvSPhh4il8SeHZFvrs29xPcEWnBbaFABDHvk5oA+bPEWkXOg61eabeKRNbyFMkY3AHhh7Ec19KeC7Uad8PvD8gunguX01mg2rklmLttVeMtlsg9TjFcn8aPAEz6F/wkNvcGd7OJftBPzGZWIywOeApJ45wDVnV7i5m1TQ9PtkmIsLSztZB5mzG6DfuT0OT1HoKAPWvFvhy28SeHLrR7sLHDOow/QowOQw+hr4z8RaTPoWu3+l3YPn2kzRMcY3YPDD2Iwfxr7a0a8W7tBPvV124YKwfBOMAkd+teN/HXwNdavaXXiOzCSXtlK0FxDFF80kQI2v7kA/l9KAO2+F08mmeAvDOnmEvI1i10pH8RZy3l+xKnP4VveOPD1p4k8OXGmX0Txi6cDfEoJV8YR2PscZ/KuY1Z10268N6XbCRbpVs9xD4BESZfI7cHBz613ekXQ1/QRPNE8cN0GVQrYOAxAxj6ZzQB8Oaxp1xpOq3en3iFLm2laJ1IxyDj8q+yvhdYR6b8OvDtuzLuazSY8/xP8x+uNwFeaftAfDu8ug3iXTcP5NqBeoBgyFW5cevXJHt7V2PhqeSyl0GK+Rvtml2kNrHFHLkFHjTczj8sZ7g0AdN4n0C28QWz6ZfXD+RMkm6PaCrcD+LqCuQ1fF3iHSLnQdcvdLvl23NrKY3x0OOhHsRg/jX3qIwf3fzMR1wM4rwn4+fD7+0NLbxVpoke6iws0Kpkyx5wG46Ff5fSgD1TwTZR6V8PfD9tNhUgsoncsSBkgMc+nLU7x/4V/4Sjw9daPLLsiuMASADKFTkY4x1Az7ZrHv9bGjahaaV88lrFYQfao3UtuZ9qR7R6DGWx0ruV82aD5HWGYEDJAbGG/wH60AfB+v6JeeHdZu9O1KMx3Ns5UgggMOgYH0PWvszR7jS/C3h/S7N38tYbeECMdULgAEn0Jrkvjv4BPiO1ttb0pWk1OyKoyIN3nRb8kZ9V5/lXPeM9WfS/HWo3NvIVhmEUASX5gihAGbB6YI4/OgD1vxtoEHivwpqmlTW6s0quYVYn5XB+VvYZxXxT4m0O78P6zdaRec3NtL5b4yFJ5wRnt719vaFcpNZQTSzmaeNNwdSRvRuFJAPOOOfXmuB+NHw1bxpPpesaPuN5DcR2tzGiD5od5y/PUrnp6ZoA6Ca5Ok3Wh29jrGnxtAtrBd21zKqAYRRwOzEHPT0roPFfhOz8V+Er3w/e/vWZBtnkyMTgHa4x3BznFeQfEaMQ+O73XWmjlNjKiRxCMKFQr5YU9mJb+I9Pwr2bwlftcxWllFgzhA1y3mbvJCjA/3ssCD0xwaAPhyPw7d23jWDw9qkRhu/tsdpKhPQs4HB9MHINfoNFciPUDb4UrbERDyyS2MADcO3GDivI/ij8MZdY8f+HfFOiwqZ4dQg/tEZxmNGUh8HuAAD+FOtfF8ugeO9bTUrxZFBlmVtm0LzsQZ/iPzKMe1AHoPxF8J2/ivwLqejzIGlkgd7ZmBJSUZZCpPTJ49818W+ANJnPjfStFvrZlkmv4YpYZAQyneA2fwB4PNffWhTy3NhbvK8bTeQpfjAJI6gds/jXnvjL4XLffFbw14x0ZNjR3qNqaEfeCKdsgHrwAcexoA+XfiUoT4jeKkUYVdVugB7ec1c3W94/uBd+O/EdwoIE2pXMgyMHmVj/WsGgoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAsWF9d6ddpdafcz2tygIWaCQo6ggg4I5GQSPoasrreqrEIl1O+EYtzZ7BcPjyCcmLGfuE87eme1Z1FAGtrfiDUNY1lNTuZRHdRrEkRgHliJY1CoEA+7gKOlYfjTWdU1qa1m1jUr3UJUDKr3U7Sso44BYnipqytd/wCWH/Av6UAz6j+Ec/neDdHs2nJjSyjZoSBtYMHBz7ZHT2rxLxzqkUvibVpEzBJlY7cOu0bQfnyexIH6/jXZ+DdbjsNN0hJIp5Gg0jzwYZvLXHQK3ruYYHpzXmOv3gu9YJaLbFLch1ViJG29cZ7jJx+FBJ0Xg/ULO2127glVmSXYo28xgYDjLdtrd/p617xoE9nDZ2enIlpEtxGZhHKcCV23Mx/PHH1r5XF/dJE8LkGOGMSSKPlLjIDKW4PXnv6V2OlePLv+2NPmSwkYWWJLeBm3GNcleSeuc5yfWgDI+KWrzXHjjXkmhaFFm2JGwAPyrtH4EYOPYV1/w+8RLp89rZ3CNPbjT9u2IcNjgv8AgCAfpXnviKV9S1HVJYHDpPctOVlPzh8sMDPJ4B6VBa+daot5bM4lgjWQYfk5IJIHpkjPtQB9YRx6X4j0i1s7OSSTS5sxSLEwMcqKn8fcqc9R3FePfEHUri18a38MfkzzRPCi24LHy2VScL6rt6e9b/gfxZaW9vYxQwf6dPthds7QxA3YX33Of1rzjxhPc3viFr2aKO7KecIdzlXMgbJDbecgdB9KAPVPhXqX9keEo7VmEcV5uMJJ/wBTJJkru9B/j6V6zY3NvcgwJKkk0I2Sop5B9fx618q+CkS+0S4gFxt1XBdZjJwIOGc49RtYe1eyaD4r062tdFW8kcSyQGSSeQYBZZVHzY/i+bI+lAHP+MbvyvH+s39rMGktYdkkUmcqqqB8nrkkbs9gK7nwNq19PoNvaI9slzA6wyBs7FDEkbQOhI6HpXjvip7e88Taje213HFJc3bQHb92SPHCe3y8nv0rvPh54nt2Wy0qFVgiW1kiiuABuyhUsMdwcigD1+SNJw8UoRo2wpVh1HofwzXlHiW9/s7x5JcWsDSedcLaXCgEMVUKVH0DAH6E13ul6i8jXv2lnaO3kBjk4AdSM7Qe5HOeOua8g8Ua483jW+YsY9PS4wJIuRKcggn3GcEe1AHsvhi6nu9EtrppklEwd2DjJRmYnbn0AyMVt5JUlMH0JGBzXkfhHW5rWzmuhdoLGQwu0YbJtWLFXHTkE5ye1dzouvQ6rG06KVVQ5Rdwydp2tj1Gc4PpQBxmu3MEvxC+xS3rRzGZpo51OBHlP9Ww9PUD2rqdH137RqOlyD5BNbyxvasfvMr/AOsB/An6GvGfFmqtd3PiSSRlnuFut8avwGRlbbj/AGgAOKydE12S6sBbQXDz2u97mOP/AJ54XmL1wd354oA+qImjFsrQbI0f5tn3eSSenQE5r528f6v9o8QXxbyZnM3kb1XaGA5VT+IIP1rsPBXj+SbREXUI4khTyokwSGYDhywx14ryS8m+06m8tuwdHdnWVuqY4CnjofWgD1n4YeKYrifTYo5ky9uyqrD+FXLMAf7oJAA7V7LbzRpcqgIXzfmRlPBPPf1wDz7V8ieHxc2GmywtbXEjxxziEMMM+CQB9fmz+Fer6J4tvbeyttrwRyXWbNPMJAaRIiUbnucfjigDx/xZqItfEZje7nltp2naeN3yBjcAcHtn5se/evZfAvjWO0g0J7q2kj+2ztC8ikBABCMt7HgHPFeB+IdRi1OS+aSNWuHljkdhw0bBQrkH+6Xx15ro9C1W7v7K0j1y3nulikngW0iHKyJGG3MPpnp2BoA+y4L9BaySiclIgSzlskYHOT+ea+QPE155fxA1Ka9vYr61uFZtjKcEyE7MA9CpAP5V1nhf4nXKWWoWsul2wuks5PJkiYliXIYkg9Q4OR9DXDahPGfEtgJXmuZ7gPHNcOoDodoeNQBwcA456gmgD6d+FWvoNHtLS+vUaWKJY/Ol+8ztuKoe4IAFeoTypHazTStsRIizsOoAGc18ZaP4nJbTrqSDzEAaO5kbIZ3XjPHcLx+Fe7W/xEttSt7jTYATGmlSy3Dx8zIwAAGD1yGzQB8meJJo5/EWqTQOzxSXUroznJZS5IJ98Vm1Z1Pb/aV3tGF818D0GTVagoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsrXf+WH/AAL+latZWu/8sP8AgX9KAZov4yv1t7SC2jihigtI7RlI3CTY5fcffPH0rFutSuLly8hUMWLAqMYz1A9s1LdWdra6eouJLpNUYpIsPlKYjEyhlbfvzkgjjbVWwFqbyIag8yWuf3jQKGcD2BIH60Ekt3qdzded5rL+9bc5A646D6DFTvruoNIkizbJVQJvQYZgFCjJ78CrrR+FAfludcI97eIf+z1Nqk3hS6vDLbR6vbRFUURqkRxhQCevUkZ+pNAGJc6hcXBJYqpMhlJRQp3EYJyPpVy08Raja+V5MkQMaCNSYUPyjoDkc9K0LCfwpbSTNLFq84eJ41V0i+QspG7r1Gcj3AqA/wDCKA8f24R/2yFAFK213UbaMJb3HlgTeeuFGUfuR6fSnXviHUr28a6nnBmZxJkIoG4d8YxWlJc+E3sILcWurrJEzuZg8W6TdtwDx0G3jnuahjk8Kq6sYdabDAkGSLBHp92gClZ6/qNlqh1C0mWK4LMx2ou35iSRjGMcnitNdd8Qajp15N9qVrez2zSfKgI3PgY45+Zqhv7nw1c39xcR2mqQRyyM4hSSLbGCSdo+XoOgqa01Lw/a6ff2q2+qsLxUVmM0fyBWDcfLyeMUAYttql5bSvJDMRI/ViAT0Izz3wTzV2y8U6zZLtt71lAXaMqpIHHfGewqUHwtt5TW85/vxf4VZvbzwpcR2qpZarA0MPlMY5Iv3pyTvb5evOPoBQAsvxA8Ty28kD6rL5UmNwAUdO/TisWXWNQlM5kupG88s0me5YYP5gCtrTbzwnY6jBcvY6tdRxMG8iaSLY/s3y8iqWfDRP3dYA9N0R/XFACaT4q1rSY5I7C/kjSRdrrgMCM57j1rYtvid4utnlaDV3QyEE4jQAY9BjiqUd34XGlSWb2ep+Y0yyi53RF1AUjZ06HOevUCoU/4RUgbzrgPfAiNAFG513UrmcTT3bvIGZ8kDqRgnp6Ve0PUdcktp4NNutkVpC9yyjauEBBbnGTzjiruoXPg28u3mjt9atFKqBFEISoIUA/njP1NSaTqXhXTBe+Uutubq1ktTuEXyhsc9ecYoAxLbxHq1tL5kV5IG3M/IGMscmkbxDqjFybt8upRuByCc9Kt7fCmV/e65j+L91Fz9Pm4q9cXPg6bTbK2EesRS25k3TpDDumDHI3fN26daAMs+KNYaERG9k2Yx2z69aVfFWtL5uy/lXzWV2xjqucEenXtWlp7eCre7gnnk1+ZY3VzC1tCVcA52n5+h6UmqHwVdXM89pPr1r5spcQizhZI1JJ2j96OnAH0oA5yS/upEnV5mZZiDJn+LByP1q7D4j1eG6a4ivpUnaXzi64BL4Az09AK2LV/BUNjfRSy65NPPGqxStZxDyCGDFgPN5yBt7cE1SNv4TPTUtdHudOhP/tegCta+JtYtRdCC9dPtIAlwq8gZI7cdT09abYvq2uahZafayPNdSukUCbgmW/h+bj8ya1NQPg+5hsEtrnWbZ4IPKmcWETec+5jvP74Y4bGOeFHNXvCNx4R0XxDpmqTatrMv2SdZmiOlxruwc4z55/PFAGRaeMNbs7ea2iuwIJJGldPLTBdhgkccHHpV3SfGmuQSweVc42RPb7sBco4wwPHPFPbSvBryM3/AAkerBWJPOlx/wDx78P84rd0q0+Hq6RPaSa7qjXjzxyx3Q0kMyIobdFtEpBDEg5/2aAOddzIxduSxycU2prtYEuplsp3uLUOwimePy2kTPysVydpIwcZ4qGgoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK9R+DfhqMeJNMv9f0+Ke0vrK7m0qKV0ZbueL5du0k87gcBhyQOtAHl1ZWu/8ALD/gX9K+o59JS38Q+JjpbC/8WNoVrcWVpdW9u89pIz/vYiiIEMirjkLnDV41+0NDpVn8UrxNMhtxaI0ZmhtiFjEnloZVUjgfNuzjoc0CZwniobdQtRyP9AtDz/17x1jVv+N5IJdeD2cJt7ZrO0McJff5YNvGdu7v9awKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABS0lFABRRRQAUUUUAbXhHw7qPi3xFa6JocCz6hdb/JjdwgO1C5yScD5VNXtc0G78L3dtbX8li00o3+ZZXsdyu3JGCUYgHjoeavfBnxXY+CPiVo/iHVormays/O8xLZVaQ74XQYDEDqw7jisvXNf1TxXqlveaxJbTXMcYiDQ20UACBieVjVVP3ic4z74FAE8ZzGp65Ap1CgqACMEDGPSigoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsrXf+WH/Av6Vq1la7/yw/4F/SgGO8U/8hODr/x42fX/AK9oqx61/E4xqMGRj/QbTv8A9O8dZFBIUtJXR/D3Rl1/xlpWnSBvKllzIV7KoLHPoMDrQBnazot9ozwJqMDQtNGJVBHb0+vqKza+gfif4Zj1HQdUnkt5beexEl5BLIDulUFQ+RnjOc/8Br5/oASruk6bc6teraWMTSzsrMFHfaCf6VSr3X9nLw1b3ttqmoX9q7pN/o8E38KMuGbnseV+tAHhZGDg9aSu6+L/AISm8K+LblEglXTrgiS3lccPlQWAPsSa4WgApccZ7UlfQHiz4TNbfDG0aGWSW/0+H7SAsYAkEgDMPXPQD2AoA+f6KVgVYhgQRwQe1JQAUV0nw/0NPEPiaCxmcLCUd39SAOg9/SrvxM8FXPg3XZLdyZLN8NDLjG4EZx+HT8KAOOooooAKK9l+HHw5l1fwWNUFtHcrdLOrIzYddowhQd+ea8t8Q6PcaHqktldqyyIFJ3LtPIyOKAMyl7UpA3H069anEEjKqqN7M6qoHOSc4AoA0b7w9dWnh2w1dyDDdFgEwcqASAT2wcGsWvtW18CrL8FYPD08SyX/ANg8sMUHD53AZ7YY9a+PPEWi33h3WbnS9Vh8m8t22umcj8D3HvQBm1c0e0+36rZ2mQonmSMluAMnFU69Q+AXg+Pxb8Q9PtpmYQ2/+lSsozwhBA/PigDB+KPg2TwV4lexLrNayIskMinIIIBIB9s4rnNMUmcbVbbkZB7+n/66+y/2kPh6PE/gv+0dMh8zUdKVpESIcupILDA64A/SvkLTIfLcZRtxO1ue57DPsDz+FAF8jaSOBjjikpWzuOevekoKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArO1WXyLizlCI5Ri2yRdytgg4I7j2rRrK13/lh/wL+lAMseNrg3Wv8A2hooYTLaWr+XCu1Ezbx8KvYD0rDRGckKMkAn8AMmtnxeCurRZ6/YbP8A9Jo6k8C6fb6n4mtbW7eRY2V3HlpvLFULBce+MfjQSYFesfs82iJr+saxcc2un2Lq6g4LGT5QM1T17wNLfWuoXlikUd/A32mWAHCtE6hl2j16/wCNdh+z8un2PgvxVqV/C8qieC3dUA3KnUnntnGfpQB6lpUw1bTIFuLaR5WSG2fzPnyhyOR26c5rwD4rfDbUNCv7/UtPs3/sYXBjTHLKAByR6Ek/lXtXhrxPAt3rpEyLdXd4IrTaMIzBBj8TnOOnWu+srZdV0a0N6jRu+3eynHzEEH8SPWgD4JGM819l/BrTrbTfhVoVvEyZvwZZHKk4kfLDP4AD8K8S+LHwg1Hwy0+qaeVu9LZ2LFAd0PPyhs/XtXuuoSPYeGtGsFgZES2to1ELBGlYopOM8dRjn1oApfFjwdF488OStAxSeyMkkMxzwQcOpX0+XrXx06sjFXUqwOCCMEGv0A0Oa2msEhiDhULRKX6ybeGOOp5z9a8h+OnwxXW7X+1tCtYIb2EYaKGPDTjksWI64AGPxoA+dfBdgNV8XaNYtt23F3HGd3QgsODX3dcRiWJoxuUIpjRyuQuBgD6D0r44+BdpFP8AFHR1u0wsLvKN2eHVCVz/AMCA4r6O0LxrJe+Ibe3u4Tb2jSG0Z1/1c02AUZe4U4YDNAHz98avhxP4M1FL2GZrnT72R2D7MeUxOdpP415jX3h428NQ+J9MbT7lna0nK+b/AHlAbJK+hxXyJ8RPAWoeEbuGSSGX+zbvLW8jgZAycK+P4gMGgDs/2ZdBj1XX9Wu5ojItnAjIMkfvC3HP/ATxXufxR8IJ4u8L3tr5Ci98rdbv3VxggfjyK8//AGVohbeFPEV4I1MrXccS846Lxz6ZavYvDuo/2irktGN2DGqn7y4I6Z7MGB/CgD4M1KxudNvprO9iaG5hba6MMFTUEQzIoxnnpX1L8V/g0fFWv3PiDR7yJDIpFxCVOTIoxkfXFfO2qaDd6LqTWd3GRIy4VsHDAnAI7/hQB9efA/TnsPhfocd0F8yWJpgOo2s2ax/jr8PF8QeHrjUNNtVk1WJhNuz8zKAAVPfpk11y6nF4P0jRNNe0aWJbHIMOABsVcj3+9mutgeN9PFxIVn3gIFjPyMxOCq59f6UAfnvLaNb3Tx3EeDG5V1HYjINdN8PdE/tzxhoGnFisc1/Ghb+IAZY/y4NfTPxE+C+l67aS3GlJHYXSF5i6r99jyd344rxr4O6dJpXxY8Ox3trLuS7YkAcqRE4zg9gefpQB9gbA1w0I53KCfYdz7/8A168l+NHwhk8bWS3tmbVNYgR+fLKmc5GBnPGBng9zXW2niCC58ZGW1uj/AGTAgimuWYeTKzDd8pHcZAP4etehW6LJsk2tkDgkcjmgD8zNQ0q60u8lgukKPGSMkEA9sfjX0b+yFpkseveJdRiQypbWiQIgYZYs24AHtwv616t8Y/hFY+LtJnu9MtoU12JS0LEYV+5DD1PHPrXMfs96Xf8AhDwz4t1DUrKWCcFHjtWX963lo2Rt9MnqPSgD3KxEk2kkw+SrMX8raDt6nbuH8/pXyd8ZvhrqWkeMLvVLeyQ218TdyG2U+TCf4+O2Dz9DX074J1I6hYq5WaARbo2idAFJLZDA+/8AWuhvLWO8iMVwA8DBlkiZQVdSMEHNAH5xXSGO5lRsZVyDg571FW949s4NO8deI7KzjEVrbalcwxRjoqLKwUfgAKwaCgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigC9o2lX2t6lDp+k2sl3ezbvLhjGWbapY4H0BP4Vval8O/FumWNzeX2hXcNrbRrNLIQCAh/iGDyB3xnHfFVPAPiP/AIRLxVaaz9l+1/Z0mXyfM8vdvieP72DjG/PTtXQQ/EfytKWz/srO3w9JoO/7R/flEnm429sY2/rQBzy+GLhvC1hqyyFp9QvmsrOySMtJPtA3OuOwZlXGOSaxfHnhXWvD8lgmr2LwPcNIkSh1csy7Qy/KThhuGQeea6/xJ4ntP7d8ODRxNJpOgQwRwDc0LSureZK+RyhaQtyORxVD4t/EFvFNzotxaaf/AGddWLSOLwyq9zIxKkbpERPu444zyeaBMzfiT4X1CxtdO1qW3kjs7i0tITuGCjC3QYPpkqfyrD+H7Y8W2IZiqOHR2XqFKMDj0ODwa9z+MlxHcfAPQ5bqbzb+eSzmYu+XLG3+Zj3Ocjn3rwLwkA2uQrkKxVwrE42ttOD+eKBHuNj4hsLPXtNP9lXOLxY41kkclWUAx7m7AY7evPWul8T21voKIdMuoIJn3zy2flgC5iXagUnsQWJz349K5PTb61vfDlvbajG6mGJt8qD5Y92UCj6SAEfUUl5rBkkto9dW2u9Sht90McK/NNls7skY7c570Aafh+OHGiWzW4XUJ3YTQg5XaTlsns5ULj0xx1rttCL6ncxE3IlktLV4/L3bY7hyVfdn/ZKY9icV5hY6u+laJDd2cBlvklW9nnCklowSNw9wHGQOcqK2/CviBdOFq+nzRJYtzK90vmNHLLINyqw6LkEke9AHuH7i8khW+tSJWiPySDKrzyD6kECvNfiVqKS6iy2hV7mCaKNwzY2k5GPbIHT0NdJc+KIrd71ItxnM6LbvISyFWKgHA6L1H41wvxN3W2p6msjxFLuRLnz0jw0bLtCEjqxHFAHSeDbyKO80mFk+cWUl0jjkwYAWSMj36jPeu/0i9Gq2q3EKmKMnHz/eYKSCCOw4rwPTdSGjWl9eCZ7iOdGgZ1YgqzELJjPbcN2ewrsNMuruKw1CwtLiW1u7CRLvznJdZVKAmMfXK8+5oA7aXwvpUWsv4itbZUv0tJYR5aAKwPJOPXivJ4rtNLvLWTTxFfQpJ5rLM+3HIdcH1BVgPyr0vUNUvIvDX22SN08izAuU3YO8hScc8Hk814lo7ul7NBbBJgivDFvXPmqzrkbT0YLyPcHHWgD3/QPEtvrNvZSpbTIl1CkqOV+XBUkgn2xWhrWm2+saTd2N0qmG5jZC3B2hh1BPfvXinhTUrvwzMYBObqA26pE5z5SsjsVDem5cf1r0vQdXe/BlttWimWWfzBEYsGOEfK0WM9QR19jQByU3g6PwR4MudF0x1vftt6bhfNOwhflXIx/dyMetL8O9QFvqi6SYgLmyjjRpScqgHVM57gg/nXSfEOewXT5bvUJ3gkt4maAhT1bHvz2rxbwbJqjpZxfbfKeG3eS4EifvJmIYLlup6nHpigD6V0jU7TVozNauxlCEvn72MnGR7kEiuZ8a/DfTfGSWk93ElpfQsXLxHIIzkrnuCcGuV8N3jabqrXtq8s+nRstvlW8sxqEAd3B5YD0PevVJ9VjtoVumBe3xvldSD5K+pH8XOfzz0oA8/wDFOrPLc20L28s8ME0LPIB86AnAXb3UKefwrb8I6pdW8sBmZ5I7qSCKCMR5zy2Xf+7n1rmdb1RbzUtVtIrmOHWLa8zvVCFlQ5CKT34yD9ai0y+lh0e0u7iSSO6imZI4FlwyqzEjJ6FRgADsGoA9n0K/e/t5C1qYZoZ5IHQnIBVsbge4IwfxqDVNJskkuNWESLqC2rQxzeWCV3dO3OTjntmuI8P+INau7a6MaxwXCTfvGlIMexT93aDw2DjI9K2rjxlbXFpqTjC2yaf9sRmHJGWU498qMCgDxq5ury/u5LuaOOKONjaXtlC5UQErtZiBwcDnd7D1r27wn4vDWttD9nkOkxBIFu3zvMgwNpQ8kHDfNXhqaxPrV418jWFi7KJL6VoiouQvXI75GPyrf0/xfHa6o8FmHureO5jkCxnmEupw2enlgkggdj0oA+htLnh+zwRJK06fMiTffEm33Ht+eKh8StMlk/2aJWkbK+YSMJnA5Hfgk/hXHeEtY/s/STp91NbR3r7jaxWi7YwpxyoPTBJzVb4q6zPbeHNMudKuLi4lguI7iWKJ1AuICCDnsR+X+IBB4Bubm10xnubvzfMBbIONuyTpj1xzx64r1HTrlbqFmR9+12UsEKjgn1r5kh1gx3Op3OngpBcCUR2W0jyXQHDL6ZyAfevRfCnxF1G1ns7HxRbpCYgUu7gnhCV3Rgd89QfYUAfLfxN/5KT4s/7C13/6OeuarofiJOlz8QPE08J3RS6pdOp9QZWIrnqCgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKytd/5Yf8AAv6Vq1n6lbTXl1Z21rG0s8rFI0UZLMSAAKAZ6T8RmWb4eW0jOfOjXT4Sg6bVthtOexwTx9K8x8MqDqqtsd3RGdFRclmA44+td38WbXULbT7SObTr61ihS1hnkcjynkW3UDjOdwwR+Fcl8PnvU8TwNpdqbq88uQJGGVeqEE5YgcDNBJ6BdX17ZSGKy09haRSRjyc7mkIkJyR6DBP5V0YFz/wlFhkRR3Nt/pAQ4JmQgAA+hG7p6YpLS81GC5aa68KO8rFX3nUYE6df4uhPNJd6zqVzren6pceHLVZ7LzI0H9rQDcrdN3zckDHJoAk0qF7mWBdSmS00+SaaDacBzuwwIH90YY/UVX0yzZ0ubLSlDWKJO+XztQh1y5P97btI9zWMdR1qdl/tHTtOlUCRVB1aBMBhgdG7ZP5mtK38QajHb3cUWkaInnuzFv7ahUBWQArw3PAH5UAdLoWqacmo3d/cvOLZntrUJcDG+NAcD8SBz6iuX8TTat4hkSWxaKGQ3MohglJDSKrFzjt90Cqs+ra28csCxeHY7MpGnlPq0DEbVAB3Z69waLrU9XuSDK/hqNlEjRt/a0f7suRuIwfQEfjQBZv4BdWksBaRreN/IUjAcDd85PsSwUGumn8QNY3VgjyztFEksNxbcZwU3IxP97awXr2rz2wmvtPM/mXXhmWJ4vKVP7UXhM5XB7kE9e9SWOoajbxym/u/Dd3K6Opkk1MA7mAGeO+AOKAPUvEesXz6PJatFLtuIktrsOPlc4BDR/8AAFOfc15tpkh/4SD7RYor22XuATnzHQFVIY+qcn3GKJ9W1i7to4W1HwyBHNvBOpjJJABx+Iz7VT36kJBjUfDAgBLNH/aIwemeR04FAHZeFpLeDwnezX102oMttkwH7sm6TO8dD0IBrf0q1eLS9LtNOghi1u0eNry5GcrE3Lsp9cEGuDt9bvIiqibwgLRIRD9n/tPCkZJH5E5pdO1vVbK8aa3vfC5DgEKNUwFYdD9cDpQB2XxWk1DU9UjtrcI1qqG3lNwOMqclhj/ZasKxjeCWa6dlvp4zGLaRs/vAeFcjuAP1pup+NtY1PyGm/wCESjlilSXI1JQTtOSD7HNYsOoX6OhZvCxxGFQDVVATDEjp6ZoA9EtL+Wy1hr5ljTQhlGLHPmljiQn1OTn6V0Gna7DaXIQ39ubSCNzIhBOVZDtLehU/pXkD31wdBg0qRvC5tIC+P+J0MnJBOT+Aq1Frmox2N9b2beEojeOJHk/tdGJA4wM9jxQB1dxHaaddtbwo979hlWYTznmQvgsQR1UA/wAqyQIbiSTThElvPJMyzXSk4a3Byrp/tbWHUdq5mWbVXUqt/wCGQpTlf7XTGRgZz9BjHSpba71O11iG+km8OSMiJFIDq8eHQD7uP60AejWUepRhoYixWLUeS/AnG0DI+pP5U46hsgltX+zSWpkjWe3lfAQKGYiM9wOTg9hXNr4z1TexSHw2imUyxp/a6N5e4gnHtkZ9hXN+J9d1jUNPKXN14eXeycpqUSkhd/PGMcEfrQBd15Gm12O6029ke3njEoiQDAXpsAx0IGCevSp7TUW1RYbzRtDht3aU3MCAtmQQKA4Ydc5PI6EVxl1qV6+pRXaXGhp5cSxBF1NMZAwTweh9DxR4Y1K/0bU4rxrvRJxFK0wjfU0G5mGCM8/KR270AezeCvEVxp08V1q9xssboSxWvAbyyQcjJ6Ad/QfSr1xZabqWgzaMl/PfSQJJMjn5DHGoyqjB6cH8GBrz+5+KTeUYV0fw75SsrRIdQSTy+7deDuJ/IkVXu/iVFPb2NtZ6bp9n9mLEyLqCbnY8Ak9SoUkbfQ+1AHUWd/LeXay2MjzSw2uQghBDb2UqOnOOBXoGi6jdalqNxo1xpRurYK8f2qRMMeQqqeMcHjIzXhmm/EWDTtLays7C1jxG0UcqX6l1OAB9RxwPpzxXReFPjVNYJG/2Tz7kRmNj9qXaSR8zAc4ydrY9qAPLvFiGLxTrMbKFZb2ZSoOQMOeKyqva7dC+1vULsDAnuJJQM5+8xPX8ao0FBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVla7/yw/4F/StWsrXf+WH/AAL+lAMq6nqNxqV0bm7YPKVRScYyFQIP0UVVDHOeM+wrs4n0XSPDi6Vr2n3c91dtDqKXNncIhVDGdqfMhPRiSPXHpVFb3wiqsP7G1hz2Laig/lFQSc2zlgMheBjhQK0vDmlPrWpiySVIT5M029lz/q4mkx+O3H41v6x4k8NandrcP4YuEZYooQq6jgBY0VBwI+pCgn1OTS6T4q0HSb77VZeFR5vlyRfvdRkb5XRkboB/Cx+lAHFU7awQNg7ScZ7E/wCTXTHXPDwHy+EoM+rX85/kRVmTxdph0yPT08Kad9jjna4VHuJ2IdlCk7t4J4UflQBx9OljeGRo5UZHU4KsMEfUV0n/AAkmmAgp4T0YEf3nuD/7Vq3qfjhNTvp7y88M6DJcTNuZzFLk8YH/AC0oA5GGCWbf5MTyeWpd9ik7VHUn0HvUddjaeO5LJZxZeHvD8InjMMuLZ23ocZU5c8HAquvjDbjHh3w5+Njn+bUAc5JbTxW8M8kMiQzZ8uRlIV8HBwe+DVjQ7RL/AFrT7OUssdxcRwsV6gMwBx7810Uvj28mtoLeXSNAe3t93kxNp6FY9xy2PqRUUHje7t5Ult9J0CKaNg6SJpsQZWByCDjgjFAGDrVolhrF/ZxszJbzyRKzdSFYgE/lUMVpcTWs9zFDI8EG3zZFUlU3HC5PbJrobjxnd3M8k0+l6FJLIxd3bTYssxOSTx1NSR+OtRitbm1hsNFitrnb50SadEFk2nK545weaAOTqxd2dzaCA3UEkInjE0W9SN6HOGHqDg81tDxXcAEf2XoWD/1DIeP/AB2rF5411O8S2N3baPOIIxBEH0+EmOMdFHy/dGTj8aAOdsbO4v7pLayhknuJM7Y41yzYGTgfQGq9dXZeOdSsL2O7sbPRra5j5SSLTYVZeMHB2+hNRr4xugedK0A+x0qDH/oNAGALO5Ngb0QyfZBKITNj5d5BIXPrgE1DnGcYxXYxfETVI7NrRNP0EWjSCZoRpkIQuBgNjHUAkZpq+PL7IX+yfDpHXH9kwn/2WgCr4+0e10LxRc6dZsxt0hgeMu2W+eJHOTx3Y/hWNbWc18jpZwtNIkbTuEGSqIpZmPsACa7G6+Jut3knnXtpoM05Crvk0qFmYAYHJXsMCom+Iet24MltBosBYNGWj0qAEoylWXlTlSDg+tAHC1YksrmOxhvXhdbWd3ijlI+V2QKWAPqA6/mK6JfHGpL0sPD/AEx/yBbT/wCN1YX4ja4LOK1MOitaxO0kcR0i12I7dWA8vAJwMkUAceil3VVGWY4Aqzqmn3Wlajc2GoQmC7t3McsTYJRh1BxXUL8R9bVsrbaEDxjGjWvGOn/LOrc/xQ8R3ly81xHok1zO2Xll0i1LMfUsUyfrQByel6dc3y3MlvB5kVnCbi4dTzGm4LuPPTLKPxrS0uVHSIO8alV2gM2ec8nn15/Oug0/4qeILQTosWkRCePypBHo9qN6ZyVI2cjIB59K1bX4q6sq/wDHtoWAQcnRrUA5xx9zrQBykx3Su2QcsTx0/CmVa1W4a71O8uZPK3zTPI3lIETJYn5VHAHPAHFVaCgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqzp9jdalew2en2011dTNtjhhQu7n0AHNVq9J+FmsaD4T1ey1K61bM99Y3dtODZuw02Q/LG5PPmBgMnaOAcUAcwvgrxI+tPpCaPdPqKRec8CrkqnTcSOAM8ZNcj4usbrTb77FqFvLbXcLMkkMqlWQ8cEGvebnxV4Mmm8RaTYz22mQaro9rbS6jb2Lx2z3cbbpGWFV3IjAgfd6ryOc15p8cvEmneI/iNLq+no1zp/7pAZQUNwsaIpJ7jdtPvigRzPjwBbrRsd9Isz0/6ZCuZIwcZ/EV2PxTeGXXdPltrNbKCTSrJ47dXLCJTCvygtyfxrjqBBgc8jj9aSnDBYbshc84pDjPHSgBKKKKACiiigAooooAKKWkoAKUHGenPtU8lncR2cd08Ti3kYorkcEgAkfrVegAopeMHrmlRS7qijLMcAepoAbS1PqFnNYXs1rdLtmibawzn8j6VAOtAB2pQTnOeaFALDPA/OpBBJ5ZlEb+WuAz7cgE0ANUFgRkDPOTTpQwjUEkjtnt1qRFUJ1598jjikmx5OQT97kEdOPX8qAK1FFFAC0oIHr+FIOvXFOG3Z059aAPQPghomneJvH9jpmrI01t5U0/2VJDG13IkZZYtw5GSO3OM1ofE/SLq18M6Brkuj+HdNTU3mVU0sXKSJt25imjlGAyMcZXOTnk8GvMrZ5oJo57V5I5o2DJJGSGVhyCCOQRW5qOpa74keBta1fUdSaL/Vm9uXl2DjO3cTj8PSgCePmNSTngc+tOpWXYSvPy8c0lBQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZmtj/UkHBAb+ladUdUjMhjAPQHj8qAZqfEFN97ofHJ0Sx5Oevkjmu2+Inw2h0v4f2Wo6VZXRurN40vpXGfMMsYcbR1wvINUL/RTrnjLwbp6cpdaXpqNjn+AZ+v619kwQ6fq0N9o5hR7S0UW7M38RxjIoJPzfoGM812/xZ8HTeDfGl/pcsSRRb/Pt9rZBhY/L/I/lXFbCSQMHGOlAHRfDzRU17xnounzwtPb3FyqSorYJXPPPbiul+N3w8n8Da5DJEGfS77c8D7cBGycofpxXRfsx6Dcan8QDc20kMb2dtJIA4JG4/KOP89q98+LvhIeMdEXQWglleCGSezmTr5qKAoJ755BH5UAfC9LU13azWlxLb3EbRyxOUdW7MOopiZJXjP8AnpQB7j+zD4IsPE97rl3qZ8yG2hED25AxIkoIb6EY4NeVeOvD83hvxNf2EkLxxR3EiQ7u6hiB+PSvo/8AZ90q40z4ZyahakwXWqzkLdbuIimQmV/iBOR+taPx58Ax+KPAj65AnlappcTXBjUZMgZvnGf4uRkfjQB8f09F3NjuRxT/ACtsu2YOgBIb5eQR2x6+1aPh+xF5renW/ltP50qK0aAljluRj1wKAPpWDwF/bHwT07wylrOmqzxpe288gXDSbd3lg9vlJAr5avLWazuJbe6jaKaJzG6N1Vh1BFfeG501htMs7hzbxxwXFtG4AYAP83v8oAXFeBftKeDVTVE8S6Vcx3VvPuiuiAquJUJydo64BUZ+hoA8FrsPhN4ffxL8QNG0xCE8ybczMMjauSc+nANckuDkY46+9fQf7IGnW0nirXLufaTb2QCM3VSzjOPw/nQBq/tK/DG2tdFj8Q6JbNEunJHbT4ORJEAAr/UHgmvmYA5GBn6Cv0KSbS7vw/d2WpW6nTWkks5VkYlcPJsKt6HBFfEvxB8JXHhTxtqOlzwSRRRzuIDIOHiydpB6HigDlrWIvIuR0IyOnFfUP7NPgK21zwT4k/te3hktLyURReYvzK6DqD7Eg8V856bbmSaJ3GNrkAjuAOh/CvvD4G6Yuk/DDQYWAWW4hM7E4BZmORx34xQB8TePvCuoeEPEl3o9+i742Owj5laM/dIPuP5Vzd9Gy2uT/fGcdATn9eDX2V+0x8NV13SIvEGlW7vf2EflyxJ/y0hz19yv8ia+QtYgKWa7ic+aAQRjHB/woAxYInnlWOMZdiAB7k4r3/41/BOXQvDOl+I9EhCxeRDHeWaLlkkK5LjHGM9frXn/AMHNAj1v4heGbWZfMjkvUMgPZFyxH/jtfoVf2kF/ZT2l5EstvMhSRG6MDQB+WmMNhgR7GrFuqMxBddgbJ3Dt2zXWfEjwZeeD/Et5YXlu9tCzGS3VznMbMdg+uOM+1YdraI7lFBGB128jHXp1xz+VAHqn7OXgyz8T+PHttXslvNPFlN52GwIyQArD354/CqPjrwU/g7xLeaZN89qJG+z3DBl3KDwB/tYP869q/ZF0mNbLWdUGBKGFqcLjcuAw/wA/7Ven/GbwjH4t8F3UUVssup2uJ7RwBvDA/MB9V3DHrigD4Wuf+PmXjHznj05qKp71Sl5cIVKlZGBU9Rz0NQUFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUwt5V3bXAVWeBvMVWXcrEc4K9D06Gn0gUPKisuc9D/AHfegGe9eBYRrnxs8IXd1Eit/YkF032dBGiMIOMKOFXPYV9BWNzb3d7NFZSJFdzwxzFDHwhBPzH17cV4t8LtE1C28Q2OuiBhax+EbcRSMMIXAC7c+vHSup+HfiXUrmWabVFtzG80VvHIuS8jhixB9BtH60ElT44eCIvG3htdRuW+zavpispCxbt6kg4Hr9O2TXyBf6TcWVzNbXSNGysQAUIPfFfonpenRXum2ckk8t1C++eI3Jy4Zi2PwCsQPYCuC+M/w903xh4fa4sbeO31iKMyxMq7Q6JkbTj68UAeSfAHT0g8EeMNctUxfJPBbJjghVw/GPfB+gr6L8PPc6jZ2sk8izGG5LFhxgbexHXk9/WvEvhh5eifCLxRYXIe01iG6eYx7SGAARRivQfhrqzxaZHEtwjeVdbmDfxoRt289COGoA8e+PvwgmGoX2u+HLa4nj3NJcxkfMZHcnK/7I618/21mRIpZQo3ZPfAPB9z0/8ArV+kuhmE2bWyNJOIJHilaXLEvnJHPXr/AEr5u+NvwYbT3v8AX/DaCWCaYySW6ceXuOOAOwJoA7PwfLYaD8OfB2m3MKZuraN59w3CLerYJ9N2cD8a9C0XRLWG7lQajcSrITEbV2ynyqMqBjoOv415n4+Fz4eh0aws7nCrb2tt9neMHBjRRnJ5PX9K9B0vW45b7TBEhxI7RPKy4G/Zkt9CR19gKAPBfjb8EzZy3+u6H5jvPO872xGVUFugH1Jrz/4EaSJfir4eim3xbZ3kwOGBRWP8wBX2pfILq1tYYLuNWjlXcDjc8iEOUwfUfzrzG+8D2nhv4mR+M9DQLpdsZZL4KST5jZBCj6nkUARWHiW0udeDInm38UIkQE8s7yfOme2ARXVeIIdEv/D7QiK3nMsLuIRFlgQp3n68YwfSvEb/AFufSfF94ltEY4JHFyqZ4d1k3qjegPHSvWPC/iHSLfxFrL3MUakW6vKB1SSU5kB9BzzQB8zfFb4Z3nhDWJp7CKS40kxxyeeBkRs652/hXp37KrafYabr11fuIZ7l0hh3j5XCoWYA9B0z/wDqr3G/0JPEWlX2j35iltplK5jOfL7oQTzkqcV5knw4PhLwfr+lNqCmznK3dvM74dZUyGGfTBwaAOw8KSW8V9ALS3nuXkgM91C8wdSXcYfHIJBJ59vatL4wfDuw8deHJHSMy6raxt9mdXHLZztPryPwrhvhbqMukaZb+Upub2C18hoW5fb5nb/ZyQfxr2vR5YAikSgCVgREcZVyMt+JJP40AfBN94d1HQtVn0/U7eaCaKQhxIMEEjgj1yK+27S9TSNP8OaWCkIa2iETAZIKKu4Ee65qt8Vfh/YeMNNMy2y/2tFgRTLgMQSAQT3AGSPSuc8ZtcaL4iW3keKcT4+xtMOYgFVdoPpwfyoA9dYLIm07WRgQQe4r42/aD+F0nhdYtRtTJNptzOSGVf8AVOdxCEfTgGvp/wAEXlw+mNHq7Ok1iQjSyEBX+QFiD3HzfnW9rukWGvaVPp2q26XNnOu143HX3HofegD4/wD2XtNE/wAUdNk2Z+yW085YD5R8gjH6tX2Jp1/DfCcQupeCUwyKGB2sOoNeOeA/htN4H+IHiG4BI0CTTilpcO33C0inb9Rj8eK3fgw7edq88tws0mpSteHaf4gxVj+OQPwoAZ8c/hlH4504X1vJImqWVu6wKi58znIH16/nXyFLoc2k6pJZairR3ERMcysNpTbkfga/RGvL/jJ8MbHxXptxqenwCLXoIiUaMcXGCDtYd244PXnFAEP7PUMGj/COxvJflF1cSyyN6ZlMYz7AKK9WBBAIOQe9ebeFdLbTfg9pOj39vNFO1qxkt3bbJvyXK899x6eld/p17b3kCtbyRttVdyoQdmQCAfSgD4F+JgA+JHisAYA1a7wP+2z1zVdL8Tf+Sk+LP+wtd/8Ao565qgoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA1vC2g3vifXbfSNKERvJw5QSOEX5EZzkngcKa6bUfhdrllplzffatIuYYbIagBbXqyNLBna0iAckKTgngema5zwj4hu/C3iC31jT44JLmBZFVZ1JQh42Q5AIPRj361sRfEHVY7BbRbex8saM+h5KPnyHkDlvvffyOvTHagCKPwn5nhbQrpGlfWdcv2trG1BUI8SkIXJPQmRto5A+Vvwk8QeCb/AMMahBa6jPazXErMnlWrs7oy8YK7QeSeCAQcHGcGoPE3iiPUNd0m50+0VNP0mCC3tLW5AcFY8E7wODucsx/3qv8AiTx5rHi46dFdrBaw6cWe3W3aQlGYjJ3yO754GBuwMcYoEz6l8NmTTfgppv2q2lDWunILiGQbGX93k57jGc4/CvDtJ1qOxe/UpJHGbpFeDzNxIkz07gjcATXqTapqLfB3T0e5WN5NPtJGurhixmdyAVbuwIAz+NeKX0o1XVr67s7VjI0ymXyRhY1VuSAe2RQI+mvDniq0vreyttLVPtGwNFbBhyoTkE9sH+ddR9oX7ZMqskhRVZkJACE7gefQnvXzb4ER10WQW0ksd3FIxub5c5j3RsGUd8cL0r1Xwnq0F42nLMk4e3tWt5y5z5oYnaSR15X8N1AGZ8bJoo9ItZgsX9pM8tva+UcqyuVBY47gDp65rhdOitbXVtCW2a5cWyEtHAoPmjJCv/ve3pitv41aLvtNCWASWxtbaR8SSkiMSEkZ9WGG5rjfDUUmVa4keS8igSCGGLKcA5L7u/f6+tAHvfhKe/eBJLubzLlH8hiv/LUNkhz9Op+hrorO1ngmMSNBJYM7OwbJckgkj0+9z+NeOWmvveXKJojyJbR2hEW7PMuSXBPbnHPoPevQdA8U21/ZWt84WOeIvDIGkA3KMAyfTP8AOgDy74uarbXPihp7Y+c1lFJBcGVT/oyklt+fUMOPSsXwc93eeLdP+xahLJpkL5XzZP8Aln3U9jubJFZvxPv5bnxPcQ6VESt9NJavGBjDYx8x7cnPuKyBqN3ploYbNWdrER27IDhQ0ZDM+ffp+FAH0clw07JqEMSfZhGZJ1b7zOIyAyejbm2k03xPOIvB+vxR3MRiu4GEGxSCJNvzqT/e4zk+teUaX4puFltr4W8cNszW8QjkkIKuXyz4PY4z+FWPFGtwjw/rumNLLDdXrNcRydUeTfyPYUAeY391HPqEst4kklr5bLKwPzRuD8nP0BJrf8OeIbaWxuJri33RR2sitcdCzYyN397DcYPauHvIrptCETzTG+kYPLHkcleMj2wMfjVu3mjneK3tgsGnuvmy7zhd4yGU47HP6UAez+FPH0cDae165ngNqA5UlSgwI1Uj+I4BwevSpfifrNhqPhDRoDcMPtAbyi3ys64xjPc5HWvHPD8Nncmc7o0hgYvLKTh3Yc7Y/UYFdP4o1PTtc0rRY7dVe3t3liE7YDW24gqf90cn8aAJPBup2enLbCO8aQWxEiKyfPJKC29M9dpGMe4r1PT9Rgk015dMjuYxqbG3mWRzuRjn5xnkfe6j0FfOmFF2J4Dieyk8uGNekiqwP4E8n6GvUPD+pz3H2W/v7t1+0zSiG3ZuVJTDg47Dgj3AoA+j9CuIH0+GCKYO0EYjYFssNoxk+/FfNPxC8T3Unje/aUC9WyuZTasWwFQKMqfUDNd54F19DqzFpSL5okdo4sf6QI0Ibd/tMMGvKfGL2WreLtmnKIGcsJcj5Oc8MB6cAj2FAHYeGPEd+2q6THE/+iXEWDbs/wArqCTkn8P8ivdPDXiKz1mO6+zlUEEmw5b+fpyelfMWjTTWc1vBcQL9pMaW8KehDksFJ7bTmur8CeI4m8SXK3kMiwRzySP5YAWX92wC49zz+FAHtPxJ1C307wTqk1wFdXj8lFLbdzscAZ7c182+BvFcyeI9Ejiu5FWGVkjzkBIlbJXj7wbp612fxF8VRzfD3XdLby7rTFZEtrlMiSKTIYRSZzl++RxXiM1/ceHLXS5k8meTJZMId0Tr1UnvyckewoA+yvB/i1NcguxcQGC4trgwMEBZX54ZSO3Bz6YrqVYOMqQw9Qc186/D7xFepo7TO0SSQjzoSvSdpVwox65U5+tes+HtUstF8GFtyzTWkRkmSLgu5OT+JJoAwvjRrrafJpWnRTbHvllHGMptKEN+PK++a0/Dmv6RGyXVqjr59rBDg8M+xWxhe/cV5t8Vtca28Y2F5eWlrNps8YMocBngClivPYkqeKi8O3V+2mRzRLHcGQqMgbWUksSVJzj5VHfv1oA8B+Ison+IPieUAqH1S6bDDBGZWPNc9Wp4pna58TavPIu15byZ2X0JcnFZdBQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFaOj/wCsb/eX+tFFAM+ipv8AknXh7/ryi/8AQK870f8A1mrf9eZ/nRRQSegeFf8AkIar/vr/AOi2rt/C3/HjD/1wX+YoooAxvjx/x56V/wBeb15rov8Ax+aR/wBc3oooA6nR/wDkDar/ANc4/wD0GtDS/wDkHv8A9ecn/oUVFFAHG+Kv+Rzuv+wuP5VnWv8AyCdd/wB+f+lFFACeIf8AkAr/ANdrf+Rqxc/6mH6j+tFFAGDd/wDIwH/rhN/IVBof/Hrqv+4f/QhRRQBm+H/9WfpL/wCgNXXw/wDIMtv9wf8AoJoooAs+Df8AkKWv+9J/Oq99/wAjnJ/19S/zFFFAGh4R/wCRs07/AK+pv/RVUm/5HDWP+vz/AAoooAsXf/Lv/wBdV/pV/wAJf8jLD/2ED/6A1FFAGd4j/wCQBZf9d/6iuQ8W/wDIEX/rqP8A0GiigDX8Pf8AHp4d/wCwf/7Ma9bsP+Qdpv8A192f/oAoooA858cf8efiX/sJL/6G9ehaP/yLVp/1yH8hRRQB8y+IP+Q9qX/XzJ/6EaoUUUFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Waveform panels are organized from top to bottom according to advancing gestational age. Note the progressive increase in the end-diastolic velocity and the concomitant fall in the pulsatility as the gestation advances.",
"    <div class=\"footnotes\">",
"     A: 16 weeks; B: 20 weeks; C: 24 weeks; D: 28 weeks; E: 32 weeks; F:36 weeks; G: 40 weeks; m/s: meters per second.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Maulik, D. Absent end-diastolic velocity in the umbilical artery and its clinical significance. In: Maulik, D (ed) Doppler ultrasound in obstetrics and gynecology, 1997; 129, New York, Springer Verlag. Copyright &copy; 1997 Springer-Verlag.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1383=[""].join("\n");
var outline_f1_22_1383=null;
var title_f1_22_1384="Uncombable hair syndrome";
var content_f1_22_1384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Uncombable hair syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spun glass-like, silvery-blond, unruly hair is characteristic of uncombable hair syndrome. Pili trianguli et canaliculi is visible on electron microscopy of the hair shaft. Uncombable hair syndrome does not cause fragile hair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1384=[""].join("\n");
var outline_f1_22_1384=null;
var title_f1_22_1385="Ketorolac (systemic): Pediatric drug information";
var content_f1_22_1385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketorolac (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/1/21529?source=see_link\">",
"    see \"Ketorolac (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/33/3606?source=see_link\">",
"    see \"Ketorolac (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8320258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8345791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ketorolac Injectable&reg;;",
"     </li>",
"     <li>",
"      Apo-Ketorolac&reg; Tablet;",
"     </li>",
"     <li>",
"      Ketorolac Tromethamine Injection, USP;",
"     </li>",
"     <li>",
"      Novo-Ketorolac;",
"     </li>",
"     <li>",
"      Nu-Ketorolac;",
"     </li>",
"     <li>",
"      Toradol&reg;;",
"     </li>",
"     <li>",
"      Toradol&reg; IM",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10501739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipyretic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to a lack of substantial evidence, NSAIDs are",
"     <b>",
"      not",
"     </b>",
"     recommended for use in neonates as an adjunct to postoperative analgesia (AAP, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Full-term neonates: Multiple-dose treatment: I.V.: Dose not established; limited data available; one retrospective study (n=10; mean PNA: 3 &plusmn; 4 weeks) recommends 0.5 mg/kg/dose every 8 hours for up to 1-2 days postoperatively; do not exceed 48 hours of treatment (Burd, 2002);",
"     <b>",
"      Note:",
"     </b>",
"     To reduce the risk of adverse cardiovascular and GI effects, use the lowest effective dose for the shortest period of time.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10503887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/1/21529?source=see_link\">",
"      see \"Ketorolac (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     To reduce the risk of adverse cardiovascular and GI effects, use the lowest effective dose for the shortest period of time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Infants &ge;1 month and Children &lt;2 years:",
"     </b>",
"     Multiple-dose treatment: I.V.: 0.5 mg/kg every 6-8 hours, not to exceed 48-72 hours of treatment (Burd, 2002; Dawkins, 2009; Gupta, 2004; Moffett, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Children 2-16 years and Children &gt;16 years who are &lt;50 kg:",
"     </b>",
"     Do not exceed adult doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Single-dose treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer's recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.M.: 1 mg/kg as a single dose; maximum dose: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V.: 0.5 mg/kg as a single dose; maximum dose: 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternative dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.M., I.V.: 0.4-1 mg/kg as a single dose;",
"     <b>",
"      Note:",
"     </b>",
"     Limited information exists. Single I.V. doses of 0.5-1 mg/kg have been studied in children 2-16 years of age for postoperative analgesia. In one study (Maunuksela, 1992), the median required single I.V. dose was 0.4 mg/kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral: One study used 1 mg/kg as a single dose for analgesia in 30 children (mean &plusmn; SD age: 3 &plusmn; 2.5 years) undergoing bilateral myringotomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Multiple-dose treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M., I.V.: 0.5 mg/kg every 6 hours, not to exceed 5 days of treatment (Buck, 1994; Dsida, 2002; Gupta, 2004; Gupta, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: No pediatric studies exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Children &gt;16 years and &gt;50 kg and Adults &lt;65 years:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Single-dose treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M.: 60 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 30 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Multiple-dose treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M., I.V.: 30 mg every 6 hours; maximum dose: 120 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: Initial: 20 mg, then 10 mg every 4-6 hours; maximum dose: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adults &ge;65 years, renally impaired, or &lt;50 kg:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Single-dose treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M.: 30 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 15 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Multiple-dose treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M., I.V.: 15 mg every 6 hours; maximum dose: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 10 mg every 4-6 hours; maximum dose: 40 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8353206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as tromethamine: 15 mg/mL (1 mL, 2 mL); 30 mg/mL (1 mL, 2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as tromethamine: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8345793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8345784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089165.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089165.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10512521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May administer with food or milk to decrease GI upset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: Administer slowly and deeply into muscle; 60 mg/2 mL vial is for I.M. use only",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. bolus: Administer over at least 15 seconds; maximum concentration: 30 mg/mL;",
"     <b>",
"      Note:",
"     </b>",
"     I.V. ketorolac has been infused over 1-5 minutes in children.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8349369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, cisatracurium, dexmedetomidine, fentanyl, hetastarch in lactated electrolyte injection (Hextend&reg;), hydromorphone, methadone, morphine, pantoprazole, remifentanil, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Azithromycin, fenoldopam, haloperidol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dexamethasone sodium phosphate, dimenhydrinate, metoclopramide, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Haloperidol, hydroxyzine, nalbuphine, prochlorperazine edisylate, promethazine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diazepam, hydromorphone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10503865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light; store in carton until use. Injection is clear and has a slight yellow color; additional color change indicates degradation; precipitation may occur at relatively low pH values; do not mix in same syringe with morphine, meperidine, promethazine, or hydroxyzine (precipitation will occur)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Store at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10503767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M., I.V.: Single-dose administration for moderately severe acute pain (FDA approved in ages &ge;2 years and adults). Short-term (&le;5 days) management of moderate to severe pain, usually postoperative pain (FDA approved in adults); has also been used to treat visceral pain associated with cancer, pain associated with trauma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Short-term (&le;5 days) management of moderate to severe pain, usually postoperative pain, and only as continuation therapy of I.M. or I.V. ketorolac (FDA approved in adults); the combined duration of oral and parenteral ketorolac should not be &gt;5 days due to the increased risk of serious adverse effects",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8320263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ketorolac may be confused with Ketalar&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Toradol&reg; may be confused with Foradil&reg;, Inderal&reg;, TEGretol&reg;, traMADol, tromethamine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Toradol [Canada and multiple international markets] may be confused with Theradol brand name for tramadol [Netherlands]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8346959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, purpura, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, dyspepsia, flatulence, GI bleeding, GI fullness, GI pain, GI perforation, GI ulcer, heartburn, nausea, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal function abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal thinking, acute pancreatitis, acute renal failure, agranulocytosis, alopecia, anaphylactoid reaction, anaphylaxis, angioedema, anxiety, aplastic anemia, arrhythmia, aseptic meningitis, asthma, azotemia, blurred vision, bradycardia, bronchospasm, bruising, chest pain, CHF, cholestatic jaundice, coma, confusion, conjunctivitis, cough, cystitis, depression, dyspnea, dysuria, eosinophilia, epistaxis, eructation, erythema multiforme, esophagitis, euphoria, excessive thirst, exfoliative dermatitis, extrapyramidal symptoms, fever, flank pain, flushing, gastritis, GI hemorrhage, glossitis, hallucinations, hearing loss, hematemesis, hematuria, hemolytic anemia, hemolytic uremic syndrome, hepatitis, hyperglycemia, hyperkalemia, hyperkinesis, hypersensitivity reactions, hyponatremia, hypotension, inability to concentrate, infection, infertility, inflammatory bowel disease exacerbation, insomnia, interstitial nephritis, jaundice, laryngeal edema, leukopenia, liver failure, Lyell's syndrome, lymphadenopathy, maculopapular rash, melena, MI, nephritis, nervousness, oliguria, pallor, palpitation, pancytopenia, paresthesia, photosensitivity, pneumonia, polyuria, proteinuria, psychosis, pulmonary edema, rectal bleeding, renal failure, respiratory depression, rhinitis, seizure, sepsis, somnolence, Stevens-Johnson syndrome, stomatitis (ulcerative), stupor, syncope, tachycardia, thrombocytopenia, tongue edema, toxic epidermal necrolysis, tremor, urinary frequency increased, urinary retention, urticaria, vasculitis, vertigo, weakness, weight gain, wound hemorrhage (postoperative), xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10503768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketorolac or any component; history of asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs; patients with the \"aspirin triad\" [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); patients with active peptic ulcer disease (PUD), recent GI bleeding or perforation, or history of PUD or GI bleeding; advanced renal dysfunction; patients at risk for renal failure due to hypovolemia; women in late pregnancy; women in labor and delivery or breast-feeding; preoperative prophylactic analgesia; perioperative pain in the setting of coronary artery bypass graft (CABG); patients with cerebrovascular bleeding, incomplete hemostasis, hemorrhagic diathesis, or at high risk of bleeding; contraindicated for epidural or intrathecal use due to alcohol content; concomitant use of probenecid or pentoxifylline; do not administer with aspirin or other NSAIDs",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10503805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with decreased hepatic function; closely monitor patients with abnormal LFTs; severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop or if systemic manifestations occur. Use with caution in patients with asthma; asthmatic patients may have aspirin-sensitive asthma which may be associated with severe and potentially fatal bronchospasm when aspirin or NSAIDs are administered. Anemia (due to occult or gross blood loss from the GI tract, fluid retention, or other effect on erythropoiesis) may occur; monitor hemoglobin and hematocrit in patients receiving long-term therapy. Use with caution and monitor carefully in patients with coagulation disorders or those receiving anticoagulants; NSAIDs inhibit platelet aggregation and may prolong bleeding time.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10503769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. NSAIDs may cause fluid retention, edema, and new onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, CHF, or fluid retention. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin's cardioprotective effect. Due the effects of platelets, use is contraindicated in patients with suspected or confirmed cerebrovascular bleeding, patients with hemorrhagic diathesis, incomplete hemostasis, those at high risk for bleeding, for use as prophylactic before any major surgery, or intraoperatively when hemostats is critical due to increased risk of bleeding",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may increase the risk of gastrointestinal inflammation, ulceration, bleeding, and perforation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events, which can be potentially fatal, may occur at any time during therapy and without warning. Avoid the use of NSAIDs in patients with active GI bleeding or ulcer disease. Ketorolac is contraindicated in patients with active peptic ulcer disease or patients with recent or history of GI bleeding or perforation. Use NSAIDs with caution in patients with other risk factors which may increase GI bleeding (eg, concurrent therapy with aspirin, anticoagulants, and/or corticosteroids, longer duration of NSAID use, smoking, use of alcohol, and poor general health). Use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may compromise existing renal function. Renal toxicity may occur in patients with impaired renal function, dehydration, heart failure, liver dysfunction, and those taking diuretics and ACE inhibitors; use with caution in these patients; monitor renal function closely. Ketorolac is contraindicated in patients with advanced renal disease",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Long-term use of NSAIDs may cause renal papillary necrosis and other renal injury.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity reactions have been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use is contraindicated in patients with a history of hypersensitivity to ketorolac or other NSAIDs; patients with the \"aspirin triad\" who receive NSAIDs may be at higher risk. NSAIDs may cause serious dermatologic adverse reactions, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use is contraindicated for pregnant women during labor and delivery due to potential adverse effects on fetal circulation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; also avoid use in late pregnancy; contraindicated in nursing mothers due to potential adverse effects in neonates",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Duration of ketorolac therapy should not exceed 5 days and should not exceed recommended dose due to adverse effects",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; if multiple dosage forms are used, total duration of combined therapy should not exceed 5 days. Dosage adjustment is required for patients &ge;65 years and those who weigh &lt;50 kg",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Use is contraindicated in patients currently receiving aspirin or other NSAIDs due to risk of cumulative toxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8347281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants: Ketorolac (Systemic) may diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Ketorolac (Systemic) may enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Ketorolac (Systemic) may enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Ketorolac (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: Ketorolac (Systemic) may enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased with this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Ketorolac (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10501740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High-fat meals may delay time to peak (by ~1 hour) and decrease peak concentrations",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8345796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8345797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies ketorolac as pregnancy category C. Ketorolac crosses the placenta. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians).",
"     <b>",
"      [U.S. Boxed Warning]: Ketorolac is contraindicated during labor and delivery (may inhibit uterine contractions and adversely affect fetal circulation).",
"     </b>",
"     The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10512522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of pain relief (eg, increased appetite and activity); BUN, serum creatinine, liver enzymes, CBC, serum electrolytes, occult blood loss, urinalysis, urine output; signs and symptoms of GI bleeding",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10512523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic: 0.3-5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toxic: &gt;5 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10503884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10503885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M., I.V.: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 1.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M., I.V.: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10503886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Well-absorbed; 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Crosses placenta, crosses into breast milk, poor penetration into CSF; follows two-compartment model",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     beta:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 4-8 years: 0.19-0.44 L/kg (mean: 0.26 L/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 0.11-0.33 L/kg (mean: 0.18 L/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: In the liver; undergoes hydroxylation and glucuronide conjugation; in children 4-8 years, V",
"     <sub>",
"      dss",
"     </sub>",
"     and plasma clearance were twice as high as adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral, I.M.: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants 6-18 months of age (n=25): S-enantiomer: 0.83 &plusmn; 0.7 hours; R-enantiomer: 4 &plusmn; 0.8 hours (Lynn, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1-16 years (n=36): Mean: 3 &plusmn; 1.1 hours (Dsida, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     3-18 years (n=24): Mean: 3.8 &plusmn; 2.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     4-8 years (n=10): Mean: 6 hours; range: 3.5-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Mean: ~5 hours; range: 2-9 hours [S-enantiomer ~2.5 hours (biologically active); R-enantiomer ~5 hours]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     With renal impairment: Scr 1.9-5 mg/dL: Mean: ~11 hours; range: 4-19 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Renal dialysis patients: Mean: ~14 hours; range: 8-40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: ~45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: 30-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 1-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Renal excretion: 60% in urine as unchanged drug with 40% as metabolites; 6% of dose excreted in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10512604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/33/3606?source=see_link\">",
"      see \"Ketorolac (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID); NSAIDs may cause serious adverse reactions, especially with overuse; use exactly as directed; do not increase dose or frequency. NSAIDs may increase the risk for heart attack, stroke, or ulcers and bleeding in stomach or intestines; GI bleeding, ulceration, or perforation can occur with or without pain. Notify physician before use if you have hypertension, heart failure, heart or kidney disease, history of stomach ulcers or bleeding in stomach or intestines, or other medical problems. Read the patient Medication Guide that you receive with each prescription and refill of ketorolac.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     While using this medication, do not use alcohol, excessive amounts of vitamin C, other prescription or OTC medications containing aspirin or salicylate, or other NSAIDs without consulting prescriber. Ketorolac may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Notify physician if stomach pain or upset occurs, if swelling or redness occurs in painful area, or if any new symptoms appear. Stop taking medication and report ringing in ears; persistent cramping or stomach pain; unresolved nausea or vomiting; respiratory difficulty or shortness of breath; unusual bruising or bleeding (mouth, urine, stool); skin rash; unusual swelling of extremities; chest pain; palpitations; or weight gain.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not exceed 5 days total use (I.M., I.V., oral).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10512605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     30 mg provides analgesia comparable to 12 mg of morphine or 100 mg of meperidine; ketorolac may possess an opioid-sparing effect; diarrhea, pallor, vomiting, and labored breathing may occur with overdose",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     A single I.V. dose of ketorolac (0.75 mg/kg) in 21 children (2.5-9 years of age) undergoing outpatient strabismus surgery was associated with less postoperative emesis than morphine plus metoclopramide (Munro, 1994). However, a single dose of I.V. ketorolac (1 mg/kg) in 25 children (2-15 years of age) undergoing tonsillectomy was associated with an increase in surgical bleeding, more patients requiring extra hemostatic measures (eg, synthetic collagen, extra Neo-Synephrine&reg; packing), and a higher estimated blood loss compared to rectal acetaminophen (Rusy, 1995); further studies are needed.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Fetus and Newborn; American Academy of Pediatrics Section on Surgery; Canadian Paediatric Society Fetus and Newborn Committee, et al, \"Prevention and Management of Pain in the Neonate: An Update,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(5):2231-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/17079598/pubmed\" id=\"17079598\" target=\"_blank\">",
"        17079598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buck ML, &ldquo;Clinical Experience With Ketorolac in Children,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(9):1009-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/7803871/pubmed\" id=\"7803871\" target=\"_blank\">",
"        7803871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burd RS and Tobias JD, \"Ketorolac for Pain Management After Abdominal Surgical Procedures in Infants,\"",
"      <i>",
"       South Med J",
"      </i>",
"      , 2002, 95(3):331-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/11902701/pubmed\" id=\"11902701\" target=\"_blank\">",
"        11902701",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dawkins TN, Barclay CA, Gardiner RL, et al, \"Safety of Intravenous Use of Ketorolac in Infants Following Cardiothoracic Surgery,\"",
"      <i>",
"       Cardiol Young",
"      </i>",
"      , 2009, 19(1):105-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/19134246/pubmed\" id=\"19134246\" target=\"_blank\">",
"        19134246",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dsida RM, Wheeler M, Birmingham PK, et al, \"Age-Stratified Pharmacokinetics of Ketorolac Tromethamine in Pediatric Surgical Patients,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2002, 94(2):266-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/11812682/pubmed\" id=\"11812682\" target=\"_blank\">",
"        11812682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta A, Daggett C, Drant S, et al, \"Prospective Randomized Trial of Ketorolac After Congenital Heart Surgery,\"",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 2004, 18(4):454-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/15365927/pubmed\" id=\"15365927\" target=\"_blank\">",
"        15365927",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta A, Daggett C, Ludwick J, et al, \"Ketorolac After Congenital Heart Surgery: Does It Increase the Risk of Significant Bleeding Complications?\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2005, 15(2):139-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/15675931/pubmed\" id=\"15675931\" target=\"_blank\">",
"        15675931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumpulainen E, Kokki H, Laisalmi M, et al, \"How Readily Does Ketorolac Penetrate Cerebrospinal Fluid in Children?\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2008, 48(4):495-501.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/18272673/pubmed\" id=\"18272673\" target=\"_blank\">",
"        18272673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lynn AM, Bradford H, Kantor ED, et al, \"Postoperative Ketorolac Tromethamine Use in Infants Aged 6-18 Months: The Effect on Morphine Usage, Safety Assessment, and Stereo-Specific Pharmacokinetics,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 104(5):1040-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/17456651/pubmed\" id=\"17456651\" target=\"_blank\">",
"        17456651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maunuksela E, Kokki H, and Bullingham RES, &ldquo;Comparison of Intravenous Ketorolac With Morphine for Postoperative Pain in Children,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1992, 52(4):436-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/1424417/pubmed\" id=\"1424417\" target=\"_blank\">",
"        1424417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moffett BS, Wann TI, Carberry KE, et al, \"Safety of Ketorolac in Neonates and Infants After Cardiac Surgery,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2006, 16(4):424-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/16618297/pubmed\" id=\"16618297\" target=\"_blank\">",
"        16618297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Munro HM, Reigger LQ, Reynolds PI, et al, &ldquo;Comparison of the Analgesic and Emetic Properties of Ketorolac and Morphine for Paediatric Outpatient Strabismus Surgery,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1994, 72(6):624-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/8024908/pubmed\" id=\"8024908\" target=\"_blank\">",
"        8024908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rusy LM, Houck CS, Sullivan LJ, et al, \"A Double-Blind Evaluation of Ketorolac Tromethamine Versus Acetaminophen in Pediatric Tonsillectomy: Analgesia and Bleeding,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1995, 80(2):226-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/7818104/pubmed\" id=\"7818104\" target=\"_blank\">",
"        7818104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watcha MF, Jones MB, Lagueruela RG, et al, \"Comparison of Ketorolac and Morphine as Adjuvants During Pediatric Surgery,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1992, 76(3):368-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/1539847/pubmed\" id=\"1539847\" target=\"_blank\">",
"        1539847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zuppa AF, Mondick JT, Davis L, et al, \"Population Pharmacokinetics of Ketorolac in Neonates and Young Infants,\"",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 2009, 16(2):143-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/22/1385/abstract-text/19300040/pubmed\" id=\"19300040\" target=\"_blank\">",
"        19300040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16007 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-71969A6E96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1385=[""].join("\n");
var outline_f1_22_1385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8320258\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345791\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501739\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443758\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503887\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8353206\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345793\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345784\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512521\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8349369\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503865\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503767\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8320263\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346959\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503768\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503805\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503769\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299558\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8347281\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501740\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345796\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345797\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512522\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512523\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503884\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503885\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503886\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512604\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512605\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16007\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16007|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/48/4872?source=related_link\">",
"      Ketorolac (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/59/41909?source=related_link\">",
"      Ketorolac (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/32/35332?source=related_link\">",
"      Ketorolac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/0/19460?source=related_link\">",
"      Ketorolac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/51/43827?source=related_link\">",
"      Ketorolac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/1/21529?source=related_link\">",
"      Ketorolac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/33/3606?source=related_link\">",
"      Ketorolac (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_22_1386="Foreign bodies of the esophagus and gastrointestinal tract in children";
var content_f1_22_1386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Foreign bodies of the esophagus and gastrointestinal tract in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/22/1386/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1386/contributors\">",
"     Mark A Gilger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1386/contributors\">",
"     Ajay K Jain, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1386/contributors\">",
"     Mark E McOmber, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/22/1386/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1386/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1386/contributors\">",
"     Jonathan I Singer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/22/1386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/22/1386/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/22/1386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants put almost everything into their mouths, and toddlers eat just about anything. Of more than 100,000 cases of foreign body ingestion reported each year in the United States, 80 percent occur in children [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The majority of foreign body ingestions occur in children between the ages of six months and three years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. Fortunately, most foreign bodies that reach the gastrointestinal tract pass spontaneously. Only 10 to 20 percent will require endoscopic removal, and less than 1 percent require surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/1,5,7\">",
"     1,5,7",
"    </a>",
"    ]. Although mortality from foreign body ingestion is extremely low, deaths have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, coins are the most common foreign bodies ingested by children. Other objects, including toys, toy parts, magnets, batteries, safety pins, screws, marbles, bones, and food boluses have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/3,7,10-12\">",
"     3,7,10-12",
"    </a>",
"    ]. Ingestion of multiple foreign objects and repeated episodes are uncommon occurrences and usually occur in children with developmental delay [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. The capsules used for capsule endoscopy are occasionally retained in the gastrointestinal tract. This complication is more common in patients with an underlying pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/14-16\">",
"     14-16",
"    </a>",
"    ] and may require endoscopic or surgical removal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and management of foreign bodies in the esophagus are discussed here. Concerns specific to ingestion of button batteries (disk batteries) are discussed in greater detail separately. Management of gastric bezoars is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15337?source=see_link\">",
"     \"Button and cylindrical battery ingestion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13142?source=see_link\">",
"     \"Gastric bezoars\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with esophageal foreign bodies are brought to medical attention by their parents because the ingestion was witnessed or reported to them [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/1,5,19,20\">",
"     1,5,19,20",
"    </a>",
"    ]. In these settings, they often are asymptomatic. As an example, in a case series of 325 pediatric patients, only half of the children with an esophageal foreign body displayed symptoms at the time of the ingestion, such as retrosternal pain, cyanosis, or dysphagia, and in many of these cases the symptoms were transient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When symptoms do occur, they are often related to the location of the foreign body. Older children may localize the sensation of something \"stuck\" to the neck or lower chest, suggesting irritation in the upper or lower esophagus, respectively. Patients of any age may present with refusal of feeds or dysphagia, drooling, or respiratory symptoms including wheezing, stridor, or choking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"     \"Approach to wheezing in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal foreign bodies tend to lodge in areas of physiologic narrowing, such as the upper esophageal sphincter (cricopharyngeus muscle), the level of the aortic arch, and the lower esophageal sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. Objects that appear in the middle portion of the esophagus are more likely to represent esophageal pathology, such as a stricture. Similarly, children presenting with food bolus impaction commonly have underlying esophageal pathology (eg, a stricture) directly responsible for the impaction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/2,22\">",
"     2,22",
"    </a>",
"    ]. Previous surgery or congenital malformations (eg, tracheoesophageal fistula) pose an increased risk as sites for obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longstanding esophageal foreign bodies may cause weight loss or recurrent aspiration pneumonia, due to decreased caloric intake and mishandling of oral secretions, respectively. They also can damage the mucosa and lead to strictures, or erode the esophageal wall, creating a fistula with the trachea or other nearby structures. Sharp objects may perforate the esophagus, resulting in neck swelling, crepitus, or pneumomediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/5\">",
"     5",
"    </a>",
"    ]. Erosion into the aorta also has been reported, causing life-threatening gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, foreign bodies may be retained in the distal gastrointestinal tract, where they can cause delayed complications. Case reports describe cecal retention of a coin mimicking appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/27\">",
"     27",
"    </a>",
"    ], pyogenic liver abscess caused by migration of a sharp object from the gastrointestinal tract to the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/28\">",
"     28",
"    </a>",
"    ], retention of a long object in the appendix presenting as appendicitis several years later [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/29\">",
"     29",
"    </a>",
"    ], and perforation of the ileum by ingested gravel [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/30\">",
"     30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history and physical examination are the keystones to diagnosing an esophageal foreign body and to the prevention of its complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/31\">",
"     31",
"    </a>",
"    ]. Imaging can be used to confirm the findings and to localize the site of the foreign body. The diagnostic steps and treatment depend on the patient's symptoms, the shape and location of the foreign body, whether it is radio-opaque, and whether it is a strong magnet (",
"    <a class=\"graphic graphic_algorithm graphicRef57363 \" href=\"UTD.htm?7/24/7552\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef83942 \" href=\"UTD.htm?19/36/20032\">",
"     algorithm 2A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway and breathing always should be examined first. The physical examination of the neck may reveal swelling, erythema, or crepitus, suggesting esophageal perforation has occurred, and surgical consultation is mandatory. The chest examination may reveal inspiratory stridor or expiratory wheezing, suggesting a lodged esophageal foreign body with tracheal compression. The abdominal examination may show evidence of small bowel obstruction or perforation, in which case immediate surgical consultation and abdominal imaging should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnostic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all patients with suspected foreign body ingestion, the initial diagnostic test should be biplane radiographs (anteroposterior and lateral) of the neck, chest, and abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/5,21,34\">",
"     5,21,34",
"    </a>",
"    ]. Flat objects (eg, coins or disk batteries) usually orient in the coronal plane and appear as a circular object on an anteroposterior projection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76887 \" href=\"UTD.htm?14/15/14578\">",
"     image 1",
"    </a>",
"    ), whereas objects lodged in the trachea tend to orient in the sagittal plane and are best seen in lateral projection. However, these associations are not universal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. The lateral projection radiograph may help to identify the object or establish if more than one foreign body is present, such as stacked coins.",
"   </p>",
"   <p>",
"    Toys made of plastic or wood, and many types of bones are not readily seen on plain films [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/21,38,39\">",
"     21,38,39",
"    </a>",
"    ]. In a study of 325 children, only 64 percent of the ingested objects were radio-opaque [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/21\">",
"     21",
"    </a>",
"    ]. When the foreign body is not detected on plain film and a radiolucent foreign body is suspected, we suggest using computed tomography with 3-dimensional reconstruction as the next diagnostic procedure (",
"    <a class=\"graphic graphic_algorithm graphicRef57363 \" href=\"UTD.htm?7/24/7552\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/5,40\">",
"     5,40",
"    </a>",
"    ]. Magnetic resonance imaging can be considered for evaluation of radiolucent foreign bodies, but is contraindicated if any metallic foreign body is present.",
"   </p>",
"   <p>",
"    We avoid gastrointestinal contrast studies when possible. Although the study may help identify the foreign body,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    contrast may obscure visualization on subsequent endoscopy. Moreover, the contrast may be aspirated if the esophagus is obstructed. Because of these concerns, endoscopy may be preferred over contrast even if radiographs are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/5,39\">",
"     5,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A handheld metal detector has been employed with variable success in locating coins, and can detect materials that are metallic but not radio-opaque, such as aluminum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. This instrument is less reliable in detecting metallic objects other than coins, limiting its use [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Urgent intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent intervention is indicated if any of the following warning signs are present (",
"    <a class=\"graphic graphic_algorithm graphicRef57363 \" href=\"UTD.htm?7/24/7552\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the ingested object is sharp, long (&gt;5 cm), and is in the esophagus or stomach.",
"     </li>",
"     <li>",
"      When the ingested object is a high-powered magnet or magnets (",
"      <a class=\"graphic graphic_algorithm graphicRef83942 graphicRef86069 \" href=\"UTD.htm?25/14/25832\">",
"       algorithm 2A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When a disk battery is in the esophagus (and in some cases in the stomach). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15337?source=see_link\">",
"       \"Button and cylindrical battery ingestion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When the patient shows signs of airway compromise. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"       \"Emergent evaluation of acute upper airway obstruction in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When there is evidence of near-complete esophageal obstruction (eg, patient cannot swallow secretions).",
"     </li>",
"     <li>",
"      When there are signs or symptoms suggesting inflammation or intestinal obstruction (fever, abdominal pain, or vomiting) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/5,39\">",
"       5,39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Expectant management",
"    </span>",
"    &nbsp;&mdash;&nbsp;For blunt foreign bodies without the above characteristics that are lodged in the esophagus in an asymptomatic patient, observation for 12 to 24 hours is reasonable because spontaneous passage often occurs (",
"    <a class=\"graphic graphic_algorithm graphicRef57363 \" href=\"UTD.htm?7/24/7552\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/2,44-48\">",
"     2,44-48",
"    </a>",
"    ]. In one study, coins lodged in the esophagus passed spontaneously into the stomach in about one-third of patients with a \"simple\" presentation (defined as no history of esophageal disease or surgery, coin lodged for less than 24 hours, and no respiratory compromise) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Objects lodged for more than 24 hours or for an unknown duration should be removed promptly [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/5\">",
"     5",
"    </a>",
"    ]. After this period, complications such as transmural erosion, perforation, and fistulae are more likely to occur. As an example, in a case series of 167 children, duration of lodgement for more than 24 hours was the strongest predictor of complications, which included injury to the esophageal mucosa, bleeding, stricture, and obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/25\">",
"     25",
"    </a>",
"    ]. Complications also were more likely if the foreign body was a sharp or pointed object, disk battery, non-radio-opaque, or located below the upper third of the esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various methods have been used to remove esophageal foreign bodies. They include rigid and flexible endoscopy, bougienage, Foley catheterization of the esophagus, and the \"penny pincher\" technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Flexible endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexible endoscopy is preferred in most circumstances because the foreign body can be directly visualized and manipulated, and the surrounding gastrointestinal tract can be examined for potential complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/1,5,10,49-51\">",
"     1,5,10,49-51",
"    </a>",
"    ]. This procedure is performed under conscious sedation or general anesthesia, depending upon the patient's age, ability to cooperate, and the type and number of objects to be removed. The endoscopist should have a complete array of equipment to grasp the foreign object, such as a rat-tooth and alligator forceps, polyp snare, retrieval net, and helical baskets. It is helpful to practice grasping a duplicate of the foreign body using the retrieval tools before beginning the procedure. A foreign body protector hood is the preferred method of protecting the esophagus if the object is sharp or pointed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rigid endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigid endoscopy utilizes a non-flexible channeled device that is introduced into the esophagus under general anesthesia. It is most useful for impacted sharp objects that are located in the proximal esophagus, at the level of the hypopharynx and cricopharyngeus muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/53\">",
"     53",
"    </a>",
"    ]. The technique requires considerable skill and may cause complications such as esophageal abrasion and perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/10,51\">",
"     10,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Magill forceps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magill forceps can be used to extract foreign bodies impacted in the oropharynx or upper esophagus. In some cases, an object impacted in the upper esophageal sphincter is visible at the time of tracheal intubation and can be directly removed with the Magill forceps without the need for intubation. However, in most cases, an endotracheal tube is placed to protect the airway, and a laryngoscope is used to gently open the esophagus and visualize the foreign body [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/21\">",
"     21",
"    </a>",
"    ]. In one case series, esophageal coins were removed in 23 out of 36 patients using Magill forceps. In many of these cases, the extraction was performed easily although the coin was not visible with the laryngoscope. No complications were reported in this study [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bougienage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bougienage (passage of a dilator) has been used to push objects into the stomach. Although the procedure is less costly than endoscopy, it does not permit visualization of the esophagus and does not retrieve the foreign body. Therefore, it is most appropriate for foreign bodies that are very likely to pass beyond the stomach without complications, and in situations where there is a low risk of esophageal injury. Thus, the technique has a role only for selected patients, such as those with witnessed coin ingestion of less than 24 hours duration, and many providers do not recommend it at all if endoscopy is available [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/5,21,50,55\">",
"     5,21,50,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Foley catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;For this technique, a deflated Foley catheter is passed beyond the foreign body. The balloon is then inflated using a radio-opaque contrast dye, and the catheter is slowly drawn back under fluoroscopic guidance, to remove the foreign body through the mouth. The technique can be successful with proximal esophageal foreign bodies when performed by an experienced operator. It does not permit visualization of the esophagus and carries the risk of esophageal perforation if the balloon is inflated below a stricture. In addition, this approach may cause aspiration of the foreign body if it is inadvertently dragged into the trachea [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/5\">",
"     5",
"    </a>",
"    ]. For these reasons, many providers do not recommend this technique if endoscopy is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Penny pincher technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"penny pincher\" technique involves insertion of a grasping forceps through a nasogastric tube, under fluoroscopic guidance and usually without anesthesia or endotracheal intubation. This approach is an improvement over the Foley catheter method because it permits direct control of the object, reducing the risk of dropping it into the airway. However, it also does not allow inspection of the esophagus and should only be used for objects that can be firmly grasped and controlled by the forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     APPROACHES FOR SPECIFIC TYPES OF FOREIGN BODIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Coins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coins are by far the most common foreign body ingested by children [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/1,50,57,58\">",
"     1,50,57,58",
"    </a>",
"    ]. A small percentage of the ingested coins become lodged in the esophagus, and these can cause serious complications, including aspiration, if not removed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/57\">",
"     57",
"    </a>",
"    ]. Approximately two-thirds of ingested coins are in the stomach at the time of initial radiographic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/12,57\">",
"     12,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a coin is visualized in the esophagus and the patient is asymptomatic, the child can be observed for up to 24 hours after ingestion of the coin. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Expectant management'",
"    </a>",
"    above.) In such patients, 20 to 30 percent of coins will pass into the stomach spontaneously during the observation period (two-thirds of these during the first eight hours). Spontaneous passage is more common in older children and when coins are located in the distal third of the esophagus.",
"   </p>",
"   <p>",
"    The esophageal coin should be removed promptly if the patient is symptomatic or if the time of ingestion is not known. If the child is asymptomatic and the coin does not pass spontaneously by 24 hours after ingestion, it should be removed. In our practice, we prefer to remove most coins using flexible endoscopy. Rigid endoscopy or Magill forceps are acceptable approaches for proximally located coins, with experienced operators. The penny pincher or Foley catheter techniques are cost-effective alternatives for selected patients, but require fluoroscopy and do not allow direct inspection of the esophagus. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Urgent intervention'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Techniques'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because coins lack sharp edges and the metal is not toxic, coins that reach the stomach can be managed expectantly, and most will pass out uneventfully within one to two weeks. For these patients, most providers check the location of the coin with a plain radiograph about once a week. If the coin has not passed beyond the stomach by four weeks, endoscopic removal is recommended. If the child develops any signs or symptoms of obstruction, abdominal pain, vomiting, or fever, then the patient is promptly reevaluated with radiographs and the coin is removed endoscopically. Although there have been theoretical concerns about zinc toxicity from retained gastric pennies minted after 1982, evidence demonstrating the need for extraction is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/1,21,50,59\">",
"     1,21,50,59",
"    </a>",
"    ], except in the case of ingestion of extremely large numbers of post-1982 pennies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Batteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of ingestions of disk or &ldquo;button&rdquo; batteries is increasing substantially [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/61\">",
"     61",
"    </a>",
"    ]. More alarming, when lodged in the esophagus, these batteries are associated with significant morbidity, so they represent a medical emergency. In addition to direct pressure necrosis, contact of the flat esophageal wall with both poles of the battery conducts electricity, resulting in liquefaction necrosis and perforation of the esophagus. Retained batteries also can cause problems through leakage of caustic material (generally batteries contain a heavy metal like mercury, silver,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"     lithium",
"    </a>",
"    , and a strong hydroxide of sodium or potassium) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/5,6,39\">",
"     5,6,39",
"    </a>",
"    ]. Animal studies have demonstrated mucosal necrosis within one hour of ingestion and ulceration within two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/62\">",
"     62",
"    </a>",
"    ], with perforation as early as eight hours after ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It may be difficult to differentiate between a disk battery and a coin on a radiograph. This distinction is most important when the foreign body is in the esophagus, since batteries require immediate removal whereas coins may or may not. Radiographic features that can help distinguish between the two are discussed separately (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52816 \" href=\"UTD.htm?23/58/24480\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15337?source=see_link&amp;anchor=H16#H16\">",
"     \"Button and cylindrical battery ingestion\", section on 'Radiographic localization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like coins, most disk or cylindrical batteries pass harmlessly once they reach the stomach. However, because of the potential for direct mucosal injury and toxicity, batteries should be removed from the stomach under certain conditions. An overview of the management of battery ingestions is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15337?source=see_link\">",
"     \"Button and cylindrical battery ingestion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sharp-pointed objects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common sharp-pointed objects ingested by children are straight pins, needles, and straightened paper clips; these represent 5 to 30 percent of swallowed objects [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. Sharp-pointed objects lodged in the esophagus represent a medical emergency because of a high risk of perforation (15 to 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. When lodged in the hypopharynx, they can cause a retropharyngeal abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children suspected of swallowing sharp-pointed objects must be evaluated to determine the location of the object. If the history or examination raises concern for a sharp-pointed object, endoscopy should be performed even if the radiologic exam is negative, because many sharp-pointed objects are not readily visible by x-ray.",
"   </p>",
"   <p>",
"    If the object is in the esophagus, it should be removed immediately. Endoscopic retrieval of sharp objects is accomplished with use of retrieval forceps or polypectomy snare [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/33\">",
"     33",
"    </a>",
"    ]. The risk of mucosal injury during retrieval of a sharp object can be minimized by orienting the object with the sharp-end trailing during extraction and using a protector hood on the end of the endoscope, or (in older children) an overtube [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/32,64\">",
"     32,64",
"    </a>",
"    ]. Direct laryngoscopy is a reasonable alternative for objects lodged at or above the cricopharyngeus. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Flexible endoscopy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Magill forceps'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the object is in the stomach or proximal duodenum, it also should be removed promptly, using a flexible endoscope. The risk of a complication caused by a sharp-pointed object passing through the gastrointestinal tract is as high as 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/22\">",
"     22",
"    </a>",
"    ], although some case series describe lower complication rates from sharp objects (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/65\">",
"     65",
"    </a>",
"    ]. Sharp objects that pass beyond the reach of a flexible endoscope and then cause symptoms will require surgical intervention.",
"   </p>",
"   <p>",
"    If the object has passed into the small intestine and the patient is asymptomatic, it may be followed with serial radiographs to document its passage. Surgical intervention should be considered for objects that fail to progress for three consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/2\">",
"     2",
"    </a>",
"    ]. Parents are instructed to immediately report symptoms of abdominal pain, vomiting, fever, hematemesis, or melena.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Food bolus impaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impacted meat or other food bolus is the most common esophageal foreign body in adults, but is relatively rare in children. It usually presents as dysphagia beginning acutely while eating. In children presenting with a food impaction, there is a higher incidence of underlying esophageal pathology (strictures, achalasia, or esophageal motility disorders) as compared to children with other esophageal foreign bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/2,66,67\">",
"     2,66,67",
"    </a>",
"    ]. Reflux esophagitis and eosinophilic esophagitis also predispose to food impaction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who are in acute distress or unable to swallow oral secretions require immediate attention and removal of the impaction. If the patient is comfortable and able to handle oral secretions, endoscopic intervention can be delayed, as many food impactions will pass spontaneously. However, intervention should not be delayed beyond 24 hours.",
"   </p>",
"   <p>",
"    A proteolytic enzyme, like papain, is",
"    <strong>",
"     not",
"    </strong>",
"    recommended because its use has been associated with hypernatremia, erosion, and esophageal perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/2,70,71\">",
"     2,70,71",
"    </a>",
"    ]. Some experts believe that a bolus of intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    may promote spontaneous passage of an impacted food bolus by relaxing the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. However, two small randomized trials and a large case series suggest that glucagon is no more effective than placebo, except perhaps in patients with a prior history of solid food dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Because of the lack of evidence of efficacy, particularly in children, and because nausea and vomiting are common side effects, we do not recommend the use of glucagon in the management of food impaction or other esophageal foreign bodies in children [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/75,77\">",
"     75,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal approach to removal of a food bolus depends on the location and consistency. Objects in the upper esophagus may be optimally managed with a rigid endoscope, whereas those in more distal locations typically require flexible endoscopy. Some providers find that polypectomy snares or retrieval nets (eg, Roth Net), or a friction-fit adaptor (from a band ligator) fitted to the end of the endoscope are valuable for food bolus removal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/49,67,78\">",
"     49,67,78",
"    </a>",
"    ]. The food bolus can be removed en bloc or in a piecemeal fashion. Once reduced in size, the bolus may be gently pushed into the stomach using the tip of the endoscope. Because food impaction is often caused by an underlying mucosal abnormality such as esophagitis or stricture, we recommend that esophageal mucosal biopsies be obtained at the time of endoscopic disimpaction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21353?source=see_link&amp;anchor=H8#H8\">",
"     \"Ingested foreign bodies and food impactions in adults\", section on 'Food bolus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Magnets",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the increasing use of small magnets in toys and household items, ingestion of magnets has become a serious health hazard in children [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/80-83\">",
"     80-83",
"    </a>",
"    ]. High-powered magnets composed of neodymium (also known as &ldquo;rare earth&rdquo; magnets) are now common components of household appliances. Furthermore, these magnets are commonly available in the form of desk &ldquo;toys&rdquo; and &ldquo;stress relievers&rdquo; (eg, Buckyballs&reg;), which consist of 200 or more small magnetic balls, cubes, or cylinders. Although these are marketed to adults, they have been involved in many ingestion incidents in children. Many of the children with complications from multiple magnet ingestion had underlying conditions such as developmental delay or autism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. In some cases, an older child has inadvertently swallowed these magnets while using them to imitate a pierced tongue, so the risk is not limited to young children. In 2011, the United States Consumer Safety Product Commission (CPSC) issued an",
"    <a class=\"external\" href=\"file://www.cpsc.gov/cpscpub/prerel/prhtml12/12037.html\">",
"     alert",
"    </a>",
"    describing the safety risks of this type of magnet [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two or more strong magnets, especially if ingested at different times, may attract across layers of bowel leading to pressure necrosis, fistula, volvulus, perforation, infection, or obstruction; this may result in serious consequences including intestinal resection. It is postulated that intraperitoneal hemorrhage could occur if mesenteric vessels are trapped between attracted bowel loops [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suspected magnet ingestion requires urgent evaluation. Radiographs of the neck and abdomen should be performed, including a lateral view. In most cases the radiographs cannot determine whether bowel wall is compressed between the magnets, although the finding of magnets that appear to be stacked but are slightly separated (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52524 \" href=\"UTD.htm?38/43/39615\">",
"     image 3",
"    </a>",
"    ) is suspicious for bowel entrapment. Management depends on the number, location and type of magnets, and on the timing of the ingestion, as described in the algorithms (",
"    <a class=\"graphic graphic_algorithm graphicRef83942 graphicRef86069 \" href=\"UTD.htm?25/14/25832\">",
"     algorithm 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingestion of a",
"      <strong>",
"       single magnet",
"      </strong>",
"      can generally be managed conservatively, with the following precautions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serial radiographs should be performed to confirm that the magnet progresses through the gastrointestinal tract and to confirm that multiple magnets are not present. Radiographs do not reliably distinguish between single and multiple magnets, since it is possible for magnets to stick together or overlap on a single view and be misdiagnosed as a single magnet [",
"      <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/82\">",
"       82",
"      </a>",
"      ]. To reduce the risk of misinterpreting the radiograph, both AP and lateral radiographs should be performed initially, and all subsequent radiographs should be closely examined for any indication that multiple magnets might be present. &nbsp;",
"     </li>",
"     <li>",
"      The child should be kept away from any magnetic or metallic materials (including metallic buttons or buckles in clothing), until the magnet has passed out of the gastrointestinal tract.",
"     </li>",
"     <li>",
"      Because even single magnets have some risk, endoscopic removal should be considered if the magnet is accessible.",
"     </li>",
"     <li>",
"      Ingestion of a single magnet with another metallic object should be managed using the protocol for multiple magnet ingestion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingestion of",
"      <strong>",
"       multiple magnets",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef86069 \" href=\"UTD.htm?9/53/10070\">",
"       algorithm 2B",
"      </a>",
"      ) has a high risk of complications and warrants preemptive removal [",
"      <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/82,87\">",
"       82,87",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Magnets in the esophagus or stomach should be promptly removed via endoscopy.",
"     </li>",
"     <li>",
"      Management of patients with multiple magnets beyond the stomach depends on symptoms and progression. Asymptomatic patients should be followed closely with serial radiographs and examinations every four to six hours. Alternatively, magnets can be removed by enteroscopy or colonoscopy if accessible. Symptomatic patients, or any patient with multiple magnets that do not progress on serial radiographs, should undergo surgery for operative removal of the magnets.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to endoscopic removal of magnets is similar to that for other blunt objects. Magnetic probes have been used to retrieve magnetic and metallic foreign bodies with varying success [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/21\">",
"     21",
"    </a>",
"    ]. A series of",
"    <a class=\"external\" href=\"file://limelightdc.com/clientarea/naspghan_magnets_podcast_5_12/\">",
"     podcasts",
"    </a>",
"    is available to guide endoscopic and surgical management [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/88\">",
"     88",
"    </a>",
"    ]. In addition to the steps outlined above, some experts have suggested administration of polyethylene glycol without electrolytes (PEG 3350, Miralax&reg;) or other laxatives to expedite the progression of the magnetic object through the intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Long objects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foreign bodies that are long and blunt, such as toothbrushes, batteries, and spoons, are most frequently ingested by older children, adolescents, or adults. Objects longer than 6 to 10 cm generally cannot pass beyond the stomach and should be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/39,65,89\">",
"     39,65,89",
"    </a>",
"    ]. Objects of intermediate length (longer than 5 cm) may pass the stomach, but up to 50 percent become impacted in the ileocecal region [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/65\">",
"     65",
"    </a>",
"    ]. Thus, these should be removed promptly if they are in the stomach. If they pass into the small intestine they should be followed by serial radiographs, and surgical removal should be considered if they fail to progress.",
"   </p>",
"   <p>",
"    The use of a long (greater than 45 cm) overtube that extends beyond the gastroesophageal junction may be beneficial in these older children. The object can be grasped with a snare or basket and maneuvered into the overtube. The entire apparatus, foreign body, overtube, and endoscope then can be withdrawn in one motion, avoiding losing grasp of the object in the overtube itself [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Objects containing lead",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute lead toxicity may occur in children ingesting objects with high lead content, including the lead weights used for fishing (\"sinkers\"), curtain weights, air rifle pellets, and some toys or medallions. Fatalities have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Markedly elevated lead levels have been measured within 90 minutes of ingestion of a foreign body containing lead [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. The acid environment of the stomach enhances dissolution of the metal.",
"   </p>",
"   <p>",
"    Acute lead toxicity presents with nonspecific symptoms including lethargy and vomiting. Providers should be alert to this possibility in a child with a retained foreign body and should measure serum lead levels if there is any suspicion of lead toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Objects suspected to have a high lead content should be removed from the esophagus or stomach as quickly as possible. Administration of proton pump inhibitors may decrease the dissolution of lead [",
"    <a class=\"abstract\" href=\"UTD.htm?1/22/1386/abstract/95\">",
"     95",
"    </a>",
"    ]. Treatment for acute lead toxicity is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"     \"Childhood lead poisoning: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/24/14722?source=see_link\">",
"       \"Patient information: Swallowed objects (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many children with esophageal foreign bodies are asymptomatic or had transient symptoms at the time of the ingestion, such as retrosternal pain, cyanosis, or dysphagia. When symptoms do occur, they may include a sensation of something stuck in the chest, refusal of feeds or dysphagia, drooling, or respiratory symptoms including wheezing, stridor, or choking. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with long-standing esophageal foreign bodies may present with weight loss, aspiration pneumonia, fever, or signs and symptoms of esophageal perforation including crepitus, pneumomediastinum, or gastrointestinal bleeding. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of a patient with suspected foreign body ingestion should include biplane radiographs (anteroposterior and lateral) of the neck, chest, and abdomen (",
"      <a class=\"graphic graphic_algorithm graphicRef57363 \" href=\"UTD.htm?7/24/7552\">",
"       algorithm 1",
"      </a>",
"      ). Other imaging modalities or direct advancement to upper endoscopy may be helpful in identifying radiolucent foreign bodies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnostic examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urgent and sometimes emergent intervention to remove a foreign body is indicated in the following situations (",
"      <a class=\"graphic graphic_algorithm graphicRef57363 \" href=\"UTD.htm?7/24/7552\">",
"       algorithm 1",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H6\">",
"       'Urgent intervention'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When the object is sharp, long, or consists of magnets",
"     </li>",
"     <li>",
"      When the object is a disk battery in the esophagus",
"     </li>",
"     <li>",
"      If airway compromise, such as tracheal compression, is present",
"     </li>",
"     <li>",
"      If there is evidence of esophageal obstruction (eg, the patient is unable to swallow secretions)",
"     </li>",
"     <li>",
"      If there are signs or symptoms suggesting inflammation or intestinal obstruction (fever, abdominal pain, or vomiting)",
"     </li>",
"     <li>",
"      If the object is in the esophagus and the suspected ingestion occurred 24 or more hours prior to the evaluation, or if the time of ingestion is unknown",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suspected magnet ingestion requires urgent evaluation. Management depends on the timing, location, type, and number of magnets (",
"      <a class=\"graphic graphic_algorithm graphicRef83942 graphicRef86069 \" href=\"UTD.htm?25/14/25832\">",
"       algorithm 2A-B",
"      </a>",
"      ). Single magnets can generally be managed conservatively, but with precautions. Ingestion of multiple magnets has a high risk of complications and warrants preemptive removal. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Magnets'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For patients without the above characteristics who are comfortable and able to handle oral secretions, intervention can be delayed for up to 24 hours. Coins, food impactions, and other blunt objects often will pass spontaneously into the stomach and beyond. Recommendations for removal of disk batteries that are in the stomach depend on the timing of ingestion and composition of the battery, and are discussed separately. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Expectant management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Batteries'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15337?source=see_link\">",
"       \"Button and cylindrical battery ingestion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A variety of techniques are used to extract foreign bodies from the esophagus or stomach. We suggest flexible endoscopy for most foreign body extractions (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This preference is because the technique can be adapted to a variety of foreign bodies in the esophagus, stomach, or proximal duodenum, and allows direct assessment of the mucosa for injury. Rigid endoscopy or retrieval with Magill forceps are useful techniques for objects in the hypopharynx or proximal esophagus. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend prompt removal of any sharp object in the esophagus (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) or proximal gastrointestinal tract (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). This is because of high rates of complications from sharp objects. For the same reason, we recommend prompt removal of magnets if more than one is present in the proximal gastrointestinal tract (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). If these objects have passed beyond the proximal duodenum and the patient is asymptomatic, they can be managed with close observation and serial radiographs. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Sharp-pointed objects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Magnets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Objects that have passed beyond the proximal duodenum are not accessible to the endoscope, and most will pass without complications. The progress of radio-opaque objects down the gastrointestinal tract should be monitored with serial radiographs. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Coins'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/1\">",
"      Wyllie R. Foreign bodies in the gastrointestinal tract. Curr Opin Pediatr 2006; 18:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/2\">",
"      Webb WA. Management of foreign bodies of the upper gastrointestinal tract: update. Gastrointest Endosc 1995; 41:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/3\">",
"      Waltzman ML, Baskin M, Wypij D, et al. A randomized clinical trial of the management of esophageal coins in children. Pediatrics 2005; 116:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/4\">",
"      Little DC, Shah SR, St Peter SD, et al. Esophageal foreign bodies in the pediatric population: our first 500 cases. J Pediatr Surg 2006; 41:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/5\">",
"      Uyemura MC. Foreign body ingestion in children. Am Fam Physician 2005; 72:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/6\">",
"      Banerjee R, Rao GV, Sriram PV, et al. Button battery ingestion. Indian J Pediatr 2005; 72:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/7\">",
"      Shivakumar AM, Naik AS, Prashanth KB, et al. Foreign body in upper digestive tract. Indian J Pediatr 2004; 71:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/8\">",
"      Simic MA, Budakov BM. Fatal upper esophageal hemorrhage caused by a previously ingested chicken bone: case report. Am J Forensic Med Pathol 1998; 19:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/9\">",
"      Yardeni D, Yardeni H, Coran AG, Golladay ES. Severe esophageal damage due to button battery ingestion: can it be prevented? Pediatr Surg Int 2004; 20:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/10\">",
"      Athanassiadi K, Gerazounis M, Metaxas E, Kalantzi N. Management of esophageal foreign bodies: a retrospective review of 400 cases. Eur J Cardiothorac Surg 2002; 21:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/11\">",
"      Kay M, Wyllie R. Pediatric foreign bodies and their management. Curr Gastroenterol Rep 2005; 7:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/12\">",
"      Sharieff GQ, Brousseau TJ, Bradshaw JA, Shad JA. Acute esophageal coin ingestions: is immediate removal necessary? Pediatr Radiol 2003; 33:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/13\">",
"      Reilly S, Carr L. Foreign body ingestion in children with severe developmental disabilities: a case study. Dysphagia 2001; 16:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/14\">",
"      Barkin JS, Friedman S. Wireless capsule endoscopy requiring surgical intervention: the world's experience. Am J Gastroenterol 2002; 97:S298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/15\">",
"      Lewis B. How to prevent endoscopic capsule retention. Endoscopy 2005; 37:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/16\">",
"      Sears DM, Avots-Avotins A, Culp K, Gavin MW. Frequency and clinical outcome of capsule retention during capsule endoscopy for GI bleeding of obscure origin. Gastrointest Endosc 2004; 60:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/17\">",
"      May A, Nachbar L, Ell C. Extraction of entrapped capsules from the small bowel by means of push-and-pull enteroscopy with the double-balloon technique. Endoscopy 2005; 37:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/18\">",
"      Lee BI, Choi H, Choi KY, et al. Retrieval of a retained capsule endoscope by double-balloon enteroscopy. Gastrointest Endosc 2005; 62:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/19\">",
"      Louie JP, Alpern ER, Windreich RM. Witnessed and unwitnessed esophageal foreign bodies in children. Pediatr Emerg Care 2005; 21:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/20\">",
"      Yal&ccedil;in S, Karnak I, Ciftci AO, et al. Foreign body ingestion in children: an analysis of pediatric surgical practice. Pediatr Surg Int 2007; 23:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/21\">",
"      Arana A, Hauser B, Hachimi-Idrissi S, Vandenplas Y. Management of ingested foreign bodies in childhood and review of the literature. Eur J Pediatr 2001; 160:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/22\">",
"      Vizcarrondo FJ, Brady PG, Nord HJ. Foreign bodies of the upper gastrointestinal tract. Gastrointest Endosc 1983; 29:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/23\">",
"      Macmanus JE. Perforation of the intestine by ingested foreign bodies. JAMA 1941; 53:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/24\">",
"      Benjamin SB. Small bowel obstruction and the Garren-Edwards gastric bubble: an iatrogenic bezoar. Gastrointest Endosc 1988; 34:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/25\">",
"      Baer M, Arslant&uuml;rk H, Kisli E, et al. Primary aortoduodenal fistula due to a swallowed sewing needle: a rare cause of gastrointestinal bleeding. Ulus Travma Acil Cerrahi Derg 2007; 13:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/26\">",
"      Yamada T, Sato H, Seki M, et al. Successful salvage of aortoesophageal fistula caused by a fish bone. Ann Thorac Surg 1996; 61:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/27\">",
"      Betz JS, Hampers LC. Cecal retention of a swallowed penny mimicking appendicitis in a healthy 2 year old. Pediatr Emerg Care 2004; 20:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/28\">",
"      Lowry P, Rollins NK. Pyogenic liver abscess complicating ingestion of sharp objects. Pediatr Infect Dis J 1993; 12:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/29\">",
"      Green SM, Schmidt SP, Rothrock SG. Delayed appendicitis from an ingested foreign body. Am J Emerg Med 1994; 12:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/30\">",
"      Cross KM, Holland AJ. Gravel gut: small bowel perforation due to a blunt ingested foreign body. Pediatr Emerg Care 2007; 23:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/31\">",
"      Tokar B, Cevik AA, Ilhan H. Ingested gastrointestinal foreign bodies: predisposing factors for complications in children having surgical or endoscopic removal. Pediatr Surg Int 2007; 23:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/32\">",
"      Ginsberg GG. Management of ingested foreign objects and food bolus impactions. Gastrointest Endosc 1995; 41:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/33\">",
"      Faigel DO, Stotland BR, Kochman ML, et al. Device choice and experience level in endoscopic foreign object retrieval: an in vivo study. Gastrointest Endosc 1997; 45:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/34\">",
"      Younger RM, Darrow DH. Handheld metal detector confirmation of radiopaque foreign bodies in the esophagus. Arch Otolaryngol Head Neck Surg 2001; 127:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/35\">",
"      Conners GP, Hadley JA. Esophageal coin with an unusual radiographic appearance. Pediatr Emerg Care 2005; 21:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/36\">",
"      Raney LH, Losek JD. Esophageal coin and atypical radiograph. Pediatr Emerg Care 2008; 24:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/37\">",
"      Schlesinger AE, Crowe JE. Sagittal orientation of ingested coins in the esophagus in children. AJR Am J Roentgenol 2011; 196:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/38\">",
"      Ngan JH, Fok PJ, Lai EC, et al. A prospective study on fish bone ingestion. Experience of 358 patients. Ann Surg 1990; 211:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/39\">",
"      Eisen GM, Baron TH, Dominitz JA, et al. Guideline for the management of ingested foreign bodies. Gastrointest Endosc 2002; 55:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/40\">",
"      Kazam JK, Coll D, Maltz C. Computed tomography scan for the diagnosis of esophageal foreign body. Am J Emerg Med 2005; 23:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/41\">",
"      Seikel K, Primm PA, Elizondo BJ, Remley KL. Handheld metal detector localization of ingested metallic foreign bodies: accurate in any hands? Arch Pediatr Adolesc Med 1999; 153:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/42\">",
"      Doraiswamy NV, Baig H, Hallam L. Metal detector and swallowed metal foreign bodies in children. J Accid Emerg Med 1999; 16:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/43\">",
"      Muensterer OJ, Joppich I. Identification and topographic localization of metallic foreign bodies by metal detector. J Pediatr Surg 2004; 39:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/44\">",
"      Nandi P, Ong GB. Foreign body in the oesophagus: review of 2394 cases. Br J Surg 1978; 65:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/45\">",
"      Hachimi-Idrissi S, Corne L, Vandenplas Y. Management of ingested foreign bodies in childhood: our experience and review of the literature. Eur J Emerg Med 1998; 5:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/46\">",
"      Bendig DW, Mackie GG. Management of smooth-blunt gastric foreign bodies in asymptomatic patients. Clin Pediatr (Phila) 1990; 29:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/47\">",
"      Soprano JV, Fleisher GR, Mandl KD. The spontaneous passage of esophageal coins in children. Arch Pediatr Adolesc Med 1999; 153:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/48\">",
"      Soprano JV, Mandl KD. Four strategies for the management of esophageal coins in children. Pediatrics 2000; 105:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/49\">",
"      Katsinelos P, Kountouras J, Paroutoglou G, et al. Endoscopic techniques and management of foreign body ingestion and food bolus impaction in the upper gastrointestinal tract: a retrospective analysis of 139 cases. J Clin Gastroenterol 2006; 40:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/50\">",
"      Dahshan AH, Kevin Donovan G. Bougienage versus endoscopy for esophageal coin removal in children. J Clin Gastroenterol 2007; 41:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/51\">",
"      Gmeiner D, von Rahden BH, Meco C, et al. Flexible versus rigid endoscopy for treatment of foreign body impaction in the esophagus. Surg Endosc 2007; 21:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/52\">",
"      Nelson DB, Bosco JJ, Curtis WD, et al. ASGE technology status evaluation report. Endoscopic retrieval devices. February 1999. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 1999; 50:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/53\">",
"      Cheng W, Tam PK. Foreign-body ingestion in children: experience with 1,265 cases. J Pediatr Surg 1999; 34:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/54\">",
"      Janik JE, Janik JS. Magill forceps extraction of upper esophageal coins. J Pediatr Surg 2003; 38:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/55\">",
"      Arms JL, Mackenberg-Mohn MD, Bowen MV, et al. Safety and efficacy of a protocol using bougienage or endoscopy for the management of coins acutely lodged in the esophagus: a large case series. Ann Emerg Med 2008; 51:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/56\">",
"      Gauderer MW, DeCou JM, Abrams RS, Thomason MA. The 'penny pincher': a new technique for fast and safe removal of esophageal coins. J Pediatr Surg 2000; 35:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/57\">",
"      Waltzman ML. Management of esophageal coins. Curr Opin Pediatr 2006; 18:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/58\">",
"      Waltzman M. Management of esophageal coins. Pediatr Emerg Care 2006; 22:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/59\">",
"      Cetinkursun S, Sayan A, Demirbag S, et al. Safe removal of upper esophageal coins by using Magill forceps: two centers' experience. Clin Pediatr (Phila) 2006; 45:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/60\">",
"      Dhawan SS, Ryder KM, Pritchard E. Massive penny ingestion: the loot with local and systemic effects. J Emerg Med 2008; 35:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/61\">",
"      Kimball SJ, Park AH, Rollins MD 2nd, et al. A review of esophageal disc battery ingestions and a protocol for management. Arch Otolaryngol Head Neck Surg 2010; 136:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/62\">",
"      Votteler TP, Nash JC, Rutledge JC. The hazard of ingested alkaline disk batteries in children. JAMA 1983; 249:2504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/63\">",
"      Maves MD, Carithers JS, Birck HG. Esophageal burns secondary to disc battery ingestion. Ann Otol Rhinol Laryngol 1984; 93:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/64\">",
"      Bertoni G, Sassatelli R, Conigliaro R, Bedogni G. A simple latex protector hood for safe endoscopic removal of sharp-pointed gastroesophageal foreign bodies. Gastrointest Endosc 1996; 44:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/65\">",
"      Velitchkov NG, Grigorov GI, Losanoff JE, Kjossev KT. Ingested foreign bodies of the gastrointestinal tract: retrospective analysis of 542 cases. World J Surg 1996; 20:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/66\">",
"      Lao J, Bostwick HE, Berezin S, et al. Esophageal food impaction in children. Pediatr Emerg Care 2003; 19:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/67\">",
"      Smith CR, Miranda A, Rudolph CD, Sood MR. Removal of impacted food in children with eosinophilic esophagitis using Saeed banding device. J Pediatr Gastroenterol Nutr 2007; 44:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/68\">",
"      Luis AL, Ri&ntilde;on C, Encinas JL, et al. Non stenotic food impaction due to eosinophilic esophagitis: a potential surgical emergency. Eur J Pediatr Surg 2006; 16:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/69\">",
"      Vicente Y, Hernandez-Peredo G, Molina M, et al. Acute food bolus impaction without stricture in children with gastroesophageal reflux. J Pediatr Surg 2001; 36:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/70\">",
"      ANDERSEN HA, BERNATZ PE, GRINDLAY JH. Perforation of the esophagus after use of a digestant agent: report of case and experimental study. Ann Otol Rhinol Laryngol 1959; 68:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/71\">",
"      Holsinger JW, Furson RL, Sealy WC. Esophageal perforation following meat impaction and papain ingestion. JAMA 1968; 204:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/72\">",
"      Ferrucci JT Jr, Long JA Jr. Radiologic treatment of esophageal food impaction using intravenous glucagon. Radiology 1977; 125:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/73\">",
"      Trenkner SW, Maglinte DD, Lehman GA, et al. Esophageal food impaction: treatment with glucagon. Radiology 1983; 149:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/74\">",
"      Tibbling L, Bjorkhoel A, Jansson E, Stenkvist M. Effect of spasmolytic drugs on esophageal foreign bodies. Dysphagia 1995; 10:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/75\">",
"      Al-Haddad M, Ward EM, Scolapio JS, et al. Glucagon for the relief of esophageal food impaction does it really work? Dig Dis Sci 2006; 51:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/76\">",
"      Mehta D, Attia M, Quintana E, Cronan K. Glucagon use for esophageal coin dislodgment in children: a prospective, double-blind, placebo-controlled trial. Acad Emerg Med 2001; 8:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/77\">",
"      Arora S, Galich P. Myth: glucagon is an effective first-line therapy for esophageal foreign body impaction. CJEM 2009; 11:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/78\">",
"      Saeed ZA, Michaletz PA, Feiner SD, et al. A new endoscopic method for managing food impaction in the esophagus. Endoscopy 1990; 22:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/79\">",
"      Hurtado CW, Furuta GT, Kramer RE. Etiology of esophageal food impactions in children. J Pediatr Gastroenterol Nutr 2011; 52:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/80\">",
"      Centers for Disease Control and Prevention (CDC). Gastrointestinal injuries from magnet ingestion in children--United States, 2003-2006. MMWR Morb Mortal Wkly Rep 2006; 55:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/81\">",
"      Hwang JB, Park MH, Choi SO, et al. How strong construction toy magnets are! A gastro-gastro-duodenal fistula formation. J Pediatr Gastroenterol Nutr 2007; 44:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/82\">",
"      Butterworth J, Feltis B. Toy magnet ingestion in children: revising the algorithm. J Pediatr Surg 2007; 42:e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/83\">",
"      Schierling S, Snyder SK, Custer M, et al. Magnet ingestion. J Pediatr 2008; 152:294.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Consumer Product Safety Commission. CPSC warns high-powered magnets and children make a deadly mix. Released November 10, 2011. Available at: file://www.cpsc.gov/cpscpub/prerel/prhtml12/12037.html (Accessed on March 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/85\">",
"      Liu S, de Blacam C, Lim FY, et al. Magnetic foreign body ingestions leading to duodenocolonic fistula. J Pediatr Gastroenterol Nutr 2005; 41:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/86\">",
"      Hussain SZ, Bousvaros A, Gilger M, et al. Management of ingested magnets in children. J Pediatr Gastroenterol Nutr 2012; 55:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/87\">",
"      Pryor HI 2nd, Lange PA, Bader A, et al. Multiple magnetic foreign body ingestion: a surgical problem. J Am Coll Surg 2007; 205:182.",
"     </a>",
"    </li>",
"    <li>",
"     North Americal Society for Pediatric Gastroenterology and Nutrition. Dangers of neodymium magnet ingestion in pediatric patients. Podcast series, May 2012. Available at: file://limelightdc.com/clientarea/naspghan_magnets_podcast_5_12/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/89\">",
"      Pellerin D, Fortier-Beaulieu M, Guegen J. The fate of swallowed foreign bodies: Experience of 1250 instances of subdiaphragmatic foreign bodies in children. Prog Pediatr Radiol 1969; 2:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/90\">",
"      Chinitz MA, Bertrand G. Endoscopic removal of toothbrushes. Gastrointest Endosc 1990; 36:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/91\">",
"      Berkowitz S, Tarrago R. Acute brain herniation from lead toxicity. Pediatrics 2006; 118:2548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/92\">",
"      Hugelmeyer CD, Moorhead JC, Horenblas L, Bayer MJ. Fatal lead encephalopathy following foreign body ingestion: case report. J Emerg Med 1988; 6:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/93\">",
"      McKinney PE. Acute elevation of blood lead levels within hours of ingestion of large quantities of lead shot. J Toxicol Clin Toxicol 2000; 38:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/94\">",
"      Treble RG, Thompson TS. Elevated blood lead levels resulting from the ingestion of air rifle pellets. J Anal Toxicol 2002; 26:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/22/1386/abstract/95\">",
"      Mowad E, Haddad I, Gemmel DJ. Management of lead poisoning from ingested fishing sinkers. Arch Pediatr Adolesc Med 1998; 152:485.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5888 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1386=[""].join("\n");
var outline_f1_22_1386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnostic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Urgent intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Expectant management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Flexible endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rigid endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Magill forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bougienage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Foley catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Penny pincher technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      APPROACHES FOR SPECIFIC TYPES OF FOREIGN BODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Coins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Batteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sharp-pointed objects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Food bolus impaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Magnets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Long objects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Objects containing lead",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5888\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5888|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/24/7552\" title=\"algorithm 1\">",
"      Management foreign body ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?19/36/20032\" title=\"algorithm 2A\">",
"      Management of single magnet ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/53/10070\" title=\"algorithm 2B\">",
"      Management of multiple magnet ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5888|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/15/14578\" title=\"diagnostic image 1\">",
"      Esophageal foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/58/24480\" title=\"diagnostic image 2\">",
"      Disk battery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/43/39615\" title=\"diagnostic image 3\">",
"      Multiple magnets GI tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=related_link\">",
"      Approach to wheezing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=related_link\">",
"      Assessment of stridor in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15337?source=related_link\">",
"      Button and cylindrical battery ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=related_link\">",
"      Childhood lead poisoning: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13142?source=related_link\">",
"      Gastric bezoars",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21353?source=related_link\">",
"      Ingested foreign bodies and food impactions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/24/14722?source=related_link\">",
"      Patient information: Swallowed objects (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_22_1387="Fungi health effects";
var content_f1_22_1387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Health effects of indoor fungal exposure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ingestional mycotoxicosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asthma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Allergic rhinitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypersensitivity pneumonitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Allergic bronchopulmonary aspergillosis (ABPA)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Allergic fungal sinusitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fungus balls",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Bush, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1387=[""].join("\n");
var outline_f1_22_1387=null;
var title_f1_22_1388="Localized scleroderma";
var content_f1_22_1388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of localized scleroderma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Circumscribed (plaque) morphea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One or more circumscribed patches of skin with sclerotic changes in one anatomic site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Involvement is confined to the superificial panniculus (subcutaneous tissue)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Generalized morphea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Four or more plaques that affect at least two anatomic sites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often located on the trunk or limbs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Similar clinical and histologic features as circumscribed morphea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bullous morphea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bullous involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May occur in other forms of morphea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Linear morphea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Most common form of morphea in children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One or more elongated sclerotic areas of skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lesions are typically asymmetric and oriented along the affected limb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated with growth impairment of the involved extremity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lesions on the face or scalp are called en coup de sabre",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Deep morphea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Least common form of morphea in children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Most disabling form of morphea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary site of involvement is the panniculus (subcutaneous tissue)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1388=[""].join("\n");
var outline_f1_22_1388=null;
var title_f1_22_1389="Catheters used for venous and arterial access";
var content_f1_22_1389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Catheters used for venous and arterial access",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Catheter type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Entry site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Length",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral venous catheters",
"       </td>",
"       <td>",
"        Usually inserted in veins of forearm or hand",
"       </td>",
"       <td>",
"        &lt;3 inches",
"       </td>",
"       <td>",
"        Phlebitis with prolonged use; rarely associated with bloodstream infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral arterial catheters",
"       </td>",
"       <td>",
"        Usually inserted in radial artery; can be placed in femoral, axillary, brachial, posterior tibial arteries",
"       </td>",
"       <td>",
"        &lt;3 inches",
"       </td>",
"       <td>",
"        Low infection risk; rarely associated with bloodstream infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Midline catheters",
"       </td>",
"       <td>",
"        Inserted via the antecubital fossa into the proximal basilic or cephalic veins; does not enter central veins, peripheral catheters",
"       </td>",
"       <td>",
"        3 to 8 inches",
"       </td>",
"       <td>",
"        Anaphylactoid reactions have been reported with catheters made of elastomeric hydrogel; lower rates of phlebitis than short peripheral catheters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nontunneled central venous catheters",
"       </td>",
"       <td>",
"        Percutaneously inserted into central veins (subclavian, internal jugular, or femoral)",
"       </td>",
"       <td>",
"        &ge;8 cm depending on patient size",
"       </td>",
"       <td>",
"        Account for majority of CRBSI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary artery catheters",
"       </td>",
"       <td>",
"        Inserted through a Teflon",
"        <sup>",
"         &reg;",
"        </sup>",
"        introducer in a central vein (subclavian, internal jugular, or femoral)",
"       </td>",
"       <td>",
"        &ge;30 cm depending on patient size",
"       </td>",
"       <td>",
"        Usually heparin bonded; similar rates of bloodstream infection as CVCs; subclavian site preferred to reduce infection risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripherally inserted central venous catheters (PICC)",
"       </td>",
"       <td>",
"        Inserted into basilic, cephalic, or brachial veins and enter the superior vena cava",
"       </td>",
"       <td>",
"        &ge;20 cm depending on patient size",
"       </td>",
"       <td>",
"        Lower rate of infection than nontunneled CVCs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tunneled central venous catheters",
"       </td>",
"       <td>",
"        Implanted into subclavian, internal jugular, or femoral veins",
"       </td>",
"       <td>",
"        &ge;8 cm depending on patient size",
"       </td>",
"       <td>",
"        Cuff inhibits migration of organisms into catheter tract; lower rate of infection than nontunneled CVC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Totally implantable",
"       </td>",
"       <td>",
"        Tunneled beneath skin and have subcutaneous port accessed with a needle; implanted in subclavian or internal jugular vein",
"       </td>",
"       <td>",
"        &ge;8 cm depending on patient size",
"       </td>",
"       <td>",
"        Lowest risk for CRBSI; improved patient self-image; no need for local catheter-site care; surgery required for catheter removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Umbilical catheters",
"       </td>",
"       <td>",
"        Inserted into either umbilical vein or umbilical artery",
"       </td>",
"       <td>",
"        &le;6 cm depending on patient size",
"       </td>",
"       <td>",
"        Risk for CRBSI similar with catheters placed in umbilical vein versus artery",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CRBSI: catheter related bloodstream infection; CVC: central venous catheter.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52:e162, by permission of Oxford University Press. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1389=[""].join("\n");
var outline_f1_22_1389=null;
var title_f1_22_1390="Systolic BP cardiovascular events HOT trial";
var content_f1_22_1390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Systolic pressure and cardiovascular events in HOT trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 322px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated incidence (95 percent CI) of major cardiovascular events in relation to achieved mean systolic blood pressure in the HOT trial. The systolic pressure at the lowest point of the curve is indicated (minimum).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hansson, L, Zanchetti, A, Carruthers, SG, et al, Lancet 1998; 351:1755.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1390=[""].join("\n");
var outline_f1_22_1390=null;
var title_f1_22_1391="Second CA after treatment HL";
var content_f1_22_1391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Site-specific risk of second primary malignancy according to treatment of Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"8\" width=\"10%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Chemotherapy only",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Chemotherapy plus radiotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        #&nbsp;of patients",
"       </td>",
"       <td class=\"subtitle2\">",
"        SIR",
"       </td>",
"       <td class=\"subtitle2\">",
"        95% CI",
"       </td>",
"       <td class=\"subtitle2\">",
"        AER",
"       </td>",
"       <td class=\"subtitle2\">",
"        #&nbsp;of patients",
"       </td>",
"       <td class=\"subtitle2\">",
"        SIR",
"       </td>",
"       <td class=\"subtitle2\">",
"        95% CI",
"       </td>",
"       <td class=\"subtitle2\">",
"        AER",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All malignancies, except nonmelanoma skin cancer and Hodgkin lymphoma*",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        2.0",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.7 to 2.4",
"       </td>",
"       <td>",
"        32.9",
"       </td>",
"       <td>",
"        302",
"       </td>",
"       <td>",
"        3.9",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        3.5 to 4.4",
"       </td>",
"       <td>",
"        65.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        2.9",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2.0 to 3.9",
"       </td>",
"       <td>",
"        10.7",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        5.1",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        3.8 to 6.5",
"       </td>",
"       <td>",
"        14.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-Hodgkin lymphoma",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        11.5",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        7.8 to 16.3",
"       </td>",
"       <td>",
"        11.6",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        17.1",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        12.7 to 22.5",
"       </td>",
"       <td>",
"        13.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemia, excluding CLL",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        26.7",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        18.4 to 37.5",
"       </td>",
"       <td>",
"        13.0",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        30.6",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        22.1 to 41.4",
"       </td>",
"       <td>",
"        11.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemia",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        18.4",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        12.7 to 25.9",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        22.7",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        16.3 to 30.7",
"       </td>",
"       <td>",
"        11.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonmelanoma skin cancer",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.2 to 1.0",
"       </td>",
"       <td>",
"        -2.8",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        2.4",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.6 to 3.4",
"       </td>",
"       <td>",
"        5.1",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast (female)",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.2 to 1.2",
"       </td>",
"       <td>",
"        -1.8",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        2.4",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.6 to 3.4",
"       </td>",
"       <td>",
"        5.1",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unspecified primary",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.1 to 1.9",
"       </td>",
"       <td>",
"        -0.7",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        4.7",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2.7 to 7.6",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon, rectum",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"       <td>",
"        0.5 to 1.9",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        2.0",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1.2 to 3.2",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophagus",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.01 to 2.9",
"       </td>",
"       <td>",
"        -0.4",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        4.1",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        1.6 to 8.4",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stomach",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"       <td>",
"        0.3 to 2.9",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2.7",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1.2 to 5.3",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft tissue",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0 to 7.9",
"       </td>",
"       <td>",
"        -0.2",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        8.9",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2.9 to 20.7",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melanoma",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.01 to 2.8",
"       </td>",
"       <td>",
"        -0.4",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        2.7",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1.1 to 5.5",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tongue, mouth, pharynx",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"       <td>",
"        0.2 to 4.6",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        3.5",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1.3 to 7.7",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nervous system",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"       <td>",
"        0.2 to 3.5",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"       <td>",
"        0.9 to 4.8",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervix",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"       <td>",
"        0.2 to 4.9",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2.7",
"       </td>",
"       <td>",
"        1.0 to 5.8",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreas",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        0.1 to 3.7",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"       <td>",
"        0.9 to 6.7",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small intestine",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0 to 20.1",
"       </td>",
"       <td>",
"        -0.1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        16.2",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        3.3 to 47.3",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"       <td>",
"        0.1 to 12.9",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        5.1",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1.1 to 15.0",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostate",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        0.2 to 1.9",
"       </td>",
"       <td>",
"        -0.6",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        0.5 to 3.2",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0 to 20.7",
"       </td>",
"       <td>",
"        -0.1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        9.0",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1.1 to 32.5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"       <td>",
"        0.4 to 12.5",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"       <td>",
"        0.4 to 13.3",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleura",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        6.3",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1.3 to 18.5",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"       <td>",
"        0.5 to 15.9",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corpus uteri",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0 to 3.1",
"       </td>",
"       <td>",
"        -0.5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        0.2 to 5.5",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testis",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"       <td>",
"        0.2 to 6.2",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        0.01 to 3.3",
"       </td>",
"       <td>",
"        -0.2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Second primary malignancies identified in a cohort of 3564 men and 2234 women treated for Hodgkin lymphoma in Britain from 1963 to 2001.",
"    <div class=\"footnotes\">",
"     AER: absolute excess risk per 10,000 person-years; CLL: chronic lymphocytic leukemia; SIR: standardized incidence ratio.",
"     <br>",
"      * In addition to specified sites, one laryngeal, one gallbladder, two ovarian, two bladder, and two kidney cancers occurred in chemotherapy-only patients, and one laryngeal, one heart, one adrenal, two ovarian, two bladder, and three kidney cancers and one myeloma and three cancers of ill-defined site occurred in mixed-modality patients.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       p&lt;0.001; &loz; p&lt;0.05; &sect; p&lt;0.01",
"       <br>",
"        &Delta; By coincidence, results for nonmelanoma skin cancer and for breast (female) cancer after chemotherapy plus radiotherapy are the same with one digit after the decimal point. This is not a typographical error.",
"        <br>",
"         <br/>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: Swerdlow AJ, Higgins CD, Smith P, et al. Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. J Clin Oncol 2011; 29(31):4096-4104. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_22_1391=[""].join("\n");
var outline_f1_22_1391=null;
